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Abstract 
Background 
The first study to demonstrate that life expectancy in patients with a severe 
mental illness (SMI) was reduced was by Farr in 1841. More recently, 
comparative research has demonstrated a higher level of cardiovascular 
disease (CVD) than the rest of the population in this group. Despite this 
knowledge, little has changed in routine practice. One barrier could be that the 
educational needs of the primary care healthcare professionals in this area are 
not being met.  
Aims 
The aim of this programme of research is to address the physical health needs 
of people with SMI by improving the practice of healthcare professionals in 
primary care.  
Methods  
The methods employed are the development of a training package and a 
programme of research divided into eight studies: 
1. A retrospective audit to find out whether patients will attend for a health 
check if they are invited. 
2. A prospective audit to see if a tool used for people with physical illnesses 
to improve their lifestyle (a food diary) is as effective when used with the 
SMI population. 
3. A systematic search to find out what evidence there is for the efficacy of 
healthcare professional educational outcomes in studies of physical 
health in SMI. 
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4. The development of a training package for practice nurses to teach them 
how to carry out physical health checks for people with SMI. 
5. A retrospective audit to establish whether as many people with SMI are 
being screened for cardiovascular disease as people with physical 
conditions in Northampton.  
6. An audit to find out whether as many people with SMI are being 
screened for cardiovascular disease as people with physical conditions in 
England. 
7. A before and after study to measure the effect of a physical health and 
SMI training on the practice nurses’ motivation to carry out physical 
health checks for people with SMI. 
8. A before and after study to establish whether training practice nurses to 
carry out physical health checks for people with SMI increases the level 
of screening for cardiovascular risk in this group. 
9. A qualitative study using interviews with patients with SMI to find out 
what they think about the physical health checks.  
Results 
There were a total of 2,796 patients and eight healthcare professionals included 
in the programme in Northampton and 2,911,914 patients in the national study. 
People with SMI will attend for a health check if invited by letter giving them an 
appointment with a named practitioner (66%). The patients with schizophrenia 
were all successful in completing food diaries. There were no studies identified 
as suitable for a systematic review. In the five participating primary care 
practices in Northampton, the people with SMI received less CVD screening 
than those with diabetes (21% v 96%, CI=64.53 to 126.55: p<.01). In the 
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national study, patients with diabetes received higher levels of screening in the 
previous 15 months than those with SMI (97.3% vs 74.7%; p<0.0001). The 
attitudes of the practice nurses involved in the study towards their role in 
providing health checks appeared to be modified in a positive direction. 
Following the training of practice nurses, each individual patient received more 
CVD screening and lifestyle information (3.85 v 2.69: t=8.22, p<.05). The 
patients who were interviewed about their physical health check had a good 
understanding of the importance of a healthy diet and taking regular exercise 
but did not appear aware of the risk of cardiovascular disease.  
Conclusion 
Simple changes in the way patients with SMI are invited to attend a health 
check increases attendance rates. The quality of primary care health checks for 
this population is inferior to those provided to patients with diabetes. Training 
practice nurses improves the quality of the health checks but still not to the 
levels received by other patient groups. 
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Chapter one: What is severe mental illness and how is it 
treated? 
 
1.1 What is severe mental illness 
In primary care mental health conditions are identified through disease registers 
alongside the physical conditions. Severe Mental Illness (SMI) includes 
Schizophrenia, Bipolar Disorder and other psychoses. In this chapter I have 
talked about the two main conditions (schizophrenia and bipolar disorder). 
Other psychoses includes schizotypal personality, persistent delusional 
disorder, acute/transient psychotic disorders, induced delusional disorders, 
schizoaffective disorders, manic episodes, severe depression with psychosis 
schizotypal personality and non organic psychosis. These conditions are not 
explained individually in this thesis as they all share symptoms with 
schizophrenia or bipolar disorder. Mental illnesses, such as depression and 
eating disorders, are not discussed because the care of patients with SMI is 
considered separately in United Kingdom (UK) guidance (NICE 2006, 2010, 
BMA and NHS Employers 2011). 
 
1.1.1 Schizophrenia 
Schizophrenia is a psychotic disorder characterized by positive, negative and 
cognitive symptoms (figure 1.1).  Positive symptoms include hallucinations 
(hearing voices or seeing visions), delusions (beliefs held strongly by the patient 
but not shared by people around them) and thought disorder (for example 
conversation jumping from one thought to a completely unrelated thought). 
Social isolation and withdrawal are examples of negative symptoms. Cognitive 
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symptoms are very common and include problems in concentration and task 
planning. Schizophrenia is a long term condition and life expectancy is reduced 
by around 20 years compared to the general population (Wahlbeck et al. 2011). 
About two thirds of the excess mortality is due to natural causes, including heart 
disease, cancer, and cerebrovascular, respiratory, and lung diseases (Colton 
and Manderscheid 2006).  The symptoms of schizophrenia often result in major 
social or occupational disturbance. For example few patients with schizophrenia 
are in employment (Rosenheck et al. 2006). 
 
Figure 1.1 Symptoms of schizophrenia 
 
 
Positive symptoms (that are not normal for the person)  
 
 Hallucinations 
 
 Delusions 
 
 Thought disorder 
 
Negative symptoms (that the person doesn’t usually experience)  
 
 Poor motivation 
 
 Social isolation 
 
 Withdrawal 
 
Cognitive symptoms 
 
 Impaired attention and memory 
 
 Difficulty forward-planning and problem solving 
 
Affective or mood symptoms 
 
 Signs of depression and/or anxiety 
 
 
Adapted from Andreasen (1995) 
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Epidemiology 
Schizophrenia is not a common illness, affecting approximately one person in a 
hundred at some point in their lives (Saha et al. 2005). A meta-analysis of 
international studies of schizophrenia found using the pooled data, a prevalence 
estimate of 4.2 per 1000 (Saha et al. 2008). This means that in a primary care 
practice with 6,000 patients, there will possibly be 25 patients with 
schizophrenia on the SMI register.   
 Onset tends to be when patients are in their teens to early twenties, and 
although schizophrenia is equally common in men and women, men tend to 
develop the illness when they are younger than women. This may be explained 
by the female hormone oestrogen having a protective effect against 
schizophrenia (Palmer et al. 2001).  
 
Cause 
Fifty percent of the cause of schizophrenia can be attributed to genetics 
(Tsuang et al. 2001). It occurs in ten percent of people who have a first-degree 
relative with the disorder and is still more likely to develop in those who have 
second-degree relatives with the disease than the general population. The 
identical twin of a person with schizophrenia has a 40 to 65 percent chance of 
developing the disorder (Cardno and Gottesman 2000). Several genes are 
associated with an increased risk of schizophrenia (Harrison and Weinberger 
2005). Recent research has found that people with schizophrenia have higher 
rates of rare genetic mutations involving hundreds of different genes (Walsh et 
al. 2008). Other recent studies suggest that schizophrenia may result when a 
gene malfunctions that is needed to make important brain chemicals. This 
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problem may affect the part of the brain involved in developing higher 
functioning skills (Huang et al. 2007).  
 Interactions between genes and the environment are necessary for 
schizophrenia to develop. Many environmental factors may be involved, such as 
exposure to viruses or malnutrition before birth, problems during birth, and other 
not yet known psychosocial factors (Tsuang et al. 2001), 
 An imbalance in the complex, interrelated chemical reactions of the brain 
involving the neurotransmitters dopamine and glutamate, and possibly others 
also play a role in schizophrenia. Studies of brain tissue after death have 
revealed changes in the distribution or characteristics of brain cells (leading to 
faulty connections) that could have occurred before birth (Mueser and McGurk 
2004). The problem may not show up in a person until puberty when the brain 
undergoes major changes; these changes could then trigger psychotic 
symptoms.  
 In a study of 229 people with schizophrenia, the majority had prominent 
positive symptoms and a sudden onset of disease, with 69% of the cases 
having a record of heavy cannabis abuse at least one year before onset of 
psychotic symptoms. The authors argue that the high number of cases of 
schizophrenia in this cohort and the temporal relation between cannabis abuse 
and schizophrenia further supports the hypothesis that cannabis abuse may be 
a risk factor for schizophrenia. (Allebeck et al. 2007).  
 
Early detection of schizophrenia 
Making a diagnosis of schizophrenia requires psychotic symptoms to be present 
for at least a month (American Psychiatric Association 2000). GPs or practice 
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nurses are frequently the patient’s first point of contact with a health 
professional. Early detection and treatment by the primary care team is 
essential in order to ensure that patients are effectively treated as quickly as 
possible. Intervening early can improve the outcome of the illness and can 
reduce the risk of suicide (Melle et al. 2006). Early schizophrenia often starts 
with increasing social isolation and deterioration in intellectual functioning 
(Andreasen 1995).  
 
Diagnosis 
The Diagnostic and Statistical Manual of Mental Disorders (4th Edition; DSM-IV) 
are the recommended criteria for health professionals in the United Kingdom to 
use in making a diagnosis of schizophrenia and bipolar disorder (American 
Psychiatric Association 2000 – see figure 1.2). 
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Figure 1.2 DSM -IV diagnostic criteria for schizophrenia 
  
 
Two or more of the following symptoms during a one-month period (or one of 
these if the delusions are bizarre or hallucinations are commentary style): 
 
Delusions 
 
Hallucinations 
 
Disorganized speech (e.g. incoherence or derailed thinking) 
 
Grossly disorganised or catatonic behaviour 
 
Negative symptoms (e.g. avolition (loss of ability to motivate, choose or 
resolve), lack of planning, emotional blunting or poverty of speech) 
 
Social or occupational dysfunction. Disturbance in one or more major 
areas, such as work, self-care or interpersonal relationships 
 
Continuous signs of disturbance for at least six months  
 
Schizoaffective disorder and mood disorder with psychosis have been 
ruled out 
 
Substance misuse or a general medical condition have been excluded 
 
If autistic disorder or another pervasive developmental disorder is 
present, then schizophrenia can only be diagnosed if prominent 
delusions or hallucinations are present for at least one month 
 
 
1.1.2 Bipolar disorder 
Bi-polar disorder is a long term condition characterised by episodes of elated 
mood (mania or hypomania) and depression (figure 1.2). Making a diagnosis of 
bipolar disorder is challenging. Many patients experience long delays in the 
diagnosis of bipolar disorder, with an average of eight years from initial 
presentation to secondary care mental health services (Mantere et al. 2004). 
Substance use is extremely common with both epidemiological and clinical 
studies showing rates ranging from 35-60% (Grant et al. 2005, Fry et al. 2003, 
Chengappa 2000, Kessler et al. 1997, Feinman and Dunner 1996, Regier et al. 
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1990). Life expectancy is reduced in people with bipolar disorder due to the 
increased prevalence of CVD, respiratory disease and high rates of suicide 
(Colton and Manderscheid 2006).  
 
Figure 1.3 Symptoms of bipolar disorder 
 
 
Depression 
 
Feeling sad and hopeless, empty or worthless, guilty or despairing, 
pessimistic  
 
Lacking in energy 
 
Difficulty in concentrating and remembering things 
 
Loss of interest and enjoyment in everyday activities  
 
Self-doubt 
 
Problems with sleeping and waking up early 
 
Suicidal thoughts 
 
Mania 
 
Feeling extremely happy, elated or euphoric, full of energy, self-
important, full of great new ideas and having important plans 
 
Talking quickly 
 
Being easily distracted, irritated or agitated 
 
Doing pleasurable things with distressing consequences, such as 
spending large amounts of money or having risky sexual encounters 
 
Not sleeping or eating 
 
Other 
 
Psychosis may be present 
 
Some people self-harm as a distraction from mental pain and distress 
 
 
Adapted from American Psychiatric Association (2000)  
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Epidemiology 
Bipolar disorder is divided into type I and type II (Type I: episodes of mania with 
or without episodes of depression, Type II: episodes of hypomania or elevated 
mood but patients are able to function, and depression - American Psychiatric 
Association 2000). Lifetime prevalence of bipolar I reported in European studies 
vary widely from 0.1 to 2.4 percent (Pini et al. 2005, ten Have et al. 2002, 
Szadoczky et al. 1998). An Australian study reported a lifetime prevalence of 
2.5 percent (Goldney et al. 2005). Estimates of the lifetime prevalence of bipolar 
II disorder also vary widely. Authors of European studies estimate between 0.2–
2.0 percent prevalence (Faravelli, et al. 1990, Szadoczky, et al. 1998).  
 
Signs and symptoms of bipolar disorder 
Mania 
Manic symptoms include an elated mood accompanied by increased drive, over 
activity and decreased need for sleep. The patient thinks at speed and this is 
expressed in pressure of speech. To begin with they may work more efficiently 
until symptoms of poor concentration and distractibility occur. Some patients 
experience extreme irritability. Hardy and Gray (2012a) describe some common 
features: 
o Hallucinations and mood-congruent delusions and occur in nine 
out of 10 patients.  
o Loss of social inhibitions and extravagant plans may result in 
grave consequences for an individual's professional life, social 
functioning and financial stability. 
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o Mania often results in such a severe disruption of functioning, that 
hospital admission is necessary, sometimes requiring compulsory 
detention.  
 
Depression 
The symptoms and the diagnostic criteria of depression in bipolar disorder are 
the same as those for unipolar depression: low mood; loss of interest and 
pleasure; reduced energy; poor concentration; disturbed sleep; a change in 
appetite; and low self-esteem and confidence (American Psychiatric Association 
2000).  Some patients have ideas of guilt, hopelessness and suicide may occur. 
Psychotic symptoms may feature in severe episodes and are typically mood 
congruent (American Psychiatric Association 2000). 
 In comparison to unipolar depression, bipolar depression is more likely to 
present with psychomotor retardation, melancholic symptoms such as 
worthlessness, psychosis and atypical features such as hypersomnia (Hardy 
and Gray 2012a). Bipolar depressive episodes are typically shorter than in 
unipolar depression. However, patients presenting with depression directly 
following mania may be less likely to respond to treatment. 
 
Mixed states 
Some patients can experience a mixed emotional state, mania and depression 
(American Psychiatric Association 2000); for example, racing thoughts during a 
manic episode. 
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Diagnosis 
Das et al. (2005) report that bipolar disorder is associated with a high 
attendance rate in primary care, which provides the opportunity for detection 
However their study showed that little attention has been given to primary care 
patients who have current depression and past episodes of hypomania or 
mania, history that may indicate bipolar disorder and a need for specialized 
treatment.  
 
DSM-IV criteria for a depressive episode 
To meet the criteria for a major depressive episode the patients should have 
been experiencing at least five symptoms for at least two weeks. One of the 
symptoms has to be depressed mood or loss of interest or pleasure; there 
should also be distress or impairment in social or occupational functioning 
(American Psychiatric Association 2000).  
 
DSM-IV criteria for a manic episode 
The DSM-IV criteria for a manic episode are a distinct period of abnormally and 
persistently elevated, expansive or irritable mood, lasting one week (or any 
duration if hospitalisation is necessary). During the period of mood disturbance, 
three or more symptoms have persisted (four if the mood is only irritable) and 
have been present to a significant degree (American Psychiatric Association 
2000). 
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Early intervention 
Early intervention in patients with bipolar disorder can be effective in improving 
long term outcomes by ensuring the patient is prescribed and adheres with 
effective treatment. Primary care provides a necessary and valuable service for 
people with bipolar disorder because many of them never consult secondary 
care mental health services (ten Have et al. 2002). 
 
 
1.2 Treatment of Severe Mental Illness 
 
1.2.1 Schizophrenia 
Schizophrenia requires treatment with antipsychotic medication to stabilize 
psychosis and prevent relapse of symptoms. Although many patients express a 
desire to come off medication, good adherence is essential to ensure effective 
management of the illness and psychosocial recovery (Hardy and Gray 2012a).  
 
Antipsychotic medication 
Antipsychotics improve psychosis by diminishing abnormal transmission of 
dopamine by blocking the dopamine D2/3 receptor (not D1 or D4), and although 
several brain regions may be involved, it is suggested that the ventral striatal 
regions may have a particularly critical role (Kapur et al. 2006).   
 Typical antipsychotics include chlorpromazine, haloperidol, pimozide, 
and zuclopenthixol. They were first introduced in the 1950s. Although still 
commonly used, most patients with schizophrenia are now treated with atypical 
antipsychotic drugs that started to be introduced in the early 1990s (Nasrallah 
2003). Atypical antipsychotics include clozapine, olanzapine, quetiapine, 
risperidone and aripiprazole. 
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 All antipsychotics (both typical and atypical) are, clinically, equally 
effective against the positive symptoms of schizophrenia. The older or typical 
drugs do not improve the negative symptoms which are associated with low 
levels of dopamine in the cortex (Van Rossum 1967). As might be predicted by 
their pharmacology atypical medicines seem to be more effective in treating 
some of the negative and cognitive symptoms and may be more helpful in 
treating mood symptoms of schizophrenia (Darba et al. 2011).   This is because 
they are also serotonin (5-HT) antagonists at the 5-HT2A receptor subtype, they 
mitigate the negative signs and symptoms of schizophrenia by disinhibiting the 
dopamine system in the nigrostriatum and prefrontal cortex (Burns 2001). 
 Approximately a fifth of patients will fail to respond to treatment with 
antipsychotic medication (typical or atypical) and are deemed to have treatment 
resistant schizophrenia (Pantelis and Lambert 2003). These patients should be 
treated with a drug called clozapine. This is a complex to use drug but very 
effective (Pantelis and Lambert 2003). In about one per cent of patients it can 
cause agranulocytosis; consequently patients will require regular blood 
monitoring and should be registered with a clozapine patient monitoring service 
(Atkin et al. 1996). 
 
Side effects 
Antipsychotic medicines can cause a number of side effects.  
 
Extrapyramidal Symptoms  
Typical antipsychotics have diffuse effects blocking dopamine receptors 
throughout the brain. As a consequence they cause a range of dopamine 
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related side effects that include extrapyramidal symptoms (EPS). These include 
dystonia, akathisia and tardive dyskinesia (Hardy and Gray 2012a). The newer 
atypical medicines have lower affinity for dopamine receptors and this results in 
less EPS (Worrel et al. 2000).    
 
Other side-effects 
One study has shown that long-term treatment with antipsychotic drugs is 
associated with lower mortality compared with no antipsychotic use (Tiihonen et 
al. 2009). However, some of the newer antipsychotic drugs have a greater 
propensity to cause physical problems (Nasrallah 2003). They can induce 
endocrine abnormalities (for example, diabetes and galactorrhoea), metabolic 
abnormalities (for example, lipid abnormalities and weight gain) and 
cardiovascular side effects (for example, lengthening of the QT interval on 
electrocardiography) (Holt et al. 2005, Nasrallah 2003, Thakore 2005). 
However, the excess of other CVD risk factors, such as smoking, poor diet and 
physical inactivity mean that the choice of treatment is not a factor for inclusion 
in a lifestyle management programme. These problems are discussed in more 
detail in chapter two.  
 
Other treatment 
Antipsychotic medication is the main treatment of schizophrenia. Additionally 
the authors of a meta-analysis conclude that family intervention should be 
offered to people with schizophrenia who are in contact with carers, and that 
cognitive behavioural therapy (CBT) may be useful for those with treatment 
resistant symptoms (Pilling et al. 2002). This is recognised by the authors of the 
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government guidelines for schizophrenia (NICE 2010a), who recommend 
offering: 
 Cognitive behavioural therapy (CBT) to assist in promoting recovery in 
people with persisting positive and negative symptoms and for people in 
remission.  
 Family intervention to families of people with schizophrenia who live with 
or are in close contact with the service user. This may be particularly 
useful for families of people recently relapsed or are at risk of relapse or 
have persisting symptoms. 
 Arts therapies to assist in promoting recovery, particularly in people with 
negative symptoms. 
 
1.2.2 Bipolar disorder 
Medication is used in bipolar disorder to treat depression and mania, and to 
prevent depressive and manic symptoms from returning. Therefore, many 
patients require treatment with more than one medication. The medications 
used to treat bipolar disorder include: 
 Antipsychotic medication as described in 1.2.1 
 Valproate 
 Lithium 
 Lamotrigine 
 Carbamazepine 
 Selective serotonin Reuptake Inhibitors (SSRIs) 
 Benzodiazepines 
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Valproate 
Valproate (2-propylpentanoic acid) is an anticonvulsant drug used in the 
treatment of bipolar disorder (Fisher and Broderick 2003). It has a number of 
side effects including weight gain.  
 
Lithium 
Lithium is used for the prophylaxis of bipolar disorder (Cookson 2001). It is 
highly effective at preventing relapse (particularly manic episodes) and reducing 
the risk of suicide (Cipriani et al. 2005, Geddes et al. 2004). Due to the risk of 
toxicity lithium should only be started under specialist supervision and thyroid 
function, creatinine and plasma lithium levels need to be monitored regularly 
(Geddes et al. 2004). Lithium can also cause weight gain. 
 
Lamotrigine 
Lamotrigine is an anticonvulsant used to prevent depressive episodes 
associated with bipolar disorder (BNF: British Medical Association, 63, 2012a). 
Side effects include nausea, vomiting, diarrhoea, dry mouth, aggression, 
agitation, headache, drowsiness, dizziness, tremor, insomnia, ataxia, back pain, 
arthralgia, nystagmus, diplopia, blurred vision (BNF, 63, 2012a). 
 
Carbamazepine 
Carbamazepine is an anticonvulsant used for the prophylaxis of bipolar disorder 
(BNF, 63, 2012b). Side effects include dry mouth, nausea, vomiting, oedema, 
ataxia, dizziness, drowsiness, fatigue, headache, hyponatraemia, blood 
disorders, dermatitis and urticaria (BNF, 63, 2012b). 
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Selective serotonin Reuptake Inhibitors (SSRIs) 
SSRIs are antidepressants which work by inhibiting pre-synaptic reuptake of the 
neurotransmitter serotonin (5-hydroxytryptamine, 5HT). This increases the 
availability of serotonin at synapses and enhances stimulation of postsynaptic 
neurones. The increased synaptic serotonin causes changes in receptor 
sensitivity which helps to reduce depression. Side effects include headache, 
changes in sleep pattern, gastrointestinal function and sexual functioning (BNF, 
63, 2012c). The use of SSRIs in bipolar disorder is controversial as they can 
cause some patients to rebound into mania (Goodwin 2009). 
 
Benzodiazepines 
Benzodiazepines are used as anxiolytics, sedatives, hypnotics, anticonvulsants, 
and/or skeletal muscle relaxants (BNF, 63, 2012d). They are helpful in bipolar 
disorder for the treatment of behavioural disturbance or agitation; they should 
not be used for long periods because of the risk of dependence (BNF, 63, 
2012d). 
 
Acute or mixed episode 
An acute manic or mixed episode of bipolar disorder may require treatment with 
a number of medications. Some patients will also be admitted to hospital or 
receive care from a crisis or home treatment team. Goodwin (2009) explains 
which drugs to use in each phase:  
 Antipsychotics to  bring mania under control and treat any psychosis 
(alternative treatments are valporate, lithium and carbemazepine)  
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 Sleep problems and behavioural disturbances can be treated with PRN 
benzodiazepines  
 Antidepressant medication should be gradually stopped in patients 
experiencing a manic episode of illness to prevent further mania 
 
Psychological treatments are not effective in this phase of the illness (Hardy 
and Gray 2012a). 
 
Acute depressive episode 
Goodwin (2009) describes how a patient should be treated in this phase  
 SSRIs - but to prevent a switch to mania patients can be co-prescribed 
lithium, valporate or an antipsychotic. Then after 12 weeks taper 
treatment off and stop  
 Lamotrigine may be a potentially helpful treatment  
 
There is compelling evidence from a number of randomised controlled trials that 
quetiapine is effective in the treatment of bipolar depression (including any 
anxiety) and does not appear to switch patients into mania (Calabrese et al. 
2005).  
 
Long term treatment 
Long term treatment (for at least two years following the first episode of illness) 
is required in bipolar disorder to prevent the reoccurrence of both the 
depressive and manic poles of the illness (Hardy and Gray 2012a). 
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Psychological therapies 
As an addition to medication, psychosocial treatments are helpful in providing 
support, education, and guidance to people with bipolar disorder and their 
families (NICE 2006). Psychosocial interventions can lead to increased mood 
stability, fewer hospitalisations, and improved functioning in several areas 
(NICE 2006). Therapies that have been found to be helpful are described in 
figure 1.4. 
 
Figure 1.4 Psychological therapy  
 
 
After an acute episode 
Consider individual structured psychological interventions, such as cognitive 
behavioural therapy, in addition to prophylactic medication for people who are 
relatively stable, but may have mild to moderate affective symptoms. The 
therapy should normally be at least 16 sessions over 6–9 months and: 
 
 Include psychoeducation, the importance of a regular routine and 
 concordance with medication 
 
 Cover monitoring mood, detecting early warnings and strategies to     
prevent progression into full-blown episodes 
 
 Enhance general coping strategies 
 
 Be delivered by people who have experience of patients with bipolar 
disorder 
 
Consider a focused family intervention if appropriate. This should last 6–9 
months, and cover psychoeducation, ways to improve communication and 
problem solving. 
 
Psychosocial support 
 Consider offering befriending to people who would benefit from additional 
 social support, particularly those with chronic depressive symptoms. 
 
 This should be in addition to pharmacological and psychological 
treatments, and should be by trained volunteers providing, typically, at 
least weekly contact for between 2 and 6 months. 
 
 
NICE (2006). 
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1.3 Summary of chapter 
In this chapter I have described the two main conditions included on the primary 
care SMI disease register. I have explained the usual treatment offered to this 
group and some of the possible side effects of medication. 
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Chapter two: Why do people with severe mental illness die so 
young? 
 
In this chapter I discuss the increased mortality of people with SMI when 
compared to the general population and the physical conditions which are more 
prevalent in this group. The healthcare professionals’ responsibilities to screen 
for CVD risk are explained. 
 
2.1 The increased mortality of people with SMI 
The earliest study of mortality in people with SMI was in 1841 by Farr (Singer 
2001). Very early studies observed patients in hospitals and found increased 
mortality from diseases such as tuberculosis, pneumonia and gastrointestinal 
infections (Shepherd 1957). Excess mortality of people with SMI from these 
causes decreased with improved facilities (Norris 1959).  
 In epidemiological research, disease frequency is measured in a number 
of standardised ways. These include:  
 Relative risk (RR) is the ratio that denotes how much more likely a 
person in one group are likely to die at a certain age than someone in the 
general population (Richards and Donaldson 2009). A score of greater 
than one means the risk is increased. 
 Standardised Mortality Ratio (SMR) is the ratio of deaths observed to 
those expected on the basis of the mortality rates of some reference 
population (Liddell 1984). If the SMR is higher than one, then there are a 
higher number of deaths than expected. Standardised mortality ratios 
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can also be reported around 100. That means that values greater than 
100 indicate increased mortality. 
 Years of Potential Life Lost (YPLL) provides information about the risk of 
premature death by using the difference between the patient age at 
death and the current life expectancy, or mean survival age for living 
cohorts of the same age during the year of death (Colton and 
Manderscheid 2006). 
 Hazard Ratios reflect the analysis of time survived. A hazard ratio of one 
corresponds to equal survival times; a hazard ratio of two implies that at 
any time twice as many patients with SMI died compared with the 
comparator group (Duerden 2009). 
 
Relative risk (RR) 
A study in America (Babigian and Oderoff 1969) showed that the mortality in 
people with SMI was increased; with the relative risk of death being three times 
more than the general population. Innes and Millar (1970) carried out a study in 
Scotland, their results showed a relative risk of two. Harris and Barraclough 
(1998) looked at 152 reports to identify whether people with mental illness still 
died prematurely. They examined 27 different categories of mental disorder and 
eight treated categories. They concluded that all mental disorders have an 
increased risk of premature death but people with schizophrenia have a higher 
risk from unnatural causes (suicide and accidents). Joukamaa et al. (2006) 
carried out baseline comprehensive health assessments to predict the mortality 
of 7,217 people with schizophrenia treated with antipsychotics. The relative 
mortality risk between those with schizophrenia and others was 2.84. These 
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results are similar to those studies carried out 36 and 37 years earlier by 
Babigian and Oderoff (1969) and Innes and Millar (1970) suggesting that life 
expectancy for people with SMI has increased in line with the general 
population. 
 
Standardised mortality ratio (SMR)  
Mortensen and Juel (1993) studied the psychiatric case register of a Danish 
hospital and the central person registry to find out the cause of death in people 
first admitted with schizophrenia. They studied the records of 9,156 people with 
schizophrenia and found increased mortality. Fifty percent of deaths were 
caused by suicide. Pooled data showed an SMR of 3.51 and of those, avoidable 
mortality (including CVD, suicide, accidents) was SMR 2.19. This was 
consistent with the findings of a meta-analysis by Brown et al. (1997).  The 
authors found a large increased mortality from suicide and a moderate 
increased mortality from natural causes. In contrast, Brown et al. (2000) studied 
370 patients with schizophrenia over 13 years in order to measure SMR and 
find out reasons for excess mortality. All cause SMR was 2.98. Two thirds of the 
deaths were due to physical diseases. Colton and Manderscheid (2006) had 
similar findings; they compared the mortality rates in people with mental illness 
and the general population using submitted records from eight different states in 
the United States of America. All cause SMR ranged between 1.2 and 4.9 in 
different states. The authors concluded that the majority of the excess 
premature deaths in people with SMI were due to CVD, not suicide. A later 
systematic review of 37 studies drawn from 25 different nations explored the 
distribution of standardized mortality ratios (SMRs) for people with 
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schizophrenia (Saha et al. 2007). Saha et al. found that most of the major 
causes-of-death categories were elevated with the median SMR being 2.58. In 
this analysis, suicide was associated with the highest SMR but the authors note 
that the SMRs for all-cause mortality have increased during recent decades. 
Hoang et al. (2011) studied the records of people with schizophrenia and 
bipolar disorder discharged from hospital. They wanted to investigate whether 
the mortality gap has reduced in recent years between people with 
schizophrenia or bipolar disorder and the general population. They reported that 
the SMR for people with schizophrenia was 2.2 and 1.9 for people with bipolar 
disorder. There was an increase in ratios for deaths caused by circulatory and 
respiratory disease. This group of studies illustrates that in the last two 
decades, the SMR of people with SMI has remained largely unchanged. 
 
Years of Potential Life Lost (YPLL)  
Colton and Manderscheid (2006) also measured YPLL in addition to SMR in 
their study; this ranged from a mean of 13.5 to 32.2. Similarly, using a large 
secondary mental healthcare database in southeast London linked to national 
mortality returns, Chang et al. (2011) found that life expectancy in people with 
SMI was reduced by 12-19 years. Laursen (2011) had the same results. He 
used the entire Danish population as a cohort to estimate the life-expectancy of 
people with schizophrenia and bipolar disorder and make a comparison to the 
general population. Life-expectancy was 18.7 years shorter for men with 
schizophrenia and 16.3 years for women. For men with bipolar disorder it was 
13.6 years and for women, 12.1 years. Wahlbeck et al. (2011) carried out a five 
year consecutive cohort study of people admitted to hospital for mental 
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disorders in Denmark, Finland and Sweden. They wanted to evaluate trends in 
health outcomes of people with SMI. They found that men with mental disorders 
live 20 and women 15 years less, than the general population. These studies 
show that despite the general population living longer (Wang et al. 2012) people 
with SMI still have reduced life expectancy. 
 
Hazard ratios (HR) 
Osborn et al. (2007) carried out a retrospective cohort study with the objective 
of estimating the excess mortality of people with SMI and the contribution of 
antipsychotic medication, smoking, and social deprivation. A total of 46,136 
people with SMI and 300,426 without SMI were selected for the study. Hazard 
ratios were 3.22 for coronary heart disease (CHD) mortality and 2.53 for stroke 
deaths in people with SMI under 50 years of age compared with controls. 
Osborn et al. (2007) also found that patients taking a higher prescribed dose of 
antipsychotics predicted a greater risk of mortality from CHD and stroke. The 
authors explain that the dose response observed in the relationship between 
antipsychotic medication and CHD mortality might be due to adverse effects of 
higher doses. Alternatively, the dose could be an indicator of the severity of the 
mental illness, which might in turn affect mortality through diet and exercise, 
intensity of tobacco use or the stresses of psychiatric symptoms. This contrasts 
with the findings of Tiihonen et al. (2009), who found that long-term treatment 
with antipsychotic drugs is associated with lower mortality compared with no 
antipsychotic use in people with SMI. However, Osborn et al, is describing dose 
of treatment in a cross sectional study while Tiihonen et al. is reporting the 
duration of treatment in a cohort study. 
  
47 
 
 Healy et al. (2012) compared data from two epidemiologically complete 
cohorts of patients (1875-1924 and 1994-2010). The survival analysis shows 
the absolute mortality in the historical period was higher than today, but the 
actual years of life lost in the historical cohort are less than those lost now. 
 I have described a number of studies which measure the mortality of 
people with SMI in different ways (relative risk, standardized mortality ratio, 
years of potential life lost, hazard ratio). The presented studies show that YPLL, 
SMR, RR and HR for mortality remain as high as in the 1970s, and that the 
physical causation is reminiscent of the pre ninety-fifties. 
 
2.2  Suicide 
Suicide is one of the top ten causes of death world wide and one of the three 
leading causes of death in people aged between 15-35 years (World Health 
Organization 2000). However, most people with SMI (i.e those with 
schizophrenia or bipolar disorder) neither attempt nor die by suicide (Litts et al. 
2008). It is estimated that the lifetime prevalence of suicide is 6-15% for people 
with mood disorders and 4-10% for those with schizophrenia (World Health 
Organization 2000).  
 A research study (Dutta et al. 2010) involving almost 2,723 patients in 
the UK who presented with their first psychotic symptoms between 1965 and 
2004 found that the rate of suicide was highest in the first year following 
diagnosis (12 times greater than the general population). This risk reduced but 
was still four times greater than the general population ten years after diagnosis 
when there may be less intense monitoring. A key aim of this study was to 
dispute the widely held view that 10-15% of people with SMI could commit 
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suicide. They found that 1.9% took their own lives within an average period of 
11.5 years after their first episode of psychosis. 
 Leitner et al. (2008) carried out a systematic review of 24 studies to 
provide a comprehensive overview of the known effectiveness of interventions 
aimed at preventing suicidal behaviour and ideation both in key risk groups and 
in the general population. In the studies evaluating treatment for people with 
schizophrenia or schizoaffective disorder the focus was almost exclusively on 
treatment with clozapine. The outcomes for treatment with clozapine were 
universally favourable but none of the available studies chose to evaluate 
clozapine against either a placebo or treatment as usual. Only three of five 
studies provided statistical evidence of reductions in suicidal behaviour. Only 
four studies in this review specifically evaluated interventions for people with 
bipolar disorder. All of these studies evaluated treatment with lithium, either as a 
main treatment or as an adjunct. The two studies evaluating lithium alone 
reported statistically significant reductions in suicide and attempted suicide 
(Goodwin et al. 2003) and in 'suicidal acts' (Tondo et al. 1998). One study 
evaluated lithium with a limited range of other pharmaceutical interventions in 
addition to interpersonal and social rhythm therapy (Rucci et al. 2002). They 
reported no significant impact of the combined therapy on any measure of 
suicidal behaviour or suicidal ideation. One study (Baker et al. 2004) compared 
treatment using olanzapine plus lithium with olanzapine plus valproate. This 
failed to find any significant differences between the two treatments though 
there was a statistically significant reduction in suicidal ideation. 
 Suicide prevention has narrowly focused on identifying proximate, 
individual-level risk factors, rather than thinking about population mental health 
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in terms of complex social and ecological relations (Knox 2004). To prevent 
suicide in SMI the focus should be on recognizing risk factors as well as 
adopting strategies to reduce the stigma associated with having a mental illness 
(United Nations 1996). Galon and Graor (2012) report from their study of 32 
people with SMI that the process of engagement in primary care includes 
mattering, being perceived as credible and capable, and working together.  
Therefore managing people with SMI in primary care in the same way as those 
with other long term physical conditions has the potential to limit these risk 
factors because the focus of managing long term physical conditions is to  
engage the patient as a partner in care (Long term conditions Quality Innovation 
Productivity and Practice Workstream 2012)... 
 
2.3  Higher prevalence of co-morbidities 
Oud and Meyboom-de Jong (2009) carried out a systematic review of 15 
original research articles on somatic co-morbidity in patients suffering from 
psychotic disorders. They found that the prevalence of chronic physical 
illnesses among patients with SMI was as high as 74%.  
 In their comprehensive review of the literature, Leucht et al. (2007) 
highlighted the conditions which had good and very good evidence for 
increased risk in people with SMI (see table 2.1). I have discussed each 
disease. 
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Table 2.1 Physical Health - prevalence 
Disease category  Physical diseases with increased frequency  
Bacterial infections and 
mycoses 
Tuberculosis (+) 
Viral diseases HIV (++), hepatitis B/C (+) 
Neoplasms Obesity-related cancer (+) 
Musculoskeletal diseases Osteoporosis/decreased bone mineral density (+) 
Stomatognathic diseases Poor dental status (+) 
Respiratory tract diseases Impaired lung function (+) 
Urological and male 
genital diseases 
Sexual dysfunction (+) 
Female genital diseases 
and pregnancy 
complications 
Obstetric complications (++) 
Cardiovascular diseases 
Stroke, myocardial infarction, hypertension, other 
cardiac and vascular diseases (++) 
Nutritional and metabolic 
diseases 
Obesity (++), diabetes mellitus (+), metabolic 
syndrome (++), hyperlipidemia (++) 
(++) very good evidence for increased risk, (+) good evidence for increased 
risk 
Leucht et al. (2007) 
  
 
2.3.1 Tuberculosis 
There are very few epidemiological studies on the association between 
schizophrenia and bacterial infections. Single studies from Japan (Ohta et al. 
1988) and the United Kingdom (Baldwin 1979) found a higher incidence of 
tuberculosis (TB) among patients with schizophrenia compared with the general 
population. Ohta et al. studied out patients living in a city and Baldwin looked at 
the statistical linkage between diseases using the Oxford Record Linkage Study 
from which in-patient data could be extracted.  Reports from Israel (Zeenreich et 
al. 1998) and Russia (Fisher et al. 1996) were also indicative of an increased 
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prevalence of TB in psychiatric hospitals.  As most of these studies were carried 
out in hospital settings, it could be argued that it is not the mental illness that is 
the risk factor for developing TB but the patients’ environment. This view is 
shared by Cavanaugh et al. (2012) who recently suggested that assisted living 
accommodation and residential homes (commonly housing people with SMI) 
may lack TB prevention infection control procedures. They report the example 
of one such facility for adults with mental illness in America. In 2008, 15 of the 
residents and three of the non residents contracted tuberculosis. Residents 
were not routinely screened for medical problems.  
 
2.3.2 Lung function 
One study in the United Kingdom (Filik et al. 2006) found higher rates of lung 
function impairment in people with schizophrenia compared to the general 
population. The prevalence of chronic respiratory problems such as chronic 
obstructive pulmonary disease (COPD) is also significantly higher in people with 
SMI (Himelhoch et al. 2004, Sokal et al. 2004, Chafetz et al. 2005, Carney et al. 
2006, Copeland et al. 2007, Batki et al. 2009). A systematic review found that 
COPD was the most prevalent disease in this population (Oud and Meyboom-
de Jong 2009). 
 
2.3.3 Human immunodeficiency virus (HIV) 
There are many studies on the association between schizophrenia and HIV 
(Leucht et al. 2007). These show that the prevalence of HIV positivity in people 
with schizophrenia is generally higher than in the general population but is very 
variable. This may be because some studies were performed in high risk areas 
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(such as the East coast of the United States) while studies in other parts of the 
world (e.g. Asia) showed lower HIV prevalence. Factors such as the high 
frequency of substance abuse, sexual risk behaviours and a reduced 
knowledge about HIV-related issues could account for the higher prevalence. A 
study of 430 psychiatric outpatients in the United States, (Carey et al. 2004) 
found signiﬁcant rates of risky sexual behaviour in people with SMI particularly 
in those with mood disorders. 
 More recently, an American study examined 6,417,676 patients who were 
without HIV in 2001 (Prince et al. 2012). They compared the number of new 
diagnoses of HIV in 2002–2004 between people with SMI, a substance use 
disorder, and other psychiatric comorbidity. After controlling for substance 
abuse or dependence and other factors, their analyses indicated that the odds 
of new HIV/AIDS diagnoses among people with or without SMI did not differ 
significantly. Compared with people without a substance use disorder or SMI, 
individuals with a substance use disorder but without SMI were 3.1 times more 
likely, and those with both substance abuse or dependence and SMI were 2.1 
times more likely, to receive a new HIV diagnosis. However, people with SMI 
without a substance use disorder were 23% less likely than people without SMI 
or a substance use disorder to receive a new HIV diagnosis. A number of earlier 
studies have identiﬁed possible reasons why it is the people with a substance 
use disorder who may be more vulnerable to HIV and STI (Cournos et al. 1994, 
Gray et al. 2002). These include: poor decision-making about safe sex and the 
increased likelihood of having sex with someone who is injecting drugs (due to 
intoxication); hypersexuality; neglecting to use a condom; vulnerability to 
coercion for sex; and selling or swapping sex for cash or drugs.  
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2.3.4 Hepatitis B/C 
There has been little research carried out on hepatitis in psychiatric disorders, 
but studies from six different countries showed an increased prevalence of 
hepatitis in people with schizophrenia compared to the general population 
(Chaudhury et al. 1994, Cividini et al. 1997, Rosenburg et al. 2001, Said et al. 
2001, Nakamura et al. 2004, Kalkan et al. 2005). A later study illustrated similar 
findings to those relating to HIV prevalence; 2.5% of participants with SMI and a 
substance abuse disorder were infected with hepatitis compared to 0.6% of 
patients without a substance abuse disorder (Rosenburg et al. 2005). 
 
2.3.5 Sexual dysfunction 
There are a number of relatively large studies that show sexual dysfunction to 
be more frequent in people with schizophrenia compared to the rest of the 
population (Aizenberg et al. 1995, Smith et al. 2002. McDonald et al. 2003). The 
antipsychotic drugs prescribed to treat SMI are associated with sexual 
dysfunction as they can cause hyperprolactinaemia (Kasperek-Zimowska et al. 
2008). The propensity to cause hyperprolactinaemia differs between 
antipsychotics as a result of differential dopamine D2 receptor-binding affinity 
and ability to cross the blood–brain barrier (Holt and Peveler 2011). This side 
effect has a significant negative impact on the patients’ satisfaction with 
treatment and adherence (Hippisley-Cox et al. 2007). 
 
2.3.6 Obstetric complications 
There are many studies that demonstrate increased occurrence of obstetric 
complications among mothers with schizophrenia (De Hert et al. 2011a). Most 
  
54 
 
women with SMI cannot stop taking their medication as this would interfere with 
their activities of daily living, especially taking care of a baby (Einarson and 
Boskovic 2009). However, so far, there is no definitive association between the 
use of antipsychotics during pregnancy and an increased risk of birth defects or 
other adverse outcomes (Trixler et al. 2005, Einarson and Boskovic 2009). 
Therefore it may be the high rates of smoking, the use of illicit drugs and 
alcohol, and low socio-economic status that play a role in causing obstetric 
complications (Bennedsen 1998). 
 
2.3.7 Osteoporosis 
People suffering from osteoporosis have decreased bone mineral density and 
are more likely to suffer from fractures (Halbreich and Palter 1996). Leucht et al. 
(2007) found thirteen studies which consistently established that more people 
with schizophrenia had osteoporosis compared to normal controls (Baastrup et 
al. 1980, Ataya et al. 1988, Delva et al. 1989, Halbreich et al. 1995, Keely et al. 
1997, Bergemann et al. 2002, Bilici et al. 2002, Zhang-Wong and Seeman  
2002, Abraham et al. 2003, Liu-Seifert et al. 2004, Meaney et al. 2004, Hummer 
et al. 2005, Kishimoto et al. 2005, O’Keane and Meaney 2005). Most of the 
studies examined had very small samples, the smallest cohort being just 10 
patients and the largest 402. Despite this knowledge, there is evidence that 
people with schizophrenia receive less care for their osteoporosis than age-
matched controls (Bishop et al. 2004). 
 Reduced bone mineral density can be caused by a sedentary life style, 
lack of exercise, smoking, alcohol and drug abuse, dietary and vitamin 
deficiencies, decreased exposure to sunshine and polydipsia inducing 
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electrolyte imbalance; these are behaviours frequently chosen by people with 
schizophrenia (Halbreich and Palter 1996). Additionally, many antipsychotic 
drugs increase prolactin levels which can cause osteoporosis (Holt and Peveler 
2011). 
 A more recent meta-analysis (De Hert et al. 2011a) has found further 
studies which confirm the increased prevalence of osteoporosis in people with 
mental illness, particularly those taking antipsychotics. However, they report 
that data describing the epidemiology of osteoporotic fracture and 
antipsychotics in patients with SMI are limited and there are some conflicting 
results.  
 
2.3.8 Cancer 
Studies relating to cancer and people with schizophrenia have conflicting 
findings. Some have established that there is actually a decreased risk of 
cancer in this population (Barak et al. 2005, Dalton et al. 2005, Goldacre et al. 
2005, Grinshpoon et al. 2005, Dalton et al. 2004, Lichtermann et al. 2004, 
Dalton et al. 2003, Cohen et al. 2001, Lawrence et al. 2000, Mortensen 1994, 
Gulbinat et al. 1992, Mortensen 1992, Mortensen 1989, Dupont et al. 1986, 
Nakane et al. 1986, Driscoli et al. 1978). The authors of these studies 
speculated that genetic factors that may lead to schizophrenia could protect the 
person from cancer. Other theories are that certain antipsychotic drugs may 
prevent tumours growing (Driscoli et al. 1978), or frequent admissions to 
hospital that provide good medical care and less exposure to urban air 
pollutants may be protective (Mortensen 1989, Grinshpoon et al. 2005, 
Goldacre et al. 2005, Dalton et al. 2003). In contrast, a large study carried out in 
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Finland found an increased cancer risk in patients with schizophrenia 
(Lichtermann et al. 2004). The results are also contradictory when examining 
studies looking at specific cancer sites. For example, some studies show 
decreased risks of lung cancer in people with schizophrenia (Mortensen 1989, 
1994) while others show increased risks (Lichtermann et al. 2004, Grinshpoon 
et al. 2005).  Prostate cancer is an exception, the studies consistently found this 
to be rarer in patients with schizophrenia compared to the general population 
(Barak et al. 2005, Dalton et al. 2005, Goldacre et al. 2005, Grinshpoon et al. 
2005, Lichtermann et al. 2004, Lawrence et al. 2000, Mortensen 1992, Dupont 
et al. 1986). 
 More recently, in a cohort analysis within a large UK primary care 
database, the incidence of colo-rectal, breast and lung cancer and of all 
common cancers, did not differ significantly in people with SMI, including 
schizophrenia, compared with people without SMI (Osborn et al. 2013). It is 
worth noting that people with SMI are less likely to get screened for cancer. For 
example, a number of studies have shown that in comparison to the general 
population, women with schizophrenia were less likely to have received a 
mammogram in the last two years (Chochinov 2009, Carney and Jones 2006, 
Werenke 2006, Druss 2002).  
 Turning from incidence of cancer to mortality from cancer, one study has 
shown that having a SMI does not increase the risk of death from the seven 
most common cancers in the UK (Osborn et al. 2007). 
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2.3.9 Poor dental status 
There are a number of studies which highlight the poor dental status of people 
with schizophrenia (Thomas et al. 1996, Velasco et al. 1997, Kenkre and 
Spadigam 2000, Lewis et al. 2001, McCreadie et al. 2004, Tang et al. 2004, 
Velasco-Ortega et al. 2005).  Caries, gingivitis and periodontal disease may be 
caused by poor diet, neglecting oral hygiene and smoking; behaviours which 
are common in people with schizophrenia (Frielander and Marder 2002). In 
addition, antipsychotics, antidepressants and mood stabilisers can cause 
reduced saliva flow which causes additional risk (Frielander and Marder 2002).  
 
2.4 Cardiovascular disease  
The most common cause of premature death in people with SMI is CVD 
(Hennekens et al. 2005). Multiple risk factors for CVD are significantly increased 
in this patient group (Osborn et al. 2006). People with SMI have a higher risk of 
developing metabolic syndrome (prevalence of 36%) and there is a much higher 
prevalence of diabetes mellitus (9–14%) than the general population (Holt and 
Peveler 2010, Oud and Meyboo-de Jong 2009). 
 CVD is a term mainly used to describe disorders affecting the heart 
and/or the arteries and veins that are associated with atherosclerosis (the build 
up of fatty deposits and debris inside blood vessels). CVD, such as coronary 
heart disease and peripheral artery disease, are long term conditions but acute 
events such as myocardial infarction and stroke can occur suddenly when a 
vessel supplying blood to the heart or brain becomes blocked or bursts.  
 It is the combination of lifestyle factors (McCreadie 2003), poorer 
physical healthcare (Thornicroft 2011) and the side-effects of antipsychotic 
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medication (De Hert et al 2009a) which result in the high incidence of CVD in 
people with severe mental illness.  
 
2.4.1 Risk factors for cardiovascular disease 
Family history and ageing are the strongest risk factors for developing CVD. 
The most important behavioural risk factors for CVD are unhealthy diet, physical 
inactivity and tobacco use, which together cause about 80% of coronary heart 
disease (CHD) and stroke (World Health Organization (WHO) 2011). The 
effects of these unhealthy behaviours can contribute to metabolic risk factors 
such as raised blood pressure, raised blood glucose and cholesterol, and 
obesity. Therefore, public health initiatives focus on decreasing the 
development of CVD by encouraging people to follow a healthy diet, avoid 
smoking, exercise regularly, control blood pressure and blood glucose, and 
lower blood cholesterol. Underlying determinants of CVD may include poverty, 
stress and hereditary factors (WHO 2011). Risk factors for CVD can be divided 
into those that cannot be modified and modifiable types. 
 
Risk factors that cannot be modified 
Risk factors that cannot be modified are those that a patient cannot change, 
such as age, gender, ethnicity and genetics. 
 
Age and gender 
In the general population, the incidence of CVD increases with age (World 
Heart Federation 2012). CVD is more common in males than females up to the 
age of 65, when the incidence equalises across the genders (World Heart 
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Federation 2012). Men aged 35 to 44 years are more than six times more likely 
to die from CVD than their female counterparts of the same age, although 
mortality due to CVD equalises in men and women over 75 years of age 
(Mercuro et al. 2010). In comparison, in a study of 46,163 people with SMI 
(Osborn et al 2007), risk of death from CHD was increased between the ages of 
18-75 years but did not increase further over the age of 75. The study also 
revealed that risk of stroke was increased in people with SMI people aged 18-
49 years, but this increased risk disappeared in people aged over 50 years 
(Osborn et al. 2007).  
 
Ethnicity 
Risk factors vary significantly by ethnic group; for example, atherosclerotic 
disease and CHD are relatively rare in black Africans and black Caribbeans (Lip 
et al. 2007). Despite this group having an increased risk of glucose intolerance, 
very low density lipoprotein (VLDL), small dense LDL, and lower triglyceride 
concentrations than in Europeans, the latter does not increase to the same 
extent in the presence of glucose intolerance (Chaturvedi 1994). In contrast, the 
prevalence rates of CVD in South Asians are at epidemic proportions (Lip et al. 
2007). Risk factors such as smoking, blood pressure, obesity, and cholesterol 
vary between subgroups of South Asians, some levels are equivalent to, or 
lower than, a comparable European population; however, levels of glucose 
intolerance, central obesity, fasting triglyceride, and insulin are uniformly 
elevated in comparison (McKeigue 1991). 
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Family history 
Individuals with a family history of CVD are at greater risk of an early CVD event 
(Williams et al 2001). A positive family history is defined as having a father 
diagnosed with CVD younger than 55 years of age or a mother diagnosed 
younger than 65 years of age (Wood et al 1998). 
 
Modifiable risk factors 
Modifiable risk factors are within the patient’s control, such as obesity, smoking, 
dyslipidaemia, physical activity, diet, blood pressure, alcohol intake and 
diabetes management.  
 Several antipsychotic drugs, particularly the atypicals such as clozapine 
and olanzapine, appear to contribute to cardiometabolic risk. In patients 
maintained on some of these antipsychotics, rates of metabolic syndrome and 
diabetes (or prediabetes) can exceed 50% (Manu et al. 2012). In contrast, a 
number of studies found that the rate of metabolic syndrome is 10% in patients 
with schizophrenia who are untreated (Manu et al. 2012, Chiu et al. 2010). This 
disparity could be due to the difference in severity of the SMI rather than the 
medication. 
 
Obesity 
There is strong evidence of an association between obesity and 
atherosclerosis, high blood pressure, high total blood cholesterol and type 2 
diabetes (Wilson et al 2002). This is due to an altered metabolic profile, a 
variety of adaptations/alterations in cardiac structure and function as adipose 
tissue accumulates in excess amounts (Poirier 2006). Some antipsychotic 
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medication can cause weight gain (Allison and Casey 2001). One study 
concluded that histamine receptor blockade is the primary cause of 
antipsychotics-induced weight gain and diabetes mellitus (Matsui-Sakata et al. 
2005). However, Holt and Peveler (2009) argue that it is too simplistic to ascribe 
all obesity in people with SMI to their drug treatment. They suggest that the 
development of obesity in SMI results from the complex interaction of the 
genotype and environment of the person with mental illness, the mental illness 
itself and antipsychotic medication.  
 Two recent meta-analyses of patients with schizophrenia and bipolar 
disorder who were systematically monitored found about half were obese 
(Vancomfort et al. 2013, Mitchell et al. 2011).  
 
Smoking 
Smoking rates are high in people with SMI. Two meta-analyses of patients with 
SMI found about half smoked (Vancomfort et al. 2013, Mitchell et al. 2011). 
More recently, a study showed the same results, with approximately 50% of 
people with SMI smoking compared with 28% of the general population (Osborn 
et al. 2013). Patients with SMI have reported an improvement in their symptoms 
when using smoking to self medicate (Johnson et al. 2010). This may be due to 
an increased dopamine release in the pre-frontal cortex which alleviates 
positive and negative symptoms (Lavin et al. 1996). Additionally there may be a 
reduction in side effects of antipsychotic medication because of the enhanced 
metabolism of these drugs in smokers (Jeste et al. 1996). 
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Dyslipidaemia  
The two major lipids (or fat chemicals) in the blood are cholesterol and 
triglyceride. As they are both insoluble they are transported in the blood by 
lipoprotein structures: low-density lipoproteins (LDL) known as ‘bad’ cholesterol 
and high-density lipoproteins (HDL) known as ‘good’ cholesterol. Dyslipidaemia 
is an abnormally high concentration of lipids or lipoproteins in the blood (it may 
also refer to abnormally low concentrations of HDL cholesterol) and is a risk 
factor for CVD; for example, a prospective cohort study of 7587 women and 
6394 men showed that elevated triglyceride levels were associated with 
increased risk of heart disease and death (Nordestgaard et al. 2007). 
 A primary care study showed that patients with SMI had significantly 
lower HDL-cholesterol levels and higher total cholesterol to HDL-cholesterol 
ratio (Osborn et al. 2006). Two recent meta-analyses of patients with SMI found 
that two in five had hypertriglyceridemia (Vancomfort et al. 2013, Mitchell et al. 
2011).   
 
Physical activity 
Regular physical activity decreases the risk of death from CVD in general and 
death from CHD in particular (Kesaniemi et al. 2001). Regular physical activity 
prevents or delays the development of high blood pressure and reduces blood 
pressure in people with hypertension (Fagard 1999). Exercise can also lower 
blood cholesterol levels and help with weight loss (Cullinane 1982, Kantor et al. 
1987). Low levels of exercise are common among people with SMI (Brown et al 
1999). This may be due to the symptoms of their condition (such as poor 
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motivation) and/or sedative effects of the antipsychotic medication they are 
taking. 
 
Diet  
Diet affects blood cholesterol levels, body weight, blood pressure and blood 
glucose levels (Parikh et al. 2005). Studies have shown that the diets of people 
with SMI tend to be poor, for example lacking in fruit and vegetables 
(McCreadie et al. 2005), high in fat, salt and carbohydrates (Henderson et al. 
2006) and low in nutritional content (Peet 2004). 
 
Blood pressure 
Persistently high blood pressure increases the risk of myocardial infarction and 
stroke (NICE 2011). The two most recent meta-analyses showed that two in five 
people with SMI had hypertension (Vancomfort et al. 2013, Mitchell et al. 2011).  
A study of 800 patients with SMI in the UK found that 34% were hypertensive 
(Eldridge et al. 2011). But in comparison, a UK survey of the general population 
showed that 32% of men and 27% of women aged over 35 were hypertensive 
(The Information Centre for Health and Social Care 2009). Other studies have 
found little overall difference in the blood pressure of people with SMI compared 
with the general population (Osborn et al 2006, Leucht et al. 2007). This may be 
due to the hypotensive effect of antipsychotic medication (Guggar 2011).  
 
Alcohol intake 
Consumption of one to two units of alcohol a day is associated with a reduced 
risk of cardiovascular disease (Rimm et al. 1991, Marmota 1983). Government 
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guidelines in the United Kingdom presently recommend a daily limit, two to 
three units (e.g. 175ml of ABV 13% wine is a standard glass of wine and is 2.3 
units) for women and three to four units for men (e.g. one pint of ABV 5.2% beer 
is 3.1 units) (Drinkaware 2011). Excessive alcohol intake is associated with 
increased all-cause mortality (Vogel R 2002). There is little recent evidence 
regarding alcohol and people with SMI. The National Psychiatric Morbidity 
Survey in England found that 16 per cent of people with schizophrenia were 
drinking over the recommended limits for that time of 21 units of alcohol for men 
and 14 units or alcohol for women a week (Meltzer et al. 1996). A population 
survey found high alcohol use in people with bipolar disorder (Kessler et al. 
1997). 
 
Psychosocial stress 
There is increasing evidence to support the hypothesis that psychosocial stress 
is an important risk factor for CVD (Bairey Merz et al. 2002). Patients with 
schizophrenia have an impaired ability to adapt to stress (Kudoh et al. 1999).  
 
Diabetes 
CVD is the main cause of death in patients with diabetes, accounting for 50% of 
all diabetes-related mortality and a high proportion of diabetes-related disability 
(Morrish et al 2001). Diabetes occurs in 15% of people with schizophrenia (Holt 
and Peveler 2005) compared with 5% of the general population (Bushe and Holt 
2004). More recent meta-analyses of patients with SMI found one in three 
having metabolic syndrome, diabetes or prediabetes (Vancomfort et al. 2013, 
Mitchell et al. 2011). Risk factors include family history of diabetes, physical 
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inactivity, poor diet, smoking and the metabolic effects of antipsychotic 
medication (Gough and Peveler 2004). Patients with diabetes are three times 
more likely to suffer from depression (Goldney et al. 2004) and/or anxiety 
symptoms (Grigsby et al. 2002). This in turn further increases their risk of CVD 
due to poor self management of their condition (Williams and Pickup 2004). 
 
2.4.2   Prevention of cardiovascular disease  
There are two general strategies for the primary prevention of CVD: the 
population approach, in which population-wide changes in risk factors are 
made, and the high-risk approach in which individuals at high risk of the disease 
are identified and targeted for preventive treatment (Rose 1992). The former 
approach works on the assumption that making relatively small reductions in the 
most important risk factors for CVD (for example, blood cholesterol levels and 
blood pressure) throughout the whole population may lead to large reductions in 
CVD burden (Strachan and Rose 1991). In the UK, the government has made 
some effort to use this approach by producing policies and guidance for the 
general population regarding both physical activity (Department of Health (DH) 
2011a) and diet (DH 2011b). However, the emphasis of current policy for the 
primary prevention of CVD is mainly placed on strategies to target those at high 
risk, for example health checks for people aged over 40 (DH 2009), diabetes 
annual reviews (British Medical Association and NHS Employers 2011) and 
smoking cessation services (DH 2011c). People with SMI are a high risk group; 
reducing any one of their independent risk factors can lead to a significant 
decrease in CVD risk (Table 2.2).  
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Table 2.2 Reductions in independent risk factors can lead to reduction in 
cardiovascular disease risk  
 
Risk factor Reduction Outcome 
Blood cholesterol1 10% decrease  30% decreased risk of 
cardiovascular disease (CVD) 
High blood pressure 
(>140mm/Hg systolic or 
90mm/Hg diastolic)1 
6mm/Hg reduction in 
diastolic blood pressure  
16% reduction in risk of CVD;  
42% reduction in risk of stroke  
Cigarette smoking1 Cessation 50% reduction in risk of CVD 
Obesity2 4-10kg weight reduction  
 
Decrease in body mass 
index of one unit 
27% reduction in risk of CVD 
 
8% reduction in risk of CVD 
1Hennekens (1998), 2Li et al (2006) 
 
2.5 The physical health check 
A Cochrane Effective Practice and Organisation Care (EPOC) Group Review 
(Tosh et al. 2010) did not identify any randomised trials which assessed the 
effectiveness of physical health monitoring in people with SMI. They concluded 
that guidance is based on expert consensus, clinical experience and good 
intentions. These experts have advocated the need to improve CVD monitoring 
and the provision of risk-factor guidance in people with SMI (Osborn et al. 2011, 
De Hert et al. 2009b, Kilbourne et al. 2007, Barnett et al. 2007). Authors of 
national guidance in the UK suggest that patients with SMI should receive a 
physical health check at least once a year, but recognize that research is 
needed (NICE 2010a, 2006). An annual review offers the opportunity to: 
 Screen for diabetes, hypertension, raised cholesterol levels and other 
risk factors, and then offer prompt treatment to reduce the associated 
risk (Hardy and Gray 2010).  
 Provide ongoing education to reduce the risks associated with poor diet, 
inactivity and smoking (Gray et al. 2009). 
 Carry out a medication review (White and Hardy 2010). 
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2.6  The role of healthcare professional in the prevention of CVD in SMI 
The authors of a qualitative study (including patients with SMI and staff from 
primary care and community mental health teams) suggest that neither primary 
nor secondary care services on their own can provide a comprehensive service 
to prevent CHD in patients with SMI (Wright et al. 2006). This view is shared by 
the charity Rethink; they have developed a tool to help primary and secondary 
care services to work together to monitor and address the physical health needs 
of people affected by mental illness (Rethink 2012).   
 Having written guidance on the prevention of CVD in people with SMI 
should aid healthcare professionals to deliver the appropriate intervention at the 
appropriate time. Eighteen specific sets of guidelines for the medical care of 
patients with severe mental illness or schizophrenia have been published since 
the year 2000 (De Hert et al. 2011). However, it is not clear whether these have 
influenced clinical practice (Mitchell et al. 2012a).  What the guidelines have 
generally not stated is who should take responsibility for monitoring, the minimal 
frequency of monitoring, or how monitoring should be audited. In the United 
States of America, the key guideline was the American Diabetes Association 
(ADA) / American Psychiatric Association (APA) consensus document (2004). 
In the United Kingdom, three key guidelines are in place, namely National 
Institute for Health and Clinical Excellence (NICE) guidelines for bi-polar 
disorder (2006), the revised  NICE schizophrenia guidelines (2010a) and the 
GP contract for primary care (BMA and NHS Employers 2011). The European 
Psychiatric Association (De Hert et al. 2009b) have developed recommended 
actions to prevent CVD in people with SMI by clearly defining what needs to be 
  
68 
 
done when the patient is newly diagnosed, at initiation of treatment and at an 
annual health check.  
 
2.6.1 Primary care 
Primary Care in England is made up of practices which provide comprehensive 
acute and continuing medical care. They are considered to be the usual place 
for people with long term conditions that have an increased risk of CVD (such 
as diabetes) to attend for preventative care (NICE 2006, 2009, 2010a, Osborn 
et al. 2007). Authors of national guidance in England recommend that patients 
with SMI should receive a physical health check at least once a year (NICE 
2006, 2010a). General Practitioners (GPs) in primary care are paid to provide 
CVD screening for this group every fifteen months through the Quality and 
Outcomes Framework (BMA and NHS Employers 2012). (In April 2013 the 
timeframe changed to the last 12 months). Between April 2004 and March 
2011, payment was received if primary care practitioners documented that they 
had completed a review in people with SMI. There should have been evidence 
that the patient was offered screening, routine health promotion and prevention 
advice appropriate to their age, gender and health status, but these were not 
mandatory. This changed in April 2011, payment is now given for recording 
patients’ alcohol consumption, body mass index (BMI), blood pressure, glucose 
and HDL cholesterol level (if over 40 years), and cervical screening within the 
last five years (if within national screening age). Waiting until patients are 40 
years old to check their glucose and cholesterol may mitigate against good care 
as many risk factors can be identified earlier than this age in this patient group 
(De Hert et al. 2011). 
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 Providing health checks for people with SMI in primary care affords the 
opportunity to enhance care integration, coordination, clinician accountability, 
and a sustained partnership in care (Galon and Graor 2012). This may be key 
to assisting individuals to meet their health needs and limit risk factors, thus 
preventing the development and progression of comorbid conditions (Galon and 
Graor 2012).  
 
2.6.2 Secondary care 
Current evidence suggests that mental health nurses do not consider the 
physical health care of their patients as being central to their role, or perceive 
themselves as inadequately trained to provide this aspect of care (Bradshaw 
and Pedley 2012). One study examining the attitudes of mental health nurses 
towards the physical health care of people with SMI (Robson et al. 2012) found 
that they were more positive if they had attended post-registration physical 
health training. However, an integrative literature review found that they are not 
routinely supported by physical health-care education and training (Blythe and 
White 2012). As many patients with SMI have no contact with secondary care 
services (Lester et al. 2004), they would be missed if mental health nurses had 
the responsibility of carrying out all health checks. However, mental health 
nurses are in a strong position to liaise between primary and secondary care 
services (DH 2006a); they should be encouraged to attain the skills required to 
assess and respond to the whole range of health needs in order to improve the 
physical wellbeing of their patients (Royal College of General Practitioners and 
the Royal College of Psychiatrists  2009, Royal College of Psychiatrists 2012, 
DH 2006a). This should include encouraging patients to attend their GP practice 
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for a physical health check or carrying out the health check themselves 
opportunistically.  (NICE 2010a) Additionally mental health nurses should where 
indicated, support patients to attend established lifestyle groups (for example, a 
dieting group meeting or a smoking cessation support group), as well as 
providing ongoing lifestyle advice. For patients unwilling or unable to attend 
primary care, the mental health nurse should carry out the CVD risk screening 
(Royal College of Psychiatrists 2012). It could be worthwhile for secondary care 
services to set up their own lifestyle intervention groups for patients unable to 
participate in those open to the general population. There is some evidence to 
show this would be of benefit for smoking cessation (Evins et al. 2001), weight 
loss (Umbricht et al. 2001) and improved physical fitness (Marzaloni et al. 
2009). 
 
2.7 Barriers to the recognition and management of physical health in 
patients with severe mental illness 
There are a number of barriers to the management of physical health in patients 
with SMI. These can be divided in to patient-related barriers and physician-
related barriers (Figure 2.3) but often they are combination.  
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Figure 2.1 Barriers to management of cardiovascular disease in patients 
with severe mental illness  
 
Patient related barriers  
 Difficulty understanding healthcare advice and/or carrying out the 
required lifestyle changes because of psychiatric symptoms and the 
adverse consequences of mental illness (SMI)  
 Low health literacy  
 Severity of mental illness  
 Less compliant with treatment 
 Unawareness of physical problems as a result of cognitive deficits or 
reduced pain sensitivity associated with antipsychotic drugs 
 Migrant status and/or cultural and ethnic diversity  
 Lack of social skills and difficulties communicating physical needs 
 Missed appointment letters due to disrupted residential status (then seen 
as non-attenders) 
 Frequent changes of address may prevent the formation of relationships 
with clinicians 
 
Primary care physician-related barriers 
 Stigmatisation of people with mental disorders  
 Physical complaints regarded as psychosomatic symptoms 
 Suboptimal quality of care offered by clinicians to patients with SMI: lack 
of assessment, monitoring and continuity of care of the physical health 
status of people with SMI  
 Teams unequipped or underfunded to handle the behavioural and 
emotional problems of patients with SMI 
 See patients with SMI as non-attenders 
 
Adapted from De Hert et al. (2011a) 
  
 Buhagiar et al. (2011) found that despite increased physical disease 
compared with people with non-psychotic mental illness and the general 
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population, people with SMI are likely to devote little attention to their lifestyle 
and physical health needs. The authors concluded this may be because of an 
impaired awareness of the implications of their high risk behaviour rather than a 
lack of motivation. If people with SMI do not consider themselves at risk of 
physical health problems then they may not attend for screening (Campion et al. 
2005). However, if patients attend who are experiencing an acute phase of 
illness or their symptoms are not well controlled, taking this advice on board 
may not be on their agenda (De Hert et al. 2011a). This does make the 
consultation complex,  but other research has shown that a lack of support and 
negative staff attitudes are possible barriers to their participation in lifestyle 
interventions (Roberts and Bailey 2011, Brunero and Lamont 2010).  
 Physician related barriers are not exclusive to primary care 
professionals; an Australian study of mental health workers revealed a sense of 
pessimism about improving physical health in people with chronic mental illness 
(Hyland et al. 2003). In addition, a survey carried out in the UK (Wright et al. 
2006) found that some mental health staff felt that physical health was the remit 
of primary care and that management of disease risk/modifiable risk factors 
would be an inappropriate use of their skills and time. They also felt that 
responsibility for screening for CVD would blur their professional roles and that 
they lacked the expertise and resources to provide an adequate primary 
prevention service for CHD. 
 Healthcare professionals need to consider possible patient barriers for 
each individual (Roberts and Bailey 2011) and should actively promote health 
and offer suitable therapeutic interventions that reduce modifiable risk factors 
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for CVD. They should also consider the barriers that they themselves or their 
organisation may have created in this respect. 
 
2.8  Summary of chapter 
In this chapter I have provided a brief overview of why people with SMI die 
earlier than the rest of the population and the increased prevelance of physical 
illness in this group. I have then focused on the issues pertinent to the aims and 
objectives of the research: CVD in people with SMI; the roles and 
responsibilities of healthcare professionals; and the barriers in relation to this. 
Part of this chapter has been published as: 
Hardy S and Gray R. (2012) Learning Zone: Reducing cardiovascular disease 
risk in patients with severe mental illness. Nursing Standard. 26 (45) 41-48. 
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Chapter three: Considerations of research in primary care  
In this chapter I discuss how taking part in research is relatively new to many 
practice nurses and how this could affect the level of recruitment. 
 
3.1 Background 
Ninety per cent of people's contact with the NHS is through primary care (DH 
2012). Since the new GP contract was established in 2004 (DH 2003) the 
management of many long-term conditions, such as diabetes, depression and 
hypertension has shifted from secondary to primary care and become part of 
the practice nurse role (Macdonald et al. 2008). This shift has led to a 
corresponding increase in primary healthcare research (DH 2006b) and the 
establishment of Primary Care Research Networks. Practice teams are vital in 
this research for both recruitment and intervention purposes (Cooke et al. 
2007). Current policy supports increasing involvement of nurses in this work 
(DH 2006b, UKCRC 2007).  
 The number of patients participating in research supported by the 
National Institute for Health Research (NIHR) Primary Care Research Network 
has almost doubled over the last four years; reaching nearly 150,000 in 2010/11 
(NIHR 2012a). There was considerable reinvestment in research in 
Northampton in 2010 which has led to the increase in research activity. In 2012, 
there were 20 research studies being carried out in primary care in 
Northamptonshire compared to 16 in 2011 (NIHR 2012b). At the start of this 
study in 2009 only three practices in Northamptonshire were engaged in any 
sort of research (NHS Northamptonshire 2010). This meant that being 
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approached to carry out research at this time was not usual practice for most 
healthcare professionals in primary care in Northampton.  
 
3.2 Primary care view of research 
Currently, knowledge of the perceptions and attitudes of practice nurses 
towards undertaking research as part of their clinical work is poor (Davies et al. 
2002, Boase et al. 2012). McCabe and Timmins (2006) suggest that the focus 
of nursing is on getting the work done and is often task orientated; as a result, 
research might not be given high priority in a clinical role such as practice 
nursing. Additionally, the value of primary care nurses’ commitment to the 
success of externally funded research studies is seldom acknowledged 
(Bateman et al. 2006).  
 Boase et al. (2012) found that practice nurses considered it unfair that 
they received no remuneration for absorbing the research work into their normal 
clinical time, despite their employers receiving funding. They reported a feeling 
of isolation in regard to their research role within the practice. What's more, in 
the same study, nurses experienced resentment or concern from other nurses 
in their team where it was perceived that clinical time was being taken up by 
research resulting in increased work pressure overall. On a more encouraging 
note, most of the nurses felt that the experience of taking part in the research 
had positively changed their practice. 
 A low level of enthusiasm by nurses to take part in research can be 
caused if they are not consulted when the decision was made for them to be 
involved (Lock et al. 2006).  
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3.3 Practical issues for research in primary care 
As practice nurses are employed directly by GPs and isolated from their peers, 
this may limit their independence in respect of carrying out any research activity 
(Kajermo et al. 2000). Their autonomy to run clinics varies, as does the time that 
they can allocate to each patient (Noakes and Johnson 2000). In a recent study, 
practice nurses reported that time influenced their engagement with the various 
aspects of the research including the trial process and the delivery of the 
complex intervention (Boase et al. 2012). Lack of work time was the also the 
barrier most frequently mentioned for research in a study by Griffiths et al. 
(2001). This may be exacerbated if GPs employ practice nurses to undertake 
specific tasks and do not support them as researchers (Davies et al. 2002).  
 
3.4 Being an insider researcher 
As I am working in primary care delivering physical health checks to people with 
SMI, I share the characteristics, role, and experience under study. This is 
described as being an insider (Corbin Dwyer and Buckle 2009). For other areas 
of my research I am an outsider to the commonality shared by participants. 
Being an insider researcher could enhance my understanding of the population 
that may not be accessible to someone outside the field (Kanuha 2000) and 
allow me rapid and more complete acceptance by the practice nurses (Corbin 
Dwyer and Buckle 2009). However, the objectivity, reflexivity and authenticity of 
my research could be questioned because it may be viewed that I am too close 
to the project and too similar to those being studied (Kanuha 2000). Role 
confusion can occur in any research study but there is a higher risk when the 
researcher is familiar with the research setting or participants through a role 
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other than that of researcher (Asselin 2003). Good supervision from Professor 
Richard Gray and Dr Katherine Deane will be required to keep my research 
objective.  
 
3.5 Summary of chapter 
In this chapter I have briefly explained how taking part in research is a relatively 
new role for many practice nurses. I have also given details of some of the 
barriers that researchers may find when engaging practice nurses in their 
research and how my being an insider may affect my research. These factors 
have been given consideration when developing the programme of research 
explained in the next chapter. 
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Chapter four: Developing the programme of research 
The aim of this programme of research is to address the physical health needs 
of people with SMI by improving the practice of healthcare professionals in 
primary care. This will be achieved by providing appropriate training. The 
programme of research is called the Northampton Physical Health and 
Wellbeing Project and is also known by the anacronym PhyHWell.  
 
4.1 Research methods 
Before developing the PhyHWell project I studied a number of methods which 
can be used in research. 
 
4.1.1 Design strategies 
Hennekens and Buring (1987) explain that analytical studies can be divided into 
those which are observational or experimental. 
 
Observational studies 
There are three types of observational investigation, the case control study, the 
cohort study and the cross sectional study. In a case control study, a group of 
patients who have a disease and another group of patients are selected. They 
are usually retrospective. A retrospective study looks backwards and examines 
exposures to suspected risk or protection factors in relation to an outcome that 
is established at the start of the study. Retrospective investigations are often 
criticised because error due to confounding and bias are more common than in 
prospective studies. However, there are benefits which include: being relatively 
inexpensive, smaller numbers are required, and they are quick to complete.  
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Cohort studies are usually prospective. Patients are selected on the basis of the 
presence or absence of exposure to a particular factor and then followed for a 
given period of time to observe for outcomes. The outcome of interest must be 
common or the number of outcomes observed will be too small to be statistically 
significant. Cross-sectional studies can be used to describe characteristics that 
exist in a population, but not to determine cause-and-effect relationships 
between different variables. This method is often used to make inferences 
about possible relationships or to gather preliminary data to support further 
research and experimentation. 
 
Experimental studies 
Experimental studies are also referred to as intervention studies or clinical trials.  
The intention is to improve the condition of a patient or a group of patients; for 
example, by evaluating the impact of a programme. They include RCTs, 
controlled non-randomised trials, controlled before-and-after and interrupted 
time series. 
 
4.1.2 Hierachies of evidence 
There are a number of hierarchies of evidence which have been developed to 
rank research methodologies according to their validity (Evans 2002). The 
Scottish Intercollegiate Guidelines Network (SIGN) have developed a hierarchy 
which ranks the evidence for the efficacy of an intervention (figure 4.1). This 
hierachy is used by NICE when reviewing the evidence for their guidelines 
(NICE 2004).  After high quality meta-analyses and systematic reviews (of 
randomised control trials RCTs), RCTs with a very low risk of bias are 
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considered to be the highest standard of research evidence to determine the 
efficacy or effectiveness of a healthcare intervention or service (SIGN 2001). 
However, basing care in mental health solely on evidence from trials has been 
criticized as being unrealistic (Cooper 2003). 
 
Figure 4.1 Evidence of the efficacy of an intervention – did it work? 
Type of evidence 
 
High quality meta-analyses, systematic reviews of RCTs (including cluster 
RCTs), or RCTs with a very low risk of bias 
 
 
Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a 
low risk of bias 
 
 
Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias 
 
 
High quality systematic reviews of, or individual high quality non-randomised 
intervention studies (controlled non-randomised trial, controlled before-and-
after, interrupted time series), comparative cohort and correlation studies with a 
very low risk of confounding, bias or chance 
 
 
Well conducted, non-randomised intervention studies (controlled non-
randomised trial, controlled before-and-after, interrupted time series), 
comparative cohort and correlation studies with a low risk of confounding, bias 
or chance 
 
 
Non-randomised intervention studies (controlled non-randomised trial, 
controlled before-and-after, interrupted time series), comparative cohort and 
correlation studies with a high risk of confounding, bias or chance 
 
 
Non-analytical studies (eg case reports, case series) 
 
 
Expert opinion, formal consensus 
 
 
Adapted from SIGN (2001) 
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4.2 Designing the programme 
When designing this programme of studies I considered the different design 
strategies and came to the decision that a programme of research which 
included a service evaluation would be the most informative. Using service 
evaluation as an approach can have a major impact on future health delivery 
and education and involves an intervention already in use (National Research 
Ethics Service 2009). There has been a plethora of service developments in 
primary care (e.g. DH 2008a) in response to policy drivers in the United 
Kingdom (e.g. DH 2008b, 2006c, Disability Rights Commission 2006).  
 To look at the effect of the training on nurses and patients, I have used 
the Interdisciplinary Chronic Disease Collaboration (ICDC) framework 
(Interdisciplinary Chronic Disease Collaboration 2012) and followed guidance 
from the Medical Research Council’s (MRC) framework for complex 
interventions (Craig et al. 2008). Within these frameworks I have designed the 
programme of research.  
 
4.2.1 Research questions  
From the literature it appeared that people with SMI are not being offered health 
checks in primary care (Roberts et al. 2007). Therefore the design needed to 
answer a number of questions: 
1) Will patients attend for a health check if they are invited? 
2) Are lifestyle interventions used for people with physical illnesses as 
effective when used with the SMI population? 
3) What evidence is there for the efficacy of healthcare professional 
educational outcomes in studies of physical health in SMI? 
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4) Are as many people with SMI being screened for cardiovascular disease 
as people with physical conditions?  
5) What effect will training have on the practice nurses’ motivation to carry 
out physical health checks for people with SMI? 
6) Does training practice nurses to carry out physical health checks for 
people with severe mental illness increase the level of screening for 
cardiovascular risk? 
7) What do patients think about physical health checks?  
 
4.3 Using the Interdisciplinary Chronic Disease Collaboration framework 
to provide earlier detection and management of CVD in people with SMI 
The Interdisciplinary Chronic Disease Collaboration (ICDC) is a motivated team 
of researchers whose overall objective is to improve the health of patients living 
with or at risk of a long term condition. The ICDC team is a novel collaboration 
between health care decision-makers, scientists and educators from 14 key 
disciplines that was formed to examine the issues related to treating patients 
with or at high risk of developing CVD. They have created a framework for 
researchers working with these patients (figure 4.2). SMI is a long term 
condition which carries a high risk of CVD; therefore the framework is 
appropriate with some adaptation for my research (figure 4.3). However, as 
there is little evidence and literature to support this framework I have also taken 
guidance from the Medical Research Council’s (MRC) framework for complex 
interventions (Craig et al. 2008). 
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Figure 4.2 Optimizing health outcomes for people with known chronic 
disease and earlier detection and management of undiagnosed chronic 
disease or its risk factors in patients at high risk of chronic disease.  
 
 
Interdisciplinary Chronic Disease Collaboration (2012) 
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Figure 4.3 Optimizing health outcomes for people with SMI 
 
 
Adapted from the Interdisciplinary Chronic Disease Collaboration (2012) 
 
4.4 The Medical Research Council – complex interventions framework 
Complex interventions are usually described as interventions that contain 
several interacting components. The MRC has updated and extended the 2000 
Framework for complex interventions. The intension of the revised guidance is 
not to be prescriptive but to help researchers, funders, and other decision 
makers to make appropriate methodological and practical choices (Craig et al. 
2008). It has re-emphasised some of the key messages, but also tried to 
address the limitations by providing a more flexible and less linear model of the 
process. Craig et al. suggest that identifying a single primary outcome may not 
make best use of the data; therefore a range of measures will be needed. 
Figure 4.4 summarises the main stages and the key functions and activities at 
each stage and figure 4.5 shows the adaptations for this research. The arrows 
indicate the main interactions between the phases. The stages need not follow 
THEME: to prevent or provide earlier detection of CVD in people 
with SMI by increasing the screening and lifestyle advice given to this 
group. 
 
PHASE ONE:  Establish whether this group will attend and use 
standard interventions; review current evidence; focus on research 
which may affect change in clinical practice; develop training 
package 
 
PHASE TWO: Collect data from audits, questionnaires and interviews 
to assess both medical and non medical barriers to optimizing the 
health outcomes for people with SMI. 
PHASE THREE: Evaluate the data and make recommendations for 
future training, research and policy. 
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a linear or even a cyclical sequence. Reporting is not shown as a separate 
activity, because the authors suggest it should be seen as an important element 
of each stage in the process. 
 
Figure 4.4 MRC key elements of the development and evaluation process 
 
Craig et al. (2008) 
 
Fig 4.5 PhyHWell key elements of the development and evaluation process 
 
 
 
 
 
 
 
 
 
Adapted from Craig et al. (2008) 
Feasibility and Piloting 
Establish whether this group will attend 
and use standard interventions; set up 
audits 
Development 
Review current evidence; focus on 
research which may affect change in 
clinical practice; develop training package 
Evaluation 
Collect and evaluate data to assess both 
medical and non medical barriers to 
optimizing the health outcomes for 
people with SMI. 
 
Implementation 
Dissemination; make recommendations 
for future training, research and policy. 
 
  
86 
 
4.5 A programme of studies  
A programme of studies  involves projects that are complete on their own and 
may be both qualitative and quantitative (Morse 2003). They are then used 
together to form essential components of one research programme (Morse 
2003). This brings together understanding of meaning and context to provide 
fuller discernment and greater transportability of the phenomenon under study 
(Strange and Miller 2006). Each of my studies has been designed and 
conducted to answer a specific question; this provides a more detailed and 
balanced picture of the situation than using one method alone (Altrichter et al. 
2008). A further advantage is that each study maintains its own world view 
(Morse 2003).  The separate studies are reported in concurrent chapters to 
show a logical sequence.  
 Each individual study has been published in a different journal. I intend to 
write a critique that reports the findings of all the studies so that the results of 
the whole programme are published together (Strange and Miller 2006).  
 The programme is divided into three phases using the ICDC framework. 
 
4.5.1  Phase one 
1. Identify whether patients with SMI will attend for a health check if they 
are invited. 
2. Find out if lifestyle interventions used for people with physical illnesses 
are as effective when used with the SMI population. 
3. Search for the evidence for the efficacy of healthcare professional 
educational outcomes in studies of physical health in SMI. 
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4. Develop training for practice nurses to deliver health checks for people 
with SMI (PhyHWell). 
 
4.5.2  Phase two 
1. Find out whether as many people with SMI are being screened for CVD 
as people with diabetes in Northampton.  
2. Find out whether as many people with SMI are being screened for CVD 
as people with diabetes in England.  
3. Determine the effect of the PhyHWell training on the practice nurses’ 
motivation to carry out physical health checks for people with SMI. 
4. Establish whether training practice nurses increases CVD screening and 
lifestyle intervention in people with SMI.  
5. Ascertain the patients’ views about physical health checks.  
 
4.5.3  Phase three 
1. Evaluate the data.  
2. Publish and disseminate. 
3. Make recommendations for future training, research and policy. 
 
4.6 Ethical and research governance issues 
Nurses have a duty to ensure that they provide their patients with safe and 
competent care (Nursing and Midwifery Council, 2008). As all research has the 
potential to be harmful to participants and researchers (Long & Johnson 2007), 
nurses should also make certain that their studies are safe, robust and ethical 
(Royal College of Nursing 2009). Audit studies do not have to be formally 
  
88 
 
reviewed by a research ethics committee; but as the distinction between audit 
and research is often a grey area, external ethical consideration will ensure that 
the potential moral issues are addressed fully (Wade, 2005). Therefore I took 
the programme of research to the Regional Ethical Committee. They suggested 
that most parts of the project were a service evaluation and did not need their 
approval, but the qualitative interviews with patients did, so I should resubmit 
this part separately (appendix 1). The whole programme of research was 
approved by the Research and Development department, NHS Northampton 
(appendix 2). Additionally as Community Mental Health Nurses were to be 
involved in the training I sought and was granted approval from 
Northamptonshire NHS Healthcare Trust Clinical Governance Support team 
(appendix 3).  
 
4.6.1 Declaration of Helsinki 
I ensured that this study was conducted in full conformity with the current 
revision of the Declaration of Helsinki (last amended October 2000, with 
additional footnotes added 2002 and 2004). 
 
4.6.2 ICH Guidelines for Good Clinical Practice 
I ensured that this study was conducted in full conformity with relevant 
regulations and with the ICH Guidelines for Good Clinical Practice 
(CPMP/ICH/135/95) July 1996. 
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4.6.3 Data Handling and Record Keeping 
I complied with the requirements of the Data Protection Act 1998 with regard to 
the collection, storage and processing of information and upheld the Act’s core 
principles. The participants were identified by a study specific participant 
number.  The name and any other identifying detail were not included in any 
study data electronic file. All study data were entered onto a secure computer 
system with user names and passwords. Written notes were transferred to this 
computer then shredded.  
 
4.7 Preparing practices 
Prior to training the practice nurses, I met with the Practice Manager of each 
participating surgery. I suggested that it would be helpful to give the practice 
nurses more time to carry out the heath checks for patients with SMI than they 
would have for other patients (e.g. diabetes). This is recommended in the GP’s 
contract guidance (BMA and NHS Employers 2012). However, I was unable to 
offer any remuneration for this.  
 Many of the nurses participating in the PhyHWell project had not been 
consulted by their employers when they made the decision to take part. 
Therefore I needed to show an understanding of the nurses’ position in order to 
motivate them to engage in the research. 
 
4.8 Summary of chapter 
In this chapter I have explained how I have developed my programme of 
research. I have also described the ICDC and MRC frameworks which were 
used to structure the programme and explained ethical and governance issues. 
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Chapter five: Will patients with severe mental illness attend 
primary care for a health check? 
 
This chapter explains how an invitation appointment letter is effective in 
prompting patients with SMI to attend a physical health check in primary care by 
comparing it to those with diabetes.  
 
5.1 Background 
Many clinicians believe that patients with SMI will not attend primary care for a 
health check (Lester et al. 2005), yet there is little evidence to demonstrate that 
they are actually poor at attending in response to an invitation. Consequently 
there is limited guidance on how best to promote attendance. Most primary care 
practices invite their patients to long term condition clinics by way of an 
invitation letter which asks the patient to make an appointment at their 
convenience (Brown et al. 1992, NICE 2010a). A study carried out in a primary 
care centre in England showed that letters offering patients (without a particular 
diagnosis) an appointment (with a specific date and time) for a health check 
produced a much higher attendance rate (70%) than letters containing an open 
invitation (37%) (Norman and Connor 1993).  To date only one study by Harvey 
et al. (2005) has tested whether an invitation letter (requesting the patient 
makes an appointment to attend the practice) is an effective method of 
increasing the level of attendance of patients with schizophrenia for a primary 
care physical health check. Carried out in an inner city setting, fewer than one in 
five patients, half the number who responded in the general population, made 
an appointment and actually saw a Practice Nurse.   
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5.2 Method 
My aim was to explore whether a letter offering an appointment with a 
predetermined date and time would be effective in prompting patients with SMI 
to attend for a primary care health check. If patients will not attend for a health 
check then it would not be a good use of resources to set up a clinic for this 
purpose. 
 This is a retrospective comparison of the response rate of patients with 
SMI and diabetes to an invitational appointment letter to attend for a primary 
care health check in my own practice.   
 Patients with SMI were sent an appointment at a pre-determined time 
and date to have their physical health reviewed. A letter was sent out 10 days 
prior to the appointment (figure 5.1); a copy of the letter was placed in the 
patients’ notes. For patients with diabetes, letters were sent out two to three 
weeks ahead of the fixed appointment. The gap between the letter being sent 
out and the appointment was shorter for the SMI group because of the cognitive 
problems (e.g. poor memory and planning) associated with their condition. The 
letter gave the patient an option to contact the surgery if they had any questions 
or concerns, or wanted to change the date or time of the appointment.  
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Figure 5.1 The invitational appointment letter for people with SMI 
 
I carried out an audit of all patients with SMI or diabetes who were offered an 
appointment by letter between the first of January 2010 and the 31st of 
December 2010. I examined: 
 The lists of patients who had been invited over the last year (I keep 
monthly lists in order to monitor cancellations).  
 The computer records of each patient on the on the invitation lists to see 
if an invite letter was recorded. 
 The SMI clinic and diabetes clinic lists recorded on the GP practice 
computer system to identify the invited attendees of over the last year. 
 The individual records of patients who had been offered a health check 
by written invitation and had not attended in an attempt to discover why 
they had not come, e.g. were they in hospital, incorrect address, 
regularly did not attend appointments.  
~[Title/Initial/Surname] 
~[Patient Address Block] 
~[Post Code] 
 
Dear ~[Title] ~[Surname] 
 
You are invited to …………..Medical Centre, on…………….at………….for a health 
check. 
The purpose of the appointment is to check that you are physically well and review 
the medications that you are taking. You will be offered a blood test and may be 
offered an ECG (examination of your heart). You can refuse any of the 
examinations offered to you if you so wish.  Please bring a specimen of urine. 
If you have any medical problems these can be dealt with during this appointment.  
If you have any questions or concerns, please contact the surgery by 
ringing…………  
Yours sincerely 
 
Name of Practitioner 
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Demographic information was extracted by electronic audit from the SMI and 
diabetes disease registers.  Individual patient records were examined to 
determine whether or not they attended for a health check at the date and time 
stated in the invitational letter.  
 
Data Analysis 
I sought advice from Allan Clarke, statistician at the University of East Anglia. 
He suggested that I calculate crude odds ratio to explore whether the patient’s 
diagnosis (SMI or diabetes) made a difference to the numbers responding to an 
invitation for a health check. This is the standard test used when you want to 
compare the odds of something occurring in two different groups (Plitcha and 
Garzon 2009). The odds of an event occurring is the probability of the event 
divided by the probability of an event not occurring. It is the ratio of the odds for 
the first group and the odds for the second group. 
 
Ethical approval 
I submitted the protocol to the GP practice Caldicott guardian and it was given 
written approval.  
 
5.2.1 Other possible methods 
I considered carrying this audit out prospectively in my own practice but this 
would have taken more time. Additionally, the method of inviting patients would 
not have changed. I could have carried out the audit prospectively in another 
practice to reduce the possibility of bias, but I was unaware of any Northampton 
practice carrying out regular clinics for people with SMI at that time.  
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 Other methods of invitation other than letter such as phone calls, 
opportunistic invitation with an appointment at the time, contact via carers or 
invites by other healthcare professionals such as the Community Mental Health 
Worker are all helpful methods for inviting patients with SMI to an appointment. 
They were not included in this study as I wanted to find out whether the use of 
an invitational letter alone was successful in getting patients to attend. 
 
5.3 Results 
There were approximately 10,000 patients registered at the practice. One 
hundred and twelve patients were listed on the SMI register (1.11% 
prevalence); 64 (57%) were male. Of the 534 patients on the diabetes register 
(5.3% prevalence), 289 (54%) were males (there was no significant difference 
in the gender ratio of patients). A small number (n=11) of patients were on both 
registers. Patients with SMI were significantly younger than those with diabetes 
(p<.01; see table 5.1).  
 
Table 5.1 Age groups of participants in the audit 
Age range Patients with SMI (n=112) Patients with diabetes (n=534) 
17-44 42 (37%) 57 (10.5%) 
45+ 70 (63%) 477 (89.5%) 
 
 
Letters were not sent to the 138 patients (from both groups) who were currently 
inpatient, in residential care or prison. In total, invitation letters offering an 
appointment were sent to 508 patients, 92 with SMI and 416 with diabetes. The 
majority of patients from both groups attended at the date and time specified in 
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the letter (see table 5.2). Patients with diabetes were more likely to attend for a 
health check compared with those with SMI (OR=2.20 95% CI=1.13-3.62). 
Patients with SMI that did not attend were followed up where possible by a 
telephone call either to themselves and/or their carer or community mental 
health worker. A letter was also sent offering another appointment. An 
additional four (4%) SMI patients attended a health check in response to the 
follow up increasing the total number that attended to 65 (70%). Fifty-three 
percent of patients with SMI had no contact with secondary care. 
 
Table 5.2  Attendance for health checks 
 
Attendance for health checks 
 
Diabetes (n=416) 
 
SMI (n=92) 
 Attended for a health check 
 
At the offered time and date 
 
           After changing time and date                
338 (81%) 
 
321 (77%) 
 
17 (4%) 
61 (66%) 
 
59 (64%) 
 
2 (2%) 
 Did not attend for health check 
 
Cancelled the appointment 
 
           Did not attend (no reason) 
78 (19%) 
 
22 (5%) 
 
56 (13%) 
31 (34%) 
 
7 (8%) 
 
24 (26%) 
 
 
 
5.4 Discussion 
The prevalence rate for SMI in this practice was slightly higher than the United 
Kingdom national average of 0.5-1% (National Audit Office 2007); the diabetes 
incidence equates to that of England (Diabetes UK 2011). Fifty-seven percent of 
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patients with SMI were male, but this small majority may not reflect a statistical 
significant increase in the prevalence of SMI in men. 
 The aim of this audit was to examine whether an invitation letter with a 
predetermined appointment is effective in ensuring patients with SMI attend a 
physical health check in primary care. Although I have demonstrated patients 
with SMI are less likely to attend than patients with diabetes, it is striking that 
the proportion of the SMI patients who attended in my audit was much higher 
than those in a similar study by Harvey et al. (2005). It could be that patients in 
a suburban area (as in this study) are more likely to attend than those in an 
urban one (as in Harvey et al.’s study). Alternatively, Harvey et al. required 
patients to make an appointment, I sent them one. Given that people with 
schizophrenia can have cognitive problems (Andreasen 1995) and people with 
bipolar disorder may have impairment regarding daily functioning, even during 
remission (Martínez-Arán et al. 2004), the complexity of the task might have 
been a barrier. Offering a set time and date removes steps in the process and 
may explain my enhanced response rate. It is also possible that my response 
rate was higher because our letter gave details about who would be doing the 
health check rather than asking them to make an appointment with an unnamed 
person. 
 The results revealed that patients with SMI also responded to an 
additional invitation after non-attendance. As this group experience fluctuating 
symptoms there is a need to develop an alternative strategy when they are in 
an acute phase of illness (Iyer et al. 2005). This could be inviting them again in 
a few months rather than a few weeks. 
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 The difference in attendance rates between the two groups may have 
been affected by age rather than diagnosis; patients with diabetes were older 
and it is possible they may be more likely to adhere to a letter from their doctor 
asking them to attend a clinic. To make this clearer I should have made an 
adjustment for the difference in age between the two groups in the statistical 
analysis using logistic regression methods. (The information for this study was 
extracted straight from the computer records using the current population and 
not stored on an excel or SPSS spreadsheet. It is therefore not possible to 
make this analysis now as the population may have changed). An Australian 
health survey (Deeks et al. 2009) ascertained that younger participants are less 
likely to have annual health checks, seek advice or attend education sessions. 
However, another study has shown that age is not a factor affecting response to 
an invitation to attend for a health check (Thorogood et al. 1993). It is perhaps 
also worth noting that patients with diabetes generally seem to be much better 
at attending for health checks compared to those with other long term 
conditions. This may be because as a population, patients with diabetes have 
been educated to recognise the importance of health checks from diagnosis 
through courses such as DESMOND (Davies et al. 2008). (DESMOND is 
a programme of patient education modules and related educator training, which 
have been developed by a collaborative of NHS organisations). My sample of 
SMI patients in fact compares very favourably with the attendance rates 
observed in other long term conditions.  
 It is difficult to assess whether my audit reflects the wider population. As 
health checks for people with SMI have been offered for the past six years 
(since this was part of the GPs’ payment contract in 2004) in this practice by the 
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same practitioner (at the time of the audit), the response rate to invitation letters 
is likely to be higher than that of a practice offering a new service (as in the 
study by Harvey et al.). It does, however, highlight what can be achieved over 
time. 
 
5.5 Limitations 
As this is a retrospective audit there is more risk of error due to confounding 
and bias. This risk is increased as I have carried out an audit of my own 
practice. 
 
5.6 Summary of chapter 
I have described in this chapter how sending patients with SMI in primary care 
an invitation appointment letter with a predetermined time and date for a health 
check may be effective in getting them to attend. This study has been published 
as: Hardy S and Gray R. (2012) Is the use of an invitation letter effective in 
prompting patients with severe mental illness to attend a primary care physical 
health check? Primary Health Care Research & Development. 13 347-352. 
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Chapter six: Are food diaries a useful clinical tool for people 
with Severe Mental Illness? 
 
In the last chapter I explained how patients with SMI will attend for a health 
check if they are invited. However, there is some concern from healthcare 
professionals that if these patients do attend, the tools employed to improve 
lifestyle for the general population in primary care will not be effective (Lester et 
al. 2005). As there are many approaches and different tools to help patients 
improve their lifestyle I decided to choose one as an example. In this chapter I 
explain how food diaries which are used for patients with physical conditions 
can be just as helpful in the SMI population. 
 
6.1 Background 
Lifestyle factors such as low levels of physical activity and unhealthy food 
choices are prevalent in people with SMI (Henderson et al. 2006, McCreadie 
2003, Allison & Casey 2001).  Poor diet can cause a range of other physical 
and emotional effects due to inadequate nutrition (Peet 2004).  For example a 
lack of essential fatty acids can lead to a number of problems such as infertility, 
poor wound healing and liver degeneration and a reduced intake of calcium can 
cause depression and tooth decay (Stewart 2010). 
 Studies have demonstrated that people with schizophrenia are able to 
benefit from education about nutrition and a healthy lifestyle (Bushe et al. 2005, 
Wirshing et al. 2006) and this should be a routine part of the patient’s annual 
physical review (Hardy and Gray 2010). However, there is a perception 
amongst health care workers that making lifestyle changes amongst people with 
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SMI, even if risk CHD factors are identified, would be difficult (Wright et al. 
2006). I wanted to illustrate that a tool used in the general population can be 
just as effective in people with SMI. 
 Food diaries are often used in primary care as a tool to provide tailored 
feedback to patients on the quality of their diet; there is evidence to show that 
food diaries help people to lose weight by making overt the calories they are 
actually consuming (Hollis et al. 2008). Food diaries have been suggested as a 
helpful tool for people with schizophrenia (Rethink 2010); yet, I found little 
research using food diaries as a method to give us an in-depth insight into the 
quality of the diets of people with schizophrenia, or that illustrate their benefit to 
these patients.  For example, a study by McDougall (1992) employed food 
diaries, but their use was only a small part of a larger package of education to 
eleven patients with schizophrenia and their contents were not explored; 
Henderson et al. (2006) used food diaries in their study of 88 patients with 
schizophrenia, but they used them as a data collection tool to measure the 
quantity of nutrients. The lack of employment of food diaries in this group 
maybe because clinicians and researchers perhaps have the belief that patients 
with schizophrenia do not have the cognitive ability to complete the task. 
 There is not a good understanding of the quality of the diet chosen by 
people with schizophrenia. I offer physical health checks to people with SMI and 
have observed the heterogeneity of dietary preferences and diet literacy. I 
wanted to explore whether using a food diary as a process would allow both a 
quantitative and qualitative assessment of the diet. 
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6.2 Method 
This was a prospective audit of eight patients attending for a physical health 
check with myself. I asked the first eight patients with schizophrenia who 
attended from a predetermined date: (1) to complete food diaries; and (2) for 
permission to record their opinion about their own diet during the health check. 
The food diary I used was one side of A4 paper with a column for each day of 
the week divided into hourly time slots (appendix 4). 
 When introducing the use of food diaries in the primary care setting to 
any patient, they are given specific instructions to record everything that they 
eat and drink over the period of one week in the relevant day and time slot. No 
changes were made to these instructions for the purpose of this audit. 
 I chose a sample size of eight patients as this is an ample quantity to 
achieve enough information and small enough to permit examination of each 
food diary. This was a convenience sample and as such did not allow me to 
have any control over the representativeness (gender, age, race, education, 
etc.) of the sample to the whole population of people with schizophrenia 
(Lunneborg 2007). 
 Open questions were used as part of the patient’s usual consultation to  
ask their opinion about completing the diary. These were recorded in the the 
patients records following the consultation. This is usual practice when using 
diaries with any patient in primary care. The information was then transferred in 
an anonymised form to my secure computer.  
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Data analysis 
A full thematic analysis could not be carried out from simple food intake 
recordings as I did not question beyond what the patients had written. This was 
in order for the consultation to remain usual practice. I was able to identify 
seven themes from the food diaries. I followed guidance from Howitt and 
Cramer (2010). I applied brief verbal descriptions to small chunks of data. I then 
adjusted these descriptions to become codings in the light of the full picture of 
the data. On the basis of these codings I was able to identify themes which I 
clarified with my supervisor (Richard Gray). An example of one theme was 
mealtime routines which emerged through the food diaries being divided into 
hourly slots for each day.  
 
Ethical approval 
I submitted the protocol to the GP practice’s Caldicott guardian and it was given 
written approval. Patients were informed that the information would be used in a 
professional journal publication and would remain anonymous. Before asking 
them I made an assessment of their mental capacity. All patients who attended 
were capable of giving consent and they all agreed to carry out the task and 
gave permission to record the diary contents and their responses. This verbal 
informed consent was recorded in their computer records. Written consent was 
not sought as this study was viewed as an evaluation of usual practice. 
However, if I was to carry out a study like this again I would seek approval from 
the regional ethics committee and would obtain written consent from each 
patient.  
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6.2.1 Other possible methods 
I considered carrying out the audit retrospectively but the food diaries are 
usually kept by the patients so this would not have been possible. Additionally I 
would not have had a record of their opinions about their diet. I could have 
carried out the audit in one of the participating practices. This would have 
reduced bias because I would have been evaluating an intervention delivered 
by a third party and not myself. However, as using food diaries to help people 
with SMI improve their diet may not have been usual practice in other surgeries, 
this would have involved them providing additional care. Getting practices to 
recruit to the study for training had already been an issue. 
  
6.3 Demographic information  
Demographic information (age, gender, housing status and occupational 
status), body mass index (BMI), smoking status, exercise level, contact with 
secondary care, information about who shops and cooks, and prescribed 
antipsychotic medication were obtained from the patients’ computer records. 
This group were aged between 33 years and 83 years, with a mean age of 53 
years (s.d. 15.60). There were five women and three men. Five patients lived 
alone, one in a nursing home and two with relatives. Five patients were 
unemployed, one was retired and two were working (part-time low paid 
employment). The mean body mass index was 27 kg/m2 (s.d. 4.64 - two obese, 
four overweight and two within normal range). Three patients reported that they 
were currently smoking cigarettes.  The patients’ preferred form of exercise was 
walking. They all claimed that they did this regularly, though the level of walking 
and frequency varied enormously from a short walk to the shops twice a week 
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to an hour of walking daily.  All the patients were managed in primary care apart 
from one who received a monthly visit from a community mental health nurse. 
Six of the patients bought and prepared their own food, one had food prepared 
by a relative and one by nursing home staff.  All patients were currently 
prescribed antipsychotic medication: five were taking an atypical only 
[quetiapine. risperidone, olanzapine, aripiprazole (two patients)] one was taking 
an atypical and a typical (olanzapine, chlorpromazine), one was taking two 
atypicals (amisulpride, olanzapine) and one was taking a typical only 
(trifluoperazine). 
 
6.4 Results 
Seven themes were identified: fruit and vegetables, lack of variety, meal time 
routines, a ready meal diet, fluid intake, treat eating and diet literacy.  
Responses tended to be brief which may be characteristic of the cognitive 
problems of schizophrenia. 
 
Fruit and vegetables 
Eating fruit and vegetables was largely absent, even the patient with the highest 
intake of fruit and vegetables was eating well below the recommended daily 
intake (five portions a day recommended in the United Kingdom by the Food 
Standards Agency). By viewing the type and counting the numbers of portions 
of fruit and vegetables consumed each day, I observed a considerable degree 
of variation.  For example, over the week, the patient with the highest intake 
reported eating bananas, grapes, oranges, an apple, cherry tomatoes, carrots, 
roasted parsnips, broccoli, salad and drinking daily fruit juice compared to the 
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patient with the lowest intake who reported eating some salad in a sandwich 
once that week.  Overall patients repeatedly turned their noses up and reported 
that they did not like or could not afford vegetables.  
  
  ‘No…I don’t like them.’   
 Patient 2 (33 year old female) 
 
 ‘I only like apples but I can’t bite them now…’  (Rotten teeth)                                                                       
 Patient 3 (60 year old female) 
 
   ‘I don’t really like vegetables, fruit’s ok, I suppose…I know it’s good for 
 you but I don’t really have enough money to buy them anyway.’ 
 Patient 4 (51 year old male) 
 
 ‘The only fruit I like costs too much.’  (grapes, berries) 
 Patient 6 (39 year old female) 
 
Lack of variety 
There was very little variety in most of the patients’ diets with little apparent 
insight that this may not be healthy. Patient 1 had two eggs for breakfast 
everyday, Patient 2 had a ready meal of ‘chicken dinner’ on five out of seven 
days, Patient 3 had a scone for tea and egg sandwiches for breakfast everyday 
and Patient 5 had a cheese and tomato sandwich four out of seven days. 
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  ‘I eat them (eggs) every day because they are good for you.’ 
  Patient 1 (44 year old female) 
   
  ‘I like chicken dinner…’ 
  Patient 2 (33 year old female) 
   
  I like them (scones)…?’   
  Patient 3 (60 year old female) 
 
  ‘They (café) make nice cheese sandwiches.’ 
  Patient 5 (61 year old male) 
  
Mealtime routine  
As the food diaries are divided into hourly slots for each day, I was able to get a 
sense of when meals were being eaten. Breakfast was rarely missed and 
usually eaten between 7 am and 9 am. Most of the diaries illustrated a regular 
meal time pattern. The meal most likely to be missed seemed to be the evening 
meal. 
 
  ‘I usually don’t bother to eat in the evening.  Sometimes I just go 
  to bed.’ 
  Patient 2 (33 year old female) 
 
  ‘I always have my dinner at 12.’ 
  Patient 3 (60 year old female) 
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  ‘Breakfast is the best meal of the day!’ 
  Patient 8 (83 year old female) 
    
Ready meal diet 
Some meals were home cooked but most patients relied on ready meals 
(examples: cottage pie, roast dinner, Chinese rice dinner) and convenience 
food and café bought snacks such as pizza, pies, sausage rolls, burgers, fish 
and chips or sandwiches. 
  
  ‘I just go out to the caff when I get up…’ 
  Patient 4 (51 year old male) 
   
  ‘ I really don’t feel like going shopping, then having to spend time 
  cooking and  washing up…it’s easier just to get a sandwich or a 
  pork pie.’ 
  Patient 5 (61 year old male) 
 
  ‘I get what I fancy from Morrison’s…’ 
  Patient 8 (83 year old female) 
 
Fluid intake 
Generally patients were drinking very little fluid, some recording as little as one 
or two cups of tea a day. There was a perception that they only needed to drink 
if they felt thirsty. There was one exception (Patient 7) whose food diary showed 
he was drinking about five litres a day. 
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  ‘I usually have a drink with my meals and before I go to bed.’ 
  Patient 1 (44 year old female) 
 
  ‘I don’t get thirsty, so I don’t need to drink much.’ 
  Patient 2 (33 year old female) 
 
  ‘Should I drink more…? I’m never thirsty.’ 
  Patient 3 (60 year old female) 
 
  ‘If I drank anymore I would always be running to the toilet!’ 
  Patient 8 (83 year old female) 
 
Treat Eating 
Looking through the food diaries, I noted the foods eaten outside the routine 
meal times, typically were chocolate bars, biscuits, crisps or cake. A few 
patients had pudding after some meals. Patient 5 ate four Kit Kats during this 
week. However, most of the patients were only eating treats once or twice a 
week.  
 
  ‘I like pudding…but you don’t really need it, do you?’ 
  Patient 1 (44 year old female) 
 
  ‘I always have my biscuits in the morning…they keep me going.’ 
  Patient 3 (60 year old female)  
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  ‘I really like Kit Kats!’ 
  Patient 5 (61 year old male) 
   
Diet Literacy 
It was notable that the general perception was that the food they ate was 
healthy, yet on the whole, the diaries portrayed a picture of unhealthy diets 
(high fat and salt, low nutritional content). Patient 4 only ate once a day at a 
café. Only Patient 6 recorded drinking any alcohol (5 units during this week). 
The participants gave very little detail on what they were eating but they all 
managed to complete this task. 
 
  ‘I enjoy my food and think I eat all the right things’  
  Patient 1 (44 year old female) 
 
  ‘I don’t need to worry about it (his diet) because I go to the caff.’ 
  Patient 4 (51 year old male) 
 
  ‘I don’t drink…it doesn’t mix with my medication.’ 
  Patient 5 (61 year old male) 
 
  ‘Yes, my diet’s good.’ 
  Patient 8 (83 year old female):  
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6.5 Discussion 
My sample size of patients with schizophrenia is too small to accurately 
compare with that of other larger studies; yet I have made some interesting 
observations. The mean BMI of my group was similar to larger studies (Thakore 
et al. 2002, Allison et al. 1999).  Most of the group did not smoke which is not 
consistent with the patients observed in other studies (Goff et al. 2005). As four 
of the patients I observed had never smoked, I cannot argue that this 
divergence is due to them receiving an annual physical health check which 
included smoking cessation advice over the last six years. It is recognized that 
people with SMI are more physically inactive than the general population 
(McCreadie 2003), yet, all patients in this audit reported walking regularly.  As I 
have no accurate measure of the quantity or frequency of their walking, it 
maybe that their level of activity is actually quite low.  Because physical activity 
can have a positive effect on psychological well-being in people with 
schizophrenia (Bradshaw et al. 2005) as well as a physical benefit; we need to 
consider what may be effective strategies for promoting physical activity in this 
population, as standard interventions are not always effective.  
 The patients in this audit are eating well below the recommended (in the 
United Kingdom) five portions (400g) of fruit and vegetables a day (Food 
Standards Agency 2010b). Surveys have shown that a large proportion of the 
general population of the United Kingdom are also eating less (in England in 
2006, the daily fruit and vegetables purchased was 350g, and in Scotland it was 
295g - Office for National Statistics 2008), but it is still notably more than the 
people with SMI in this audit. This reduced intake of fruit and vegetables is 
perturbing, as apart from the well known benefits of fruit and vegetables, a 
  
111 
 
study (Joshipura et al. 2001) has shown that people who eat many fruits and 
vegetables, independent of any other health factors, have fewer heart attacks.  
With the population of people with SMI being at a higher risk of heart disease, 
increasing their fruit and vegetable intake could be a preventative strategy to 
reduce cardiovascular risk. 
 One reason for the low consumption of fruit and vegetables given by the 
participants in my audit was that they are too expensive and they could not 
afford to buy them (all of our participants are in receipt of benefits or in low paid 
work).  This is consistent with the findings of a study in carried out in Scotland 
(McCreadie et al. 2005), which showed that the diet of people with 
schizophrenia can improve when they are given free fruit and vegetables. 
However, six months after the free supply had stopped; consumption fell back 
to pre-intervention levels. McCreadie et al. believe that this was because after 
the intervention stopped, patients had to buy their own fruit and vegetables. 
Providing diet advice will not make fruit and vegetables affordable either and 
one could argue that the provision of advice without the means to achieve the 
outcomes may only serve to cause frustration and resentment. 
 Variety in diet is important, not only to relieve boredom of eating the 
same foods but to ensure the adequate intake of vitamins, minerals, proteins, 
fibre carbohydrates and fats. Some of the food the diaries recorded in this audit 
did show a level of variety, but most were very routinised and repetitive.  The 
lack of adequate nourishing ingredients is consistent with the findings of 
Henderson’s study (Henderson et al. 2006) which did not look at the variety in 
the diet, but measured the intake of the above nutrients by people with 
schizophrenia and found them to be lower than the general population. The 
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patients in this audit did not appear to be bored with what they are eating and 
showed little awareness of the importance of variety in their diet. Working with 
each patient using their diary as a starting point, would provide a guide for the 
healthcare professional to explain individual improvements. Only guidance 
appropriate to that particular patient would need to be offered, taking into 
account their obvious preferences, rather than giving them general diet advice. 
This negates the need for the patients, who may by the nature of their condition 
have some cognitive impairment, to filter out less important messages. 
  The patients in this group relied on ready meals and convenience foods 
for most of their dinners. These foods tend to be high in saturated fats and salt 
which can contribute to high blood pressure and cholesterol and low in nutrients 
such as vitamins and minerals needed to promote good health. Most of the 
patients in my audit bought and prepared their own food, but that does not 
inform us of the reasons that they maybe reliant on these foods.  In order to 
provide useful education and helpful advice about eating a healthier diet, the 
healthcare professional needs to find out what these reasons are in each 
individual case.  Some patients may lack the skills of food preparation, in which 
case, practical help will be needed in order to assist them to gain these skills if 
they so wish. Given the nature of the condition and the fact they are preparing 
food for themselves and eating alone, some patients may lack the motivation to 
prepare a proper meal. In this instance, it maybe beneficial to review whether it 
is the patient’s medication is causing increased tiredness and considering a 
possible alternative. As eating is a social activity, exploring with the patient how 
their social network could be widened may improve the quality of their diet. 
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 The food diaries showed that, even though the majority of patients are 
not working, they are still getting up to eat breakfast and appear to follow an 
ordered routine. This contrasts with the chaotic lifestyle or spending the day in 
bed, which is often described in this population. Perhaps their rigid routine is 
due to a lack of flexibility and is another indication of poor cognitive function 
(MacGabe 2008). Considering this more positively, people with schizophrenia 
seem to do best in well-organized home environments with regular routines that 
include meals, sleep, work and recreation (Minato & Zemke 2006). It could be 
the case that the patients in this group have been taught that maintaining a 
routine can be helpful, or perhaps they have found this out for themselves. 
Often when we offer general diet advice we advocate developing a routine; this 
is an example of where promoting this message may be unnecessary and only 
result in clouding the important ones.  
 The diaries revealed that not all the patients were eating the same things 
in the same amounts and at the same times. This confirms my view that 
interventions offered by healthcare professionals need to be considered on an 
individual basis in order to be effective (Hardy 2009). 
 My audit revealed a lower fluid intake than recommended for healthy 
hydration (1200mls for people in the United Kingdom, Food Standards Agency 
2010c). Drinking too little is in common with the rest of the population, yet my 
group drank substantially less and reported that they did not feel thirsty. As this 
is a very small study, a much larger population is needed to explore whether my 
results are representative of the population of SMI. An American study (Farley 
et al. 1986) concluded that psychosis can severely impair the thirst mechanism 
directly. This is an old study and included only one patient; however it may go 
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some way to explain why the patients in this audit did not feel thirsty. Most 
people do not wait until they are thirsty to drink as social and cultural factors, 
e.g. work breaks, meeting up with friends prompt them; thirst offers a backup to 
these behavioural factors. We need to advise patients with schizophrenia who 
may not have these prompts to increase their fluid intake, explaining that they 
should not wait until they are thirsty to drink. Conversely, we should be mindful 
of polydipsia. A person suffering from polydipsia drinks too much fluid; this can 
cause hyponatraemia which can lead to coma and even death. It has been 
estimated that between six and 17% of psychiatric inpatients suffer from 
polydipsia (Brooks & Ahmed 2007). The food diaries also highlighted that the 
patient living in the nursing home was suffering from this condition. The patient 
in this study has spent his life in institutional care and no one had recognised 
this overconsumption of fluid. I have discussed this finding with his care staff.  
 A study showed that a higher national dietary intake of refined sugar and 
dairy products predicted a worse two year outcome of schizophrenia (Peet 
2004). A high sugar intake in a person with schizophrenia can be seen as a 
critical indicator of poor general health and well-being (Houghton 1982).  
Fortunately, the patients in this audit are not eating too many sugary or fatty 
snacks, which as well as giving them a better outcome of schizophrenia, it has 
benefits for their dental health and reduces their risk of developing 
cardiovascular disease and diabetes. I don’t know whether these patients 
recognise this benefit or whether they are unable to afford to buy themselves 
treats. 
 It is perceived that people with schizophrenia drink more alcohol than the 
general population. In the United Kingdom, at the time of study, this factor was 
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viewed as important enough to consider payment to GPs to monitor patients 
with schizophrenia for alcohol use (NICE 2010a). This has since been 
implemented through the GPs’ payment contract (BMA and NHS Employers 
2012). However, the patients in this audit did not drink alcohol. This may be 
because they are all taking antipsychotic medication, they have taken on board 
the advice that their medication can cause sedation and impair coordination (as 
described by Patient 5), and that using alcohol can further increase any 
impairment (Rethink 2008). Other reasons may be lack of money to buy alcohol, 
the fact they are not socialising or maybe they merely chose not to record their 
alcohol intake. Whatever the reasons, my results are consistent with the 
findings of Henderson et al. (2006), who also found that patients with 
schizophrenia had a lower alcohol intake than the general population.  
 McCreadie (2005) argues that many patients with schizophrenia come 
into the category of population subgroups that are not fully able to make wise, 
informed choices about dietary health. My findings certainly substantiate this 
view, as most of this group considered themselves to have a good diet despite 
recording the opposite. It could be argued that this would change if the people 
with schizophrenia were offered pertinent education about nutrition and a 
healthy lifestyle (Bushe et al. 2006, Wirshing et al. 2006). 
 It is a concern that these patients may think their diet is adequate, and 
when in a consultation with a busy healthcare professional may report that their 
diet is good. Because most of the literature regarding the physical health of 
people with schizophrenia focuses on obesity, if their body mass index (BMI) is 
within normal range, some healthcare professionals may assume diet advice is 
unnecessary. What I found alarming was that the patient with the lowest BMI 
  
116 
 
had the unhealthiest diet and without the use of the food diary I may not have 
discovered this. 
 Patients with schizophrenia who have poor dietary literacy need ongoing 
education about a healthy diet and how to prepare simple healthy meals in 
order to facilitate making a positive change. There is no one size fits all way to 
help patients with schizophrenia to improve their diet. The results show that a 
personalised approach is necessary. Education and interventions for the 
schizophrenia population should focus on overall lifestyle factors such as 
physical activity, their social situation as well as advising healthy food choices. 
Consideration should be given to how patients in financial difficulty can afford to 
buy the necessary quantity of fruit and vegetables to maintain their physical 
health. 
 
6.6 Limitations 
There is a risk of potential bias as I carried out the audit in my own practice. 
Patients may not have recorded everything that they ate or drank. I did not ask 
patients whether they had difficulty in completing the diaries. 
  
6.7 Summary of chapter 
I have observed from this audit that the food diary is a useful clinical tool.  It has 
helped determine on an individual level the importance of diet to the patient’s 
physical and emotional wellbeing. I also learnt that contrary to public belief, 
some patients with schizophrenia are capable of completing homework tasks.  
This study was published as: 
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Hardy S and Gray R. (2011) The secret food diary of a person diagnosed with 
schizophrenia. Journal of Psychiatric and Mental Health Nursing. 19 (7) 603-
609. 
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Chapter seven: What is the best evidence for training nurses 
about physical health in severe mental illness? 
  
In the previous chapters I have discussed how to invite patients to a health 
check and the utility of food diaries in primary care. In this chapter I discuss how 
I carried out a systematic search for evidence regarding the efficacy of 
healthcare professional educational outcomes in studies of physical health in 
SMI. The intention was to review this evidence to inform the development of my 
own training package, but no relevant studies were found. Carrying out a 
systematic review is recommended by Craig et al. (2008) for researchers 
evaluating a complex intervention. 
 
7.1 Background 
A recent study has found that the strongest predictors of quality of clinical care 
given by practice nurses for long term conditions in England are organisational 
factors which include education and training (Griffiths et al. 2011). SMI is 
categorized as a long term condition (BMA and NHS Employers 2012). Yet in 
the most recent analysis of practice nursing, training about SMI was not 
identified as a need (Crossman 2008). In this study, 1,161 nurses were asked to 
identify both their responsibilities and training needs. Mental health was not 
given as a responsibility of any of the respondents. Six hundred and ninety-nine 
nurses (65%) said they required more training but only 668 identified what this 
was. From this group only six nurses cited mental health as a training need.  
This mirrored my own observations in 2009. Discussions with practice nurses in 
Northampton at that time, showed they were keen to be involved with improving 
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the health of people with SMI but did not see it as their role, a number even 
quoting ‘I don’t do mental illness’. In a qualitative study of six primary care trusts 
in the West Midlands, GPs and practice nurses largely believed that the care of 
people with SMI was too specialised for their service (Lester et al. 2005). More 
recently I have observed a positive shift in the attitudes of some practice nurses 
in Northampton and the East Midlands regarding mental health. This appears to 
have coincided with screening for depression in patients with diabetes and heart 
disease becoming part of the payment contract (BMA and NHS Employers 
2012). A study of GPs and practice nurses regarding the impact of this payment 
contract reported that there was substantial improvements in teamwork and in 
the organization, consistency and recording of care for conditions incentivized in 
the scheme, but not for non-incentivized conditions (Maisey 2008). In 2012, as 
part of a local study in Northampton, I carried out a survey with practice nurses 
to examine their previous education and attitudes about screening for 
depression and anxiety in long term conditions. The majority of nurses agreed 
that everyone with a long term condition should be screened for depression and 
anxiety symptoms and that they as the healthcare professional providing the 
annual review should be the person to do it. They reported that a lack of 
relevant training and time during the consultation may prevent them from doing 
this effectively. Access to relevant training is one of the regulations in the Care 
Quality Commission workforce outcomes document (Care Quality Commission 
2012). These observations suggest that practice nurses need suitable support 
and training to increase knowledge and skill. 
 I needed to educate practice nurses to equip them with the skills to carry 
out these health checks and in doing this provide evidence that offering a 
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physical health check will be beneficial to the patients. I wanted the education to 
be evidence based so I set out to perform a systematic review with my fellow 
student Jacquie White (Jacquie is also studying for a PhD at the University of 
East Anglia. She is co-ordinating a RCT examining the effect of mental health 
nurses providing health checks for people with SMI). The aim was to identify the 
evidence of efficacy of the education of qualified health care professionals to 
deliver interventions aimed at improving the physical health of adults with SMI. 
 
7.2 Method 
We undertook a systematic search of the literature in June 2010 using the terms 
Severe Mental Illness, Physical Health and Education utilising the component 
databases: MEDLINE (Ovid) (1950-June 2010) (55 results), CINAHL (EBSCO)  
(1981 – June 2010) (24), AMED (Ovid) (1985 – June 2010) (0), Psychinfo 
(EBSCO) (1806 – June 2010) (21), Cochrane (June 2010) (0), WHO (June 
2010) (4), OpenSIGLE (June 2010) (216), EMBASE (Ovid) (1980 – week 23 
2010) (94) and Health Technology Assessments (June 2010) (O). 
 
MEDLINE search terms 
(exp "schizophrenia and disorders with psychotic features"/ OR chronic mental 
illness.mp. OR chronically mentally ill.mp. OR chronic mentally ill.mp. OR 
severe mental illness.mp. OR severely mentally ill.mp. OR exp Bipolar Disorder/ 
OR (bipolar$ adj3 disorder$).ti,ab. OR (bipolar$ adj3 depress$).ti,ab. OR 
(bipolar$ adj3 illness$).ti,ab. OR (bipolar$ adj3 disease$).ti,ab. OR (bipolar$ 
adj3 episod$).ti,ab. OR mania.ti,ab. OR manic.ti,ab. OR (hypomanic or hypo-
manic or hypomania or hypo-mania).ti,ab. OR cyclothym$.ti,ab. OR 
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(schizophren* or hebephreni* or oligophreni* or psychotic or psychosis).ab,ti.) 
AND (Health Status/ OR physical health.mp. OR Physical Fitness/ or Health/) 
AND (exp *education, continuing/ OR (education$ adj2 (program$ or 
intervention? or meeting? or session? or strateg$ or workshop? or visit?)).tw. 
OR (behavio?r$ adj2 intervention?).tw. OR (education$ adj1 (method? or 
material?)).tw. OR ((opinion or education$ or influential) adj1 leader?).tw. OR 
facilitator?.tw. OR *guideline adherence/ OR (guideline? adj2 (introduc$ or 
issu$ or impact or effect? or disseminat$ or distribut$)).tw. OR ((effect? or 
impact or evaluat$ or introduc$ or compar$) adj2 training program$).tw. OR 
(prompter? or prompting).tw. OR compliance.tw.) 
 
 No limitations on year of publication or language were applied. We 
inspected the references of all identified studies and relevant reviews for other 
appropriate studies to determine if any material may have been overlooked.  
 
Inclusion criteria 
 Education to deliver interventions to improve the physical health of 
people with SMI 
 Assessment of the impact of the education package on the healthcare 
professionals 
 Patient specific outcomes 
 
Justification for inclusion criteria 
 At first, we planned to only include RCTs as they are considered to be 
the highest standard of research evidence to determine the efficacy or 
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effectiveness of a healthcare intervention or service. We searched for RCTs 
that evaluated the efficacy of the education of qualified health care 
professionals to deliver interventions aimed at improving the physical health of 
adults with SMI. As this criteria did not uncover any relevant papers, and the 
‘most appropriate’ (or highest level of) evidence is not necessarily the RCT 
(Sanson-Fisher et al. 2007), we expanded our criteria to include service 
evaluations. However, searching for service evaluations did not prove fruitful 
either, so we removed the study design from the search criteria completely. The 
outcomes had to include some assessment of the impact of the education 
package on the healthcare professionals as well as patient specific outcomes. 
 We anticipated that the education packages would involve some face-to-
face education (of any duration) backed up by the provision of written materials 
and potentially prompting processes when the trainees returned to practice. We 
intended to note the character of education delivery (group, one-to-one, 
experiential, didactic, duration, location etc), the character of the trainer 
(profession, level of education etc), the character of the group (multi or 
uniprofessional, level of qualifications and area expertise etc) and the provision 
of support subsequent to the education event (written resources, access to 
trainers, web groups etc). 
 
7.3 Results of systematic search 
We identified 414 references from the databases: MEDLINE (55), CINAHL (24), 
AMED (0), Psychinfo (21), Cochrane (0), WHO (4), OpenSIGLE (216), 
EMBASE (94), HTA (0) and none from other sources. We screened the results 
of this electronic search. Through screening and discussion 147 papers were 
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excluded as they did not meet the criteria for this review. There were no 
difficulties or disputes during this process.  
 A number of studies (Smith et al. 2007a,b) were excluded from this 
review as although there was an implicit education package provided to 
healthcare professionals, no information was reported on the outcomes of this 
education with regard to healthcare professionals’ knowledge, attitudes and 
behaviours. The only information that these studies provided was patient 
specific outcomes. Therefore no studies were identified as suitable for a 
systematic review. See flow diagram (figure 7.1).  
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Figure 7.1 Results of systematic search 
 
References from databases (414): MEDLINE (55), CINAHL (24), 
AMED (0), Psychinfo (21), Cochrane (0), WHO (4), OpenSIGLE 
(216), EMBASE (94), HTA (0)  
  
 
 
References (without duplicates) 147 
References from other sources 0 
147 references screened 
145 references excluded 
2 full text articles assessed for eligibility 
2 full text references excluded 
 
0 studies included in review 
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7.4 Discussion 
It is significant that we were unable to identify any studies. There appears to be 
a lack of understanding regarding the importance of disseminating evidence 
based interventions in order to make them effective in practice. Specifically, it is 
important to understand the impact of an education package aimed at 
healthcare professionals on their knowledge, attitudes and behaviours. If this is 
not understood, then the reasons for any change in patient outcomes are 
impossible to determine. The lack of this information may be one of the reasons 
for the insufficiency of long term impact for such programmes as the Well-being 
Support Programme (Smith et al. 2007a,b), as critical information needed to 
apply such an intervention in practice is missing from the reports.  
 Providing health checks for people with SMI in the United Kingdom has 
become a requirement of the Quality and Outcomes Framework; along with 
providing health checks for people with other conditions such as diabetes that 
carry a high risk of developing CVD (BMA and NHS Employers 2012). The 
difference is however, there is an acceptance by the nurses that providing 
health checks for people with diabetes should be part of their role (Hall 2008). 
Additionally there are many courses about diabetes available to nurses from 
universities, local provisers and pharmaceutical companies. The lack of 
evidence based education available for qualified nurses to monitor the physical 
health of people with SMI (Blythe and White 2012, Robson et al. 2012) adds to 
the view that this is not their responsibility. The lack of specific evidence to 
demonstrate that education of the nurses will improve patients’ health makes 
advocating any education (should it be available) a difficult task.   
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  Practitioners worry, quite rightly, about patients with SMI committing 
suicide (Gray et al. 2009) and maybe this is why there is an abundance of 
research regarding interventions to prevent suicide in this group of patients. 
Leitner et al. (2008) carried out a systematic review and uncovered no less than 
24 studies in this area. This contrasts with a systematic search for the 
effectiveness of physical health monitoring in SMI which did not identify any 
studies (Tosh et al. 2010) Given the plethora of papers advocating the 
importance of monitoring the physical health check of people with SMI, it is 
striking that both my attempt and that of Tosh et al. (2010) to evaluate the 
evidence in this area by carrying out a systematic review, unearthed absolutely 
no studies. As more patients with SMI die from CVD than suicide (Gray et al. 
2009); it is vital that researchers start to publish details of healthcare 
professional education and their outcomes in physical health and SMI research.  
 
7.5 Limitations 
Although our search criteria should have been robust enough to detect relevant 
studies or service evaluations, it is possible, however, that we have failed to 
identify small studies and evaluations or studies and evaluations in progress. 
 
7.6 Summary of chapter 
There is a need not only to develop education for qualified nurses and other 
relevant healthcare professionals to provide physical health checks and 
appropriate interventions for people with SMI, it is also necessary to 
demonstrate that offering this education will improve patient outcomes.  
This study was published as:  
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Hardy S, White J, Deane K, Gray R. (2011) Educating healthcare professionals 
to act on the physical health needs of people with serious mental illness: a 
systematic search for evidence. Journal of Psychiatric and Mental Health 
Nursing. 18 (8) 721-727. 
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Chapter eight: Developing a physical health in severe mental 
illness training package for practice nurses 
 
In this chapter I have written an account of the development of the intervention, 
the physical health in SMI training package for practice nurses. This is 
recommended by Craig et al. (2008) as part of the evaluation.  
 
8.1 Background 
I have been carrying out physical health checks for people with severe mental 
illness in primary care since 2005. At that time there were no guidelines from 
the National Institute for Health and Clinical Excellence (NICE) in this area. The 
only documents available for primary care clinicians other than the Quality and 
Outcomes Framework guidance were a briefing guide about the new GP 
contract (Sainsbury Centre for Mental Health 2003) and some brief tables in 
medication books such as the BNF and the London and Maudsley NHS 
Foundation Trust, and Oxleas NHS Foundation Trust prescribing guidelines. An 
extensive search of literature by Roberts et al. (2000) to review whether offering 
routine or opportunistic health assessment in primary care to people with 
schizophrenia was effective in improving the mental and physical health found 
only three studies met their inclusion criteria. They concluded that there were 
insufficient data to suggest that health assessments of people with 
schizophrenia are effective in improving their mental and physical health. 
However, one study showed that use of a tool designed for mental health 
nurses to monitor the physical health of people with SMI was effective in 
achieving improved recording of physical illness and lifestyle needs (Phelan et 
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al. 2004). In addition, another study employing a nurse advisor to carry out 
health checks for this group accomplished improvements in the weight and diets 
of participants (Ohlsen 2005). This encouraged me to create my own best 
practice guide. Through providing these health checks I have observed 
improved health in these patients (figure 8.1). When creating the training, I 
wanted to equip practice nurses to provide patients with the same level of care. 
To assist in this process I developed two tools, a best practice manual and 
website. 
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Figure 8.1: Example of a patient with SMI invited for a health check.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The patient is a 57 years old gentleman who had not had any contact with his GP 
for three years, and only sporadic contact with staff in secondary care. I do not 
know the reasons why he had not chosen to come in; but before the introduction 
of the payment contract in 2004, patients with long term conditions were not 
routinely invited to attend for a health check. This patient was diagnosed with 
schizophrenia 35 years ago for which he was taking olanzapine. He also had 
epilepsy which was controlled with phenytoin; he was unable to tell us whether he 
was experiencing any fits. The patient lived with his elderly parents and did not 
go out. He was invited by letter for a health check and attended. Blood test 
results revealed that his phenytoin levels were low and his cholesterol and 
glucose levels were raised. His blood pressure was raised and the 
electrocardiogram showed his QT interval was lengthened. The patient had 
neglected his hygiene, leading to fungal infections on his feet, axillae and groin. 
Lifestyle advice and tactful hygiene advice was offered to the patient and he 
seemed to take this on board. Clotrimazole cream was prescribed, which along 
with his improved hygiene alleviated his fungal infections. He was subsequently 
diagnosed with diabetes, hypertension and AV heart block. The patient’s 
phenytoin dose was increased to ensure a therapeutic dose. Simvastatin, 
metformin, ramipril and aspirin were initiated to reduce cholesterol, blood sugar, 
blood pressure and lessen his risk of a heart attack or stroke. His olanzapine was 
stopped and replaced with quetiapine as olanzapine can increase the QT interval 
and increase blood glucose.  
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8.2 Developing a best practice manual 
When developing a complex intervention, Craig et al. (2008) suggest making 
the recommendations as specific as possible. I therefore developed the Health 
Improvement Profile for Primary Care or HIP-PC (in collaboration with Professor 
Gray) from the original tool, the HIP (developed for secondary care), by 
adapting it for use in primary care (Hardy and Gray 2010). The HIP was chosen 
as a suitable tool as there is positive qualitative evidence that using it results in 
improved health (Schuel et. al 2009).  
 When designing this intervention, the main focus was to enable the 
practice nurse to provide a health check as part of their usual role, rather than 
as an adjunct service. This is a practical approach to the problem, yet it remains 
complex in terms of its evaluation and dissemination. Complex interventions 
contain several interacting components (Medical Research Council 2009); the 
HIP-PC targets the practitioner, the patient and the organisation and requires 
them all to interact.  
  
8.2.1 The Health Improvement Profile (HIP) 
The Health Improvement Profile (HIP) is an evidence based physical health risk 
assessment for mental health nurses. The developers of the HIP (White et al. 
2009) identified the need to address these inequalities of physical health care 
experienced by people with SMI. They predicted that developing a specific tool 
could help mental health nurses in secondary care outline the physical health of 
the patients with severe mental illness that they work with and direct them 
towards the evidence base interventions available to address identified health 
problems. They agreed that this tool needed to address the major health 
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priorities, behaviours and problems where there is evidence of increased 
morbidity/mortality in people with SMI.   
 The HIP has 27 items and the male and female versions are slightly 
different. The HIP is undertaken annually and takes approximately 30 minutes 
to complete; drawing information from multiple sources. Basic demographic 
information, age, gender, ethnicity, weight and height are recorded at the top of 
the form. Each item is marked either ‘green’, if the observation or behaviour is 
within a healthy range or ‘red’ if it is unhealthy. A list of recommended actions 
based on best current evidence is provided to guide practice and the nurse 
should check the box indicating the intervention they have taken. The form is 
carbonated in triplicate; copies can be placed in the multi-disciplinary notes, 
sent to primary care and given to the patient (Schuel et. al 2009). The HIP is 
also available in an electronic format (eHIP). 
 
8.2.2 The Health Improvement Profile for Primary Care 
The HIP-PC is a manual which provides healthcare professionals with clear 
guidance and a rationale to help them make decisions about individual patients 
(appendix 5). I wanted to make sure there was local agreement regarding this 
manual so I discussed its proposed contents with the director of mental health 
services. He was very supportive and made some helpful comments. 
 In the United Kingdom, each GP practice uses a computerised system to 
record patient consultations, not all practices have the same system. The 
advantages of using one of these systems are that elements of the consultation 
can be coded and therefore data collection is very straightforward.  
Unfortunately, at present not all these individual systems are compatible with 
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other computer programmes. Using the HIP as it stands would mean that the 
nurse would have to record the information twice. Apart from this being an 
unpopular proposition, duplicate data entry opens the door to additional error 
and data conflicts. Therefore adapting the HIP to fit into each individual system 
as a template with the manual as accompanying guidance seemed a logical 
solution. 
 The HIP addresses all the physical elements that need to be considered 
when carrying out a health check. However, guidelines produced by NICE 
(2010a) recommend that patients managed in primary care should also have an 
assessment of their social needs. It is recognized that deprivation can impact on 
people’s physical health through cholesterol levels, blood pressure and heart 
disease (Mental Health Foundation 2009). The assessment should include 
monitoring of mental state, medication use, medication adherence, side-effects, 
social isolation, access to services, and occupational status (NICE 2010a).  This 
was also acknowledged at the time by the General Medical Services Contract 
(British Medical Association 2008). The contract required that a care plan is 
documented in the records and that the patient is followed up by the practice 
team within 14 days of non-attendance.  It also suggests that the accuracy of 
medication prescribed by the General Practitioner can also be checked at the 
time of the health check (British Medical Association 2008). Therefore added to 
the HIP-PC with a rationale and recommendations for each, are a medication 
review, care plan and follow up plan for non-attenders. 
 Despite the fact that each practice receives no payment in protecting 
patients with SMI from flu with a vaccination, this has been added to the HIP-
PC.  This group has not been recognized as being at risk by the creators of the 
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GMS contract. However, the Sainsbury Centre for Mental Health (2003) 
advocates protection against influenza by offering annual immunisation in view 
of increased occurrence of cardiac, respiratory disorders and diabetes in 
patients with SMI.  Each practice receives payments as an incentive for 
vaccinating patients with conditions such as diabetes, stroke and heart disease. 
Although no other organisations have made the recommendation for people 
with SMI to have the flu vaccination; I argue that in view of their increased 
mortality, this group are just as susceptible to the serious effects of seasonal flu 
as the other groups of patients with the conditions that receive payment. This is 
concurred by Cohen (2001) who argues that this is an under-researched area 
and that people with SMI need extra protection during the winter months by 
receiving an influenza vaccination.  
 The HIP recommends blood tests for liver function, lipids, glucose and 
prolactin when there are symptoms. In some circumstances further blood tests 
are recommended (Hardy and Gray 2009). These have been added to the HIP-
PC with a rationale and recommendations for each.  
 The HIP recommends checking prolactin levels if symptoms occur 
(breast swelling and milk production, disturbance of menstrual cycle); this is in 
line with the South London and Maudsley NHS Foundation Trust, and Oxleas 
NHS Foundation Trust prescribing guidelines (Taylor et al. 2009), NICE (2006) 
guidelines for bipolar disorder and Northampton’s local guidance (Northampton 
Healthcare 2007). However, consensus guidelines for managing prolactinaemia 
(Peveler et al. 2008) recommend that health care professionals should monitor 
proactively for hyperprolactinaemia as it maybe asymptomatic. A study has 
shown that 5% of people taking antipsychotic medication such as aripiprazole 
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and clozapine (which are not associated with elevated prolactin) had raised 
levels (Bushe et al. 2008). For this reason, the HIP-PC recommends checking 
prolactin levels on all patients taking any antipsychotic medication. This also 
makes choosing relevant blood tests, less complicated for the clinician carrying 
out the health check. 
 The HIP suggests performing an ECG if the pulse rate is increased. 
There is evidence that many typical antipsychotics increase the risk of 
ventricular arrhythmias and cardiac arrest (Ray et al.2001, Liperoti et al. 2005) 
and an association between many atypical antipsychotic drugs and the 
occurrence of unexplained sudden death (Abdelmawla and Mitchell 2006). 
Abdelmawla and Mitchell (2006) advocate that cardiac safety should be a 
routine part of clinical care in patients taking antipsychotic medication; therefore 
a preventive strategy is valuable even if the absolute risk of serious cardiac 
events is low. As it is quite simple to carry out an ECG in primary care (the 
equipment is available and most nurses in primary care will be proficient in 
carrying out this procedure) the HIP-PC suggests it is performed on all patients 
unless they are taking no medication. Carrying out an ECG also allows the 
opportunity to look for other possible problems such as gynaecomastia, hygiene 
neglect and rashes.   
 Because the HIP was designed for use by nurses in secondary care, 
some of the actions suggested by the HIP are referral to the GP or Practice 
Nurse. In these cases, the actions specified in the HIP-PC are those that the 
GP or Practice Nurse should carry out.  
  Originally a large number of manuals were printed. This proved 
invaluable at the beginning when trying to promote the project as people were 
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keen to take something away with them. The manual has since been updated 
twice to keep abreast of the latest evidence. The latest version has been printed 
for two new projects described in chapter 14.  
 The HIP-PC manual is being used by Nottingham Mental Health Trust, 
Northamptonshire Healthcare Foundation Trust, Leicestershire Partnership 
Trust and NHS London. It has been adapted for use in Norwich, Lincolnshire 
and Australia. It has been translated into German for use in Switzerland. At the 
time of writing, a request had just been received from London South Bank 
University to use it for a new training programme.  
 
8.3 The website 
A website (http://physicalsmi.webeden.co.uk/ - appendix 6) for practice nurses 
has been constructed as a repository for useful tools (e.g. letters, care-plans, 
scales, HIP-PC), relevant information about SMI (e.g. medication, mental 
capacity act, schizophrenia, bipolar disorder) and helpful links (e.g. leaflets, 
further information for healthcare professional, charities). It is easy to use as 
there are no requirements to log in or register. Housing information on a website 
means I can update and add to it as appropriate. The website can be used both 
as a training tool and a resource for practitioners. There are links to further 
information and e-learning programmes. The best practice manual and useful 
tools such as letters, scales, leaflets, forms (which can be adapted to suit each 
organisation) are available to download. Practice nurses can save the address 
to their favourites and use it during consultations with patients.  
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8.4 Summary 
The HIP is a comprehensive evidence based tool which identifies and 
addresses the physical needs of patients with severe mental illness. Adapting it 
for use in primary care and providing training for its use, will ensure that primary 
care healthcare professionals have access to best practice guidance. 
This chapter has been published as: 
 
Hardy S and Gray R. (2010) Adapting the severe mental illness physical Health 
Improvement Profile for use in Primary Care. International Journal of Mental 
Health Nursing. 19 (5) 350 -355.  
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Chapter nine: Are people with Severe Mental Illness in 
Northampton receiving health checks in primary care? 
 
I wanted to find out if as many people with SMI were being given the same level 
of care as people with physical conditions. In this chapter I discuss my study 
carried out in five primary care practices in Northampton. I aimed to determine 
the proportion of patients with SMI being screened for CVD risk factors in their 
GP practice compared to those with diabetes, and find out whether people with 
SMI receive lifestyle advice.  
 
9.1 Background 
Healthcare professionals in primary care in England have evidence-based 
recommendations to follow for patients with diabetes regarding physical health 
interventions (Diabetes UK 2005) but not for people with SMI (De Hert et al. 
2011a). Guidelines from the National Institute for Health and Clinical Excellence 
(NICE) were not available for bipolar disorder until 2006 and do not specify who 
is responsible for carrying out physical health checks. The NICE guidelines for 
schizophrenia (2010a) provide more clarity in that some responsibility falls to 
primary care. There is some evidence that people with SMI are not receiving 
CVD risk screening from primary care clinicians in the way they would if they 
had diabetes. For example, Roberts et al. (2007) found patients with 
schizophrenia were significantly less likely than the general population to have 
either blood pressure or cholesterol recorded. A possible explanation could be 
the method of remuneration to GPs. Since 2004, each primary care centre in 
England has received payment through a contract (the Quality and Outcomes 
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Framework or QOF - BMA and NHS Employers 2011) to provide care for 
people with long term conditions. Before April 2011, to receive this payment 
practices were required to offer a review to people who had a diagnosis of SMI 
every 15 months. The particular contents of this review were not specified in the 
contract. The indicators simply stated that age-appropriate health promotion 
and prevention advice should be given (this changed in April 2011 with the 
introduction of specific indicators). Consequently, although best practice should 
include cardiovascular risk assessment, this was not part of the national 
contract at that time. In patients with diabetes there were specific payment 
indicators for recording blood pressure, body mass index (BMI), cholesterol and 
HbA1c.  
 
9.2 Method 
Craig et al. (2008) suggest using audit as one method of evaluating a complex 
intervention. I used a retrospective audit. Clinical audit is a quality improvement 
process that seeks to improve patient care and outcomes through systematic 
review of care against explicit criteria and the implementation of change 
(Copeland 2005). A recent Cochrane review found that the effect of audit on 
professional behaviour is enhanced if the health professionals are not 
performing well to start out with (Ivers et al. 2012). 
 
Audit Standards 
The standards for CVD screening and lifestyle advice were derived from 
published guidelines (NICE 2006, 2009, 2010a, De Hert et al. 2009b). These 
were that all patients with SMI and diabetes should, as a minimum, have their 
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blood pressure, BMI (or waist circumference), blood glucose (or HbA1c) and 
cholesterol measured at least once a year. They should also be given advice 
about diet, exercise and smoking cessation annually.  
 
Data Collection 
This was a retrospective audit that took place between September 2009 and 
August 2010. Patients were identified from the SMI register of each of the 
participating practices. The SMI register is a list of people who have a diagnosis 
of schizophrenia, bipolar disorder or other psychosis. Each GP practice is 
required to hold a register for a range of long term conditions of which SMI is 
one (DH 2002). I instructed the member of administrative staff from each 
practice who was identified to help in this study, to check the SMI registers. This 
was to make sure that if people without an appropriate diagnosis were included 
they could remove them. To ensure that everybody with SMI was included, the 
staff carried out a search on antipsychotic medications from the computer 
records. The diagnosis and history of identified patients were then checked by 
clinicians from each practice to determine whether they met the criteria for 
inclusion. However, as I was unable to access the registers myself, I do not 
know how accurate they were. I needed to extract demographic information 
(age, gender) and evidence of whether screening and lifestyle advice had been 
given in the last year from the electronic patient records. This information was 
not collected routinely for the purposes of QOF at the time of the audit, so I 
helped each practice to set up individual audits for each measurement. All data 
were anonymised and I had no access to patient specific information. 
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 As CVD screening for patients with diabetes is a requirement under the 
GP contract, the information collected at source is also stored in a national 
database system called the Quality Management Analysis System (QMAS). 
This system determines practices' contract payments (NHS Information Centre 
2012a). All information from QMAS from the previous contract year (1st of April 
to the 31st March) is displayed on the NHS Information centre public website 
(NHS Information Service 2012b). I compared the percentage of patients with 
diabetes from the same five practices who had BP, BMI and blood glucose and 
cholesterol recorded from April 2010 to March 2011 on this website with those 
in the SMI patients from my audit. I could not make a comparison of diet, 
exercise or smoking advice. Offering diet and exercise information are not a 
contract requirement for diabetes, and are therefore were not recorded on this 
database (BMA and NHS Employers 2011). Though smoking advice is a 
contract requirement, the data is measured as a practice population of 
combined disease groups and not for each individual long term condition. 
Additionally, from this website, I was able to obtain the percentage of people 
with SMI in each practice that had a record of a review within the last 15 
months.  
 
Data Analysis 
I took advice from Allan Clarke, statistician from the University of East Anglia. I 
calculated crude odds ratio to explore whether the patient’s diagnosis (SMI or 
diabetes) made a difference to the level of screening given (odds ratio has been 
described in chapter five). For patients with SMI, descriptive statistics have 
been used to determine whether certain elements of screening and lifestyle 
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advice were given more often than others. To find out the number of 
interventions received by each patient I calculated the mean. The advantage of 
using the mean (rather than the median and mode) is that all the data is used to 
find the answer. The disadvantage using the mean can be that very large or 
very small numbers can distort the answer so I used standard deviation to show 
how much variation exists from the mean. To test whether age was associated 
with the rate of screening in SMI patients, I used standard tests for association 
(chi-square). Chi-square is a test commonly used to compare observed data 
with data we would expect to obtain according to a specific hypothesis. This 
fitted my data as it was random, raw, mutually exclusive, drawn from 
independent variables and from a large enough sample (Plitcha and Garzon 
2009). Analyses were done with SPSS, version18. 
 
Ethical Approval 
The local regional ethical committee confirmed that this project was a service 
evaluation and it did not require their approval. The manager from the 
participating practices gave written consent to take part in the audit.   
 
9.2.1 Other possible methods 
The method used in this study is recommended by Hennekens and Buring 
(1987) to compare two groups of patients. I could have asked the participants to 
set up separate audits for the diabetes patients as they did for patients with 
SMI. This would have ensured that the data was collected at the same time as 
that for the patients with SMI. However, this would have been a very 
burdensome task for the participants who were not receiving any remuneration. 
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9.3 Results 
In the participating practices, fewer than one percent of patients had SMI and 
around four percent had diabetes. Fifty-three percent of the patients with SMI 
were men.I was unable to extract demographic data for patients with diabetes 
as this was not recorded on the NHS information database. 
 Virtually all the patients with SMI (96%) in the five practices had a record 
of a review on the NHS database within the last fifteen months. 
 Table 9.1 shows that patients with SMI had lower odds of receiving CVD 
screening (blood glucose and cholesterol, BP, BMI) than those with diabetes. 
 Table 9.2 shows which elements of CVD screening and lifestyle advice 
were given to patients with SMI in the last year. Smoking cessation advice was 
given more often than diet and exercise information. Comprehensive lifestyle 
advice (smoking, diet, exercise) was given to around one in ten patients. Only 
one in twelve were given both complete CVD screening and comprehensive 
lifestyle advice. Each patient with SMI was given fewer than two of the four 
screening measures and less than one of the three components of lifestyle 
advice. 
 I sought statistical advice about whether age should be used as a 
continuous or categorical variable. It was considered most conservative to use 
three age group 16-35, 36-55, and 56 and above, Table 9.3 shows that patients 
with SMI over the age of 36 years were more likely to be given complete CVD 
screening but there was no significant difference in the level of lifestyle advice 
given. 
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Table 9.1 The proportion of patients with SMI and diabetes given CVD screening 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intervention 
Patients with 
diabetes 
(n=1875) 
Patients with 
SMI  
(n=386) 
 
Unadjusted odds ratio 
 
 
BMI 
 
 
n=1800 (96%) 
 
n=185 (48%) 
 
OR=26.08; 95% CI=19.21 to 35.39: p<.01 
Blood pressure 
 
n=1866 (99.5%) n=243 (63%) OR=99.83; 95% CI=53.29 to 187.00: p<.01 
Serum cholesterol 
 
n=1818 (97%) n=143 (37%) OR=54.20; 95% CI=38.77 to 75.76: p<.01 
Blood glucose (or 
HbA1c) 
 
n=1856 (99%) n=135 (35%) OR=181.62; 95% CI=110.38 to 298.85: p<.01 
Full CVD screen 
 
n=1800 (96%) n=81 (21%) OR=90.37; 95% CI=64.53 to 126.55: p<.01 
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Table 9.2 Elements of screening and lifestyle advice given to patients with SMI  
 
 
Proportion of patients receiving elements of screening and lifestyle advice  n          % 
 
Smoking advice 
 
n=220 (57%) 
 
Exercise advice 
 
n=54   (14%) 
 
Diet advice 
 
n=50   (13%)  
 
Full lifestyle advice (smoking, diet, exercise) 
 
n=42   (11%) 
 
Full CVD screening and lifestyle advice (blood pressure, blood glucose and cholesterol, BMI, 
smoking, diet, exercise) 
 
 
n=31   (8%) 
 
Elements of screening and lifestyle advice given to individual patients Mean    sd 
 
Number of CVD screening interventions given to each individual (from a possible four) 
 
1.84   (sd=1.53) 
 
Number of lifestyle components given to each individual (from a possible three) 
 
0.85   (sd=0.95) 
 
Number of screening and lifestyle interventions given to each individual (from a possible seven) 
 
2.69   (sd=2.22) 
 
 
 
  
146 
 
 
 
 
 
Table 9.3 CVD screening and lifestyle advice given to patients with SMI by age category (n=386) 
 
 
 
Age categories 16-35 36-55 56+ 
 
Significance 
 
 
Number of patients in each age category 
 
n=94 (24%) 
 
n=169 (44%) 
 
n=123 (32%) 
 
 
All four CVD screen (blood pressure, blood 
glucose and cholesterol, BMI) 
 
n=10 (11%) 
 
n=38   (22%) 
 
n=39   (31%) 
 

2=13.55, p=<.01 
 
All three lifestyle advice (smoking, diet, exercise) 
 
n=5   (5%) 
 
n=22   (13%) 
 
n=16   (13%) 
 

2=4.25, p=.12 
 
All CVD screen & lifestyle advice (blood pressure, 
blood glucose and cholesterol, BMI, smoking, diet, 
exercise) 
 
n=2   (2%) n=18   (11%) n=13   (11%) 2=6.56, p=.04 
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9.4 Discussion 
The aim of this study was to determine the proportion of patients with SMI being 
screened for CVD risk factors in their GP practice compared to those with 
diabetes. A secondary aim was to ascertain whether people with SMI receive 
lifestyle advice in primary care.  
 An important observation is that the NHS Information database had a 
high percentage of patients with SMI from the participating practices recorded 
as having a review compared to the actual level of screening and advice given. 
This suggests a lack of awareness of the screening, health promotion and 
prevention advice that is appropriate for this group of patients. 
 My findings show a considerable variation in CVD screening rates in SMI 
patients compared to those with diabetes in the same centres. The higher level 
of screening in the diabetes population is likely to have been achieved because 
clinics for these patients to receive their annual review have become part of 
routine clinical practice in primary care centres (Hall 2008). They are usually run 
by a nurse who has undertaken advanced education in diabetes and who will be 
offered free regular educational updates by a variety of sources (e.g. Primary 
Care Diabetes Society). The provision of these diabetes clinics may have been 
encouraged by the contract’s financial incentive. Conversely, meeting the 
physical needs of people with SMI does not appear to be common place (Shuel 
et al. 2009) and there is at present no evidence based education to address this 
discrepancy (Hardy et al. 2011). Teaching healthcare professionals in primary 
care about the increased risk of somatic co-morbidity in patients with SMI could 
develop the provision of health care for this group (Oud and Meyboom-de Jong 
2009, Leucht et al. 2007). The introduction of specific contract indicators for 
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CVD screening in people with SMI in April 2011 may further promote this 
improvement. 
 My results were comparable with Roberts et al. (2007). In both studies 
blood pressure was the most frequently recorded CVD risk factor and the 
pattern of CVD risk screening was the same. However, the levels of screening 
for CVD risk in my audit were higher overall. Perhaps one of the reasons for this 
is that the audit by Roberts et al. was carried out before the contract was 
introduced (i.e. no payment was offered to primary care for providing this 
service) and therefore this screening was not considered by primary care 
clinicians to be their responsibility at that time.  
 It is possible that CVD screening of patients with SMI is not being done in 
primary care because it is happening in secondary care. However, an audit of 
patients (n=1966) under the care of community outreach teams across the UK 
carried out in 2005 showed this not to be the case, with recordings of blood 
pressure in just over a quarter of the records, obesity in less than a fifth, blood 
glucose in less than a third and cholesterol in less than a quarter (Barnes et al. 
2007). A later study carried out at the psychiatric in-patient and out-patient units 
in Southampton and Winchester found that this had not improved with time (Holt 
et al. 2010). The following cardiovascular risk factors had been measured in the 
previous year: blood pressure (32%), glucose (16%), lipids (9%) and weight 
(2%). 
 It may be argued that the different rates of screening for each measure 
suggest that these are being carried out opportunistically rather than at a 
designated appointment. One explanation for this may be that, as Lester et al. 
(2005) found, primary care clinicians believe that patients with SMI will not 
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attend for a health check.  In contrast, my audit in one primary care practice 
confirmed if patients with SMI are invited by letter giving them a specific 
appointment time with a named person, the attendance compares very 
favourably with rates observed in other long term conditions (Hardy and Gray 
2012b). 
 My audit showed that just over half the patients with SMI were offered 
smoking advice in comparison to the other lifestyle factors. This could be 
because it was a requirement under the contract (BMA and NHS Employers 
2011). However, Roberts et al. (2007) found a similar number of participants in 
their study had smoking status recorded and this was before the contract. I 
cannot tell from this audit about the quality of the smoking cessation 
intervention, or whether the advice had been tailored to suit the specific needs 
of this population. 
 It could be argued that practitioners (despite annual screening being part 
of government guidelines) are only targeting patients with SMI who they 
perceive to be at risk and not those for example who have a normal BMI, are 
asymptomatic and their blood glucose was normal two to three years 
previously. However, based upon the increased risk in metabolic syndrome in 
these patients, baseline and periodic medical evaluations should become a 
standard component in ongoing clinical assessment (Toalson et al. 2004).  
 The low level of diet and exercise information received by this group in 
my audit suggests that the importance of these interventions have not been 
considered by the healthcare professionals. This finding is disappointing as 
people with SMI appear to give low priority to their physical requirements 
(Buhagiar et al. 2011) and would benefit from education that is focused on 
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changing health behaviours (Brar et al. 2005, Graves and Miller 2003). In fact, 
brief lifestyle guidance delivered by a non-specialist worker has been shown to 
deliver useful health gains in this population (Brown and Chan 2006).  
 The older the patients with SMI in my audit, the more likely they were to 
receive screening. This is inconsistent with a study by Osborn et al. (2011), 
which established that people with SMI over 60 years of age were less likely to 
be screened. Osborn et al. explain this may be because in the United Kingdom, 
there are no specific schemes to remunerate general practitioners for assessing 
or managing elderly people. The system of payment is targeted at a number of 
long term conditions rather than specific age groups. It may be that the 
practitioners in my study were taking heed of guidelines to assess people over 
40 years of age in primary care for CVD risk (Joint British Societies 2005).  
 The low rate of screening in the 16-55 year groups of people with SMI is 
concerning. Even the presence of a single major risk factor at age 50 
substantially raises the lifetime risk for CVD and markedly shortens survival. 
Prevention efforts need to begin decades before the age 50 years (Lloyd-Jones 
et al. 2006). 
 The provision of diet and exercise advice was extremely low in all SMI 
age groups. This is another unwelcome observation as the excess morbidity 
and mortality in this population is largely due to modifiable lifestyle risk factors 
(de Hert et al. 2011b). Providing this education at an early age (particularly 
before the presence of metabolic syndrome) will have a greater effect (Brown et 
al. 2009).  
 Training nurses in primary care may increase screening for CVD risk 
factors and the level of lifestyle advice given. My before and after study to 
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establish the effectiveness of a training package for practice nurses about the 
physical health of people with SMI has recently been published (Hardy 2012) 
and is described in chapter 11. This showed that those who completed the 
training might be more likely to accept carrying out these health checks as part 
of their role.  
 
9.5 Limitations 
The study was retrospective, not prospective. It was reliant on secondary data. 
The observations were made at different time points as the secondary data 
could only be collected from April to March. I was not able to adjust for any 
potential confounders. 
 
9.6 Summary of chapter 
In this chapter I have examined the results of my study that aimed to find out if 
people with SMI were receiving screening for CVD risk factors and lifestyle 
advice. In the five Northampton practices, the proportion of patients with SMI 
being screened for CVD risk factors was much lower compared to those with 
diabetes.  The number of people with SMI receiving lifestyle advice was also 
very low. I have discussed the possible reasons for this disparity. 
This study has been published as: 
Hardy S, Hinks P and Gray R. (2013) Screening for cardiovascular risk in 
patients with severe mental illness in primary care: a comparison with patients 
with diabetes. Journal of Mental Health. 22 (1) 42-50. 
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Chapter ten: Are people with Severe Mental Illness in England 
receiving health checks in primary care? 
 
In the last chapter I explained how people with SMI were receiving less 
screening for CVD risk then people with diabetes in five practices in 
Northampton. Since then the GP’s payment contract has changed, meaning 
that some of this data can now be collected nationally. This chapter describes 
the levels of screening received by people with SMI compared to those with 
diabetes in England. 
 
10.1 Background 
As described in the last chapter, since 2004, each primary care centre in 
England has received payment through this contract to provide care for people 
with long term conditions including the provision of medical screening of 
patients with SMI and diabetes (BMA and NHS Employers 2011).  In order to 
receive payment practices are required to offer a review every 15 months. Even 
when treatment or diagnosis takes place in secondary care, responsibility for 
monitoring is often delegated to primary care (Bobes et al. 2010). Since April 
2011, screening for CVD risk in patients with SMI and diabetes has become 
equal in the respect of payment received (figure 10.1 and 10.2 - BMA and NHS 
Employers 2011). The standards for cardiometabolic screening for diabetes and 
SMI share several similarities but are not identical. Nevertheless all patients 
with SMI and diabetes should, as a minimum, have their BP, body mass index 
(BMI), blood glucose (or HbA1c) and cholesterol (or cholesterol:HDL ratio). 
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Ideally information should be exchanged about the benefits of diet, exercise and 
smoking cessation.  
 In the last chapter I explained my study which compared the level of 
screening for CVD in five practices in Northamptonshire, England (Hardy et al. 
2013a). I used two samples, patients with diabetes and patients with SMI. There 
was significantly less screening in patients with SMI.  This study is an attempt to 
replicate this finding using a national sample.  
 
Figure 10.1 Mental Health Indicators 2011/12 
MH8. The practice can produce a register of people with schizophrenia, bipolar 
disorder and other psychoses 
MH11. The percentage of patients with schizophrenia, bipolar affective disorder 
and other psychoses who have a record of alcohol consumption in the 
preceding 
15 months 
MH12. The percentage of patients with schizophrenia, bipolar affective disorder 
and other psychoses who have a record of BMI in the preceding 15 months 
MH13. The percentage of patients with schizophrenia, bipolar affective disorder 
and other psychoses who have a record of blood pressure in the preceding 15 
months 
MH19. The percentage of patients aged 40 years and over with schizophrenia, 
bipolar affective disorder and other psychoses who have a record of total 
cholesterol:hdl ratio in the preceding 15 months 
MH20. The percentage of patients aged 40 years and over with schizophrenia, 
bipolar affective disorder and other psychoses who have a record of blood 
glucose or HbA1c in the preceding15 months 
MH16. The percentage of patients (aged from 25 to 64 in England and Northern 
Ireland, from 20 to 60 in Scotland and from 20 to 64 in Wales) with 
schizophrenia, bipolar affective disorder and other psychoses whose notes 
record that a cervical screening test has been performed in the preceding five 
years 
MH17. The percentage of patients on lithium therapy with a record of serum 
creatinine and TSH in the preceding nine months 
MH18. The percentage of patients on lithium therapy with a record of lithium 
levels in the therapeutic range in the preceding four months 
MH10. The percentage of patients on the register who have a comprehensive 
care plan documented in the records agreed between individuals, their family 
and/or carers as appropriate 
 
British Medical Association and NHS Employers (2011) 
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Figure 10.2 Diabetes Indicators 2010/11 
 
DM 19.The practice can produce a register of all patients aged 17 years and 
over with diabetes mellitus, which specifies whether the patient has Type 1 or 
Type 2 diabetes 
DM 2.The percentage of patients with diabetes whose 3 notes record BMI in the 
previous 15 months 
DM 5. The percentage of patients with diabetes who have a record of HbA1c or 
equivalent in the previous 15 months 
DM 23. The percentage of patients with diabetes in  whom the last HbA1c is 7 or 
less (or equivalent test/reference range depending on local laboratory) in the 
previous 15 months 
DM 24. The percentage of patients with diabetes in  40-70% whom the last 
HbA1c is 8 or less (or equivalent test/reference range depending on local 
laboratory) in the previous 15 months 
DM 25. The percentage of patients with diabetes in whom the last HbA1c is 9 or 
less (or equivalent test/reference range depending on local laboratory) in the 
previous 15 months 
DM 21. The percentage of patients with diabetes who have a record of retinal 
screening in the previous 15 months 
DM 9. The percentage of patients with diabetes with a record of the presence or 
absence of peripheral pulses in the previous 15 months 
DM 10. The percentage of patients with diabetes with a record of neuropathy 
testing in the previous 15 months 
DM 11. The percentage of patients with diabetes who have a record of the blood 
pressure in the previous15 months 
DM 12. The percentage of patients with diabetes in whom the last blood  
pressure is 145/85 or less                                                                                             
DM 13. The percentage of patients with diabetes who have a record of micro-
albuminuria testing in the previous 15 months (exception reporting for patients 
with proteinuria) 
DM 22. The percentage of patients with diabetes who have a record of 
estimated glomerular filtration rate (eGFR) or serum creatinine testing in the 
previous 15 months 
DM 15. The percentage of patients with diabetes with a diagnosis of proteinuria 
or micro-albuminuria who are treated with ACE inhibitors (or A2 antagonists) 
DM 16. The percentage of patients with diabetes who have a record of total 
cholesterol in the previous15 months 
DM 17. The percentage of patients with diabetes whose last measured total 
cholesterol within the previous 15 months is 5mmol/l or less 
DM 18. The percentage of patients with diabetes who have had influenza 
immunisation in the preceding 1 September to 31 March 
 
British Medical Association and NHS Employers (2011) 
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10.2 Methods 
Guideline Standards 
Since April 2011 in order to receive payment under the terms of the Quality and 
Outcomes Framework, primary care practitioners are required to offer a review 
to people with a diagnosis of SMI every 15 months. This review should include 
measuring BP and BMI; and testing for blood glucose levels (or HBA1c) and 
cholesterol: HDL ratio in patients over 40 years of age. Prior to 2012, to receive 
payment for diabetes, primary care practices were required to offer a review to 
people who had a diagnosis of diabetes every 15 months for BP, glucose, BMI 
and cholesterol. Thus the standards for mental health and diabetes are almost 
identical (apart from the age requirement for blood tests in SMI patients) and 
run in consecutive years (2011 and 2012). 
 
Data Collection 
National data regarding Quality and Outcomes Framework standards for 
2010/2011 and 2011/2012 was collected from the NHS database Health and 
Social Care Information Centre (HSCIC). This data is in the public domain. 
 As CVD screening for patients with diabetes and SMI is a requirement 
under the GP contract, the information collected at source is also stored in a 
national database system called the Quality Management Analysis System 
(QMAS). This system determines practices' contract payments. All information 
from QMAS from the previous contract year (1st of April to the 31st March) is 
displayed on the NHS Information centre public website 
(http://www.ic.nhs.uk/searchcatalogue). The percentage of patients with 
diabetes who had BP, BMI, HBA1c and cholesterol recorded from April 2010 to 
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March 2011 was compared with the percentage of people with SMI with a 
recording of BP, BMI, cholesterol:HDL ratio and blood glucose (fasting or 
random or HBA1c) in 2011/2012. A comparison of patient demographics, diet, 
exercise, smoking advice and waist circumference could not be made. 
Measuring waist circumference and offering diet and exercise information are 
not a contract requirement for diabetes or SMI, and are therefore not recorded 
on this database. As described in the previous chapter, although smoking 
advice is a contract requirement, the data is measured as a practice population 
of combined disease groups and not for each individual long term condition.  
 
Data Analysis 
Chi squared statistic was calculated to explore whether the patient’s diagnosis 
(SMI or diabetes) made a difference to the level of screening given. Analyses 
were done with Statsdirect 2.77. 
 
10.2.1 Other possible methods 
It would not have been possible to gain this information from any other source. 
 
10.3 Results 
The total sample included 2,488,948 patients with diabetes seen in 2010/2011 
and 422,966 patients with SMI in 2011/2012. In 2011/2012 there were 8123 
reporting primary care practices 
 For those with diabetes in the previous 15 months, nearly all patients 
received BMI measure, total cholesterol test, blood pressure assessment and 
HBA1c test.  For those with SMI, in the previous 15 months four-fifths received 
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a BMI measure and almost nine out of 10 patients received blood pressure 
assessment. In the patients with SMI over 40 years of age, just over seven out 
of 10 received cholesterol test (cholesterol:HDL ratio) and just over two thirds 
received a glucose test.  Comparing each category of test revealed that all 
differences were very highly significant between the two groups of patients (see 
table 10.1). However, it has been highlighted that attendance and compliance is 
a significant issue with those who have a diagnosis of SMI; possibly more than 
in diabetes (Shrivastava et al. 2012). Practices are allowed to make exclusions 
of patients who are too unwell or unwilling to attend over the period concerned. 
These exclusions can be removed from the analysis and re-analysis is shown in 
table 10.2. After exclusions, nearly nine out of ten patients with SMI received a 
BMI measure and just over nine out of 10 patients received a blood pressure 
assessment. Over four-fifths of patients over 40 years of age received a 
cholesterol test (cholesterol:HDL ratio) and a glucose test.  Comparing each 
category of test between the patients with SMI and diabetes revealed that all 
differences remained very highly significant (see table 10.2).  
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Table 10.1 
 
Adherence of QoF measures of metabolic testing in diabetes vs SMI before SMI exclusions 
 
Diabetes 
Tested 
Diabetes 
% tested 
Severe 
mental illness 
Tested 
Severe mental 
illness %Tested 
Chi 2 Statistic P value 
 
Blood 
Pressure 
2,298,767 96.1% 355,834 84.1% Chi² = 205712  
 
p <.001 
 
BMI 2,329,552 97.5% 335,652 79.4% Chi² = 691072   
 
p<.001 
 
Cholesterol 2,378,115 98.4% 218,539 71.7% Chi² = 262020   
 
p <.001 
 
HBA1c or 
glucose 
2,363,485 94.9% 197,494 64.8% Chi² = 495257   
 
p <.001 
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Table 10.2 
 
Adherence of QoF measures of metabolic testing in diabetes vs SMI after SMI exclusions 
 
 
 
 
 
 
Diabetes 
tested 
Diabetes 
% tested 
Severe 
mental illness 
tested 
Severe mental 
illness% tested 
Chi 2 Statistic P value 
Blood 
Pressure 
2,298,767 96.1% 218,539 91.7% Chi² = 97549   
 
p <.001 
 
BMI 2,329,552 97.5% 335,652 88.7% Chi² = 96465   
 
p <.001 
 
Cholesterol 2,378,115 98.4% 355,834 81.9% Chi² = 61743   
 
p <.001 
 
HBA1c or 
glucose 
2,363,485 94.9% 335,652 84.8% Chi² = 313117   
 
p <.001 
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10.4 Discussion 
This research demonstrates that in a very large UK sample, testing for CVD risk 
factors is much less common in patients with SMI than in those with diabetes.  
 Both conditions are similarly remunerated by a points system through the 
payment contract. The non-invasive clinical monitoring, for example of blood 
pressure and BMI was more thorough than those requiring a blood test 
(cholesterol, cholesterol:HDL ratio, glucose and HBA1c) in both SMI and 
diabetes patients, though fewer patients with SMI than diabetes had these 
checked. In patients with SMI only 64.8% of those over 40 years old received a 
glucose test for diabetes in the preceding 15 months, but about 95% of all those 
with diabetes received HBA1c over a similar period. It can be argued that these 
tests are not directly comparable as one test is for case-finding (glucose) and 
one is for monitoring treatment adherence (HBA1c). However the purpose of 
monitoring cholesterol, BMI and BP is the same in both groups, that is to 
monitor background metabolic risk. In patients with SMI only 71.7% of those 
over 40 years of age received a cholesterol check as compared to 96.1% of all 
patients with diabetes. If we were able to measure the record of glucose and 
cholesterol:HDL in all patients with SMI regardless of age, the level of 
monitoring is likely to be even lower.   
 These findings are consistent with other research examining routine 
monitoring prior to explicit guidelines (Mitchell et al. 2012), in that more patients 
with SMI had their BP and weight checked than their cholesterol and glucose. 
However, they differ in that the level of screening of patients wIth SMI is higher 
across all the four screening elements. Several explanations are possible. 
Financial incentives given to primary care practices might have improved 
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monitoring in line with the observation that most targets are achieved. My study 
described in the previous chapter (Hardy et al. 2013a) was carried out before 
specific payment indicators were imposed. The results showed lower rates of 
screening for all CVD risk in patients with SMI (21%) than found in this national 
study (74.7%). However, as patients under 40 years of age were not required to 
have two of the elements tested (cholesterol and glucose) in the second study; 
this higher level of achievement is not comparable. Another explanation is that 
monitoring has improved in the last one to two years. A study examining the 
monitoring of patients with SMI in UK primary care settings over 2000–2007 
found rates were very low (Osbourn et al. 2011); but there was a trend for 
improvement in both patients with and without SMI. This concurs with the 
results in the study described in the last chapter and this one. Though the 
change is small, screening for patients with diabetes has increased from 96% to 
97.3%.  
 The findings of this study show that patients with diabetes receive 
considerably more thorough CVD screening than patients with SMI. However in 
terms of years lost through mortality, SMI is probably more serious than 
diabetes with an age gap of 15-22.5 years in several studies (Wahlbeck et al. 
2011, Chang et al. 2011, Saha et al. 2007). Patients with SMI should be 
considered a vulnerable group at least equivalent to diabetes. Barriers to 
medical care include lack of resources or time, low organizational support, 
clinicians' reluctance to change, concerns over the quality of the guidelines and 
lack of ownership (Osbourn et al. 2007). 
 The relatively low achievement of SMI targets are in fact an outlier in the 
targets. Given these findings of disproportionately low surveillance of patients 
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with SMI, even in an incentivised system, what can be done to improve physical 
healthcare? At present there is no systematic education on physical comordidity 
and no culture of routine physical testing in many mental health or primary care 
organizations. In psychiatric settings physical health/metabolic clinics have 
been suggested. To date there are no RCTs of physical health monitoring 
clinics but one RCT of note has examined a package of medical care in the 
PCARE study (Druss et al. 2010). Four hundred and seven subjects with SMI 
were randomly assigned to either the medical care management intervention or 
usual care. At a 12-month follow-up evaluation, the intervention group received 
more than twice the level of preventive services compared to the usual care 
group (they also received a significantly higher proportion of evidence-based 
services for cardiometabolic conditions). However, many patients with SMI have 
no contact with secondary care services (Lester et al. 2004) and payment is 
received by GPs through their contract for screening this group for CVD risk. 
Therefore in order to reach all patients there needs to be systems for monitoring 
people with SMI in primary care too. 
 It is important to note that effective monitoring of CVD risk factors is not 
sufficient on its own, as appropriate treatment is also mandatory. Data from 
National Ambulatory Medical Care Survey from 1992 and 1996 found that in 
1,600 office visits of patients with mental illness who were documented 
smokers, psychiatrists offered smoking-cessation counselling at 12% of the 
visits, and diet and exercise counselling at 6% and 4% of visits, respectively 
(Himelhoch and Daumit 2003). In my audit of five primary care practices in 
Northampton described in chapter nine (Hardy et al. 2013a), 57% of people with 
SMI received advice about smoking, 14% were given information about 
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exercise and only 13% were offered diet guidance. In short, there is a question 
over the ability of health professionals to respond if a problem is found. Physical 
comorbidity is often unrecognized and inadequately treated in those with mental 
ill health (Bernardo et al. 2009).  
 
10.5 Limitations 
The study was retrospective, not prospective. It was reliant on secondary data. 
The observations were made at different time points as there was a change in 
the data collection requirements for each condition. It was not possible to adjust 
for any potential confounders. 
 
10.6 Summary of chapter 
In this chapter I have described how the introduction of specific contract 
incentives for people with SMI since April 2011 may be partly successful in 
increasing the level of screening in this group, but how inequalities remain 
compared with diabetes.  
This study has been published as: 
Mitchell A and Hardy S. (2013) Surveillance for metabolic risk factors in patients 
with severe mental illness vs diabetes: National Comparison of Screening 
Practices. Psychiatric Services. (in press) 
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Chapter eleven: Does training practice nurses about the 
physical health of patients with severe mental illness motivate 
them to provide screening for this group? 
 
In the last two chapters I have described how people with SMI receive less 
screening for CVD than those with diabetes. The overall aim of this thesis is to 
increase this level of screening by training practice nurses how to provide health 
checks for this group of patients. This chapter describes the effectiveness of the 
PhyHWell training package in modifying practice nurses’ attitudes and 
misconceptions about the physical health of people with SMI. 
 
11.1 Background 
I have described in chapter two that Government guidelines recommend that 
patients with SMI have an annual physical health check in order to identify risk 
factors for CVD (NICE 2010a, 2006) and that people generally attend primary 
care for routine health monitoring (Osborn et al. 2007). Despite this, my studies 
(explained in chapters nine and ten) show that there is little evidence these 
health checks are routinely taking place (Hardy et al. 2013a, Mitchell and Hardy 
2013). 
 Practice nurses are already competent in carrying out physical health 
checks (Osborn et al. 2010). However, as explained in chapter seven, they lack 
training in mental illness and the most recent analysis of their perceived 
responsibilities did not include SMI (Crossman 2008). Even if practice nurses 
are not inviting patients with SMI to attend for a physical health check, this 
group may still present themselves for other reasons (Harvey et al. 2005). Up to 
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50% of patients with SMI in England receive help from a mental health 
professional in secondary care (BMA & NHS Employers 2011) who could have 
a role in ensuring a health check has taken place in primary care (Osborn et al. 
2010). As practice nurses are not used to working specifically with people with 
SMI, they may not have a system for informing community mental health 
workers (CMHWs) about patients that they have invited for a health check. A 
survey of practice nurses revealed that only 7% have regular contact with a 
Community Psychiatric Nurse (Gray et al. 1999). It is possible that if CMHWs 
attend practice nurse training, collaborative working maybe promoted between 
primary and secondary care. Kelley et al. (2009) argue that the benefit of 
interprofessional learning is that students will have a better working knowledge 
of other professionals, enabling them to make appropriate referrals to other 
professions and work more closely with them. In my view, a focussed training 
delivered in the practice setting may be effective in breaking down practice 
nurses’ misconceptions. 
   
11.2 The training package 
When describing the intervention to participants, Craig et al. (2008) suggest 
using a multifaceted approach involving a mixture of interactive rather than 
didactic educational meetings, including feedback, reminders and local 
consensus processes. 
 
11.2.1 Developing the Package 
I developed the Health Improvement Profile for Primary Care or HIP-PC in 
collaboration with Professor Gray from the original tool developed for secondary 
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care (Hardy & Gray 2010) and constructed a website for practice nurses. This 
has been described in more detail in chapter eight. 
 
11.2.2 Intended Learning Outcomes 
Intended learning outcomes for practice nurses were: 
 Understand the definition of SMI. 
 Know the signs and symptoms of SMI. 
 Be familiar with the epidemiology of SMI. 
 Be aware of the impact of SMI on physical health particularly the 
increased risk of CVD. 
 Be confident in navigating and using the website. 
 Be confident in carrying out a health check using the HIP-PC manual. 
 Be competent in entering data onto the computer template. 
 Feel confident in providing this role within their practice. 
 Liaise with relevant healthcare professionals and agencies.  
 
11.2.3 Training 
A two hour foundation block of training was delivered at the practice nurses’ 
usual place of work. In order to ensure the learning outcomes were achieved 
the training consisted of group discussion and demonstration (carrying out a 
simulated health check using the template added to their computer system). 
This fits with the recommendations given by the authors of a qualitative 
systematic review on educational interventions in primary mental health care 
Howe et al. 2006). These are that the impact of educational interventions which 
support constructive learning from personal data are likely to be more effective 
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than courses working with theory alone or 'imaginary' patients, even when these 
are well designed and carried out.  
 The link CMHW was invited to attend the training to increase the practice 
nurse’s motivation to work with them. It was my belief that learning together 
would help them to communicate with each other. 
 
11.3 Method 
This is a before and after study. Practice nurses participating in the study were 
asked to complete two questionnaires immediately before and directly after 
training (misconceptions and attitudes – appendices 7 and 8). Their motivation 
to work with CMHWs was assessed immediately after training (appendix 9). 
Post examination was carried out instantaneously due to the difficulty in gaining 
access to practice nurses. 
 
Preparing primary care practices for training 
Prior to inviting GPs to participate in training, I attended one of their regular 
meetings where a representative from all 31 practices in Northampton is usually 
present. I carried out a presentation describing the project and what they would 
need to do in order to participate. A letter was sent (with accompanying detailed 
information – appendices 10 and 11) to each GP practice representative. A 
practice nurse was identified from each practice to be the project lead for their 
organisation. Before the training a meeting was held with the Practice Manager 
to discuss giving the practice nurse(s) adequate time and support to carry out 
the physical health checks once they had received the training. 
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 To support the delivery of the health checks by the practice nurse, the 
following additional preparatory work was undertaken with a member of the 
administrative team: 
 Checking that the SMI register was accurate to ensure every patient is 
invited. 
 Adjusting the physical health check computer template to ensure it 
contained all the necessary parameters. 
 Discussing possible systems of inviting appropriate patients. 
 
Developing the questionnaires 
I searched the literature to see if there were any validated measures of attitudes 
to the physical health of people with SMI. It is recommended to employ 
previously used validated questionnaires that have been administered in similar 
settings and capture variables that are of interest according to the study 
hypothesis as they do not need to be tested for reliability. Additionally, if the 
mode of administration is similar to the original questionnaire, results can be 
compared for different studies and also combined for meta- analysis (Edwards 
2010). As I did not discover any (there has since been a tool developed – 
Robson and Haddad 2012) I decided to develop my own evaluation. If a new 
questionnaire is to be developed, it should be pilot tested and validated in order 
to evaluate if it is measuring what it supposed to measure and is it doing it 
reliably (Streiner and Norman 2004). Consultations were carried out with 
practice nurses to develop the content of the questionnaires using an item pool 
created by me. This item pool was created from genuine statements by practice 
nurses in discussions with me over the previous year. In order to check the face 
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validity of the questionnaires, they were reviewed by six practice nurses, four 
mental health nurses and two academics who gave feedback e.g. one 
academic suggested including a question about the side effects of antipsychotic 
medication. Questions pertaining to basic demographic data (sex, ethnicity and 
years of experience as a registered nurse) were included. This feedback was 
carried out via email. Much of the feedback was positive without comment. In 
retrospect, this may have reflected that the participants had not fully analysed 
the questionnaires. A formal meeting would have assured that the professionals 
were studying the questionnaires and would have encouraged further ideas 
through discussion. 
 Misconception questionnaire. This measures the nurses’ misconceptions 
of the physical health risks factors associated with people with SMI. Ten 
misconceptions were presented for which participants indicated whether 
they agreed or disagreed. 
 Attitudes Questionnaire. This measures the nurses’ attitudes towards 
providing physical health checks for people with SMI. Participants had 
the option to either agree or disagree with these beliefs. 
 Motivation to work with CMHW Questionnaire. This aims to determine 
the practice nurses’ motivation to engage with their secondary care 
colleagues regarding patients with SMI and any service developments.  
  
Data Analysis 
I have used descriptive statistics to measure the nurses’ misconceptions, 
attitudes and motivation. Each question carried a score of which I calculated the 
mean and standard deviation reached by all the nurses. Following advice from 
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Allan Clarke, I used the unpaired t-test to measure the difference in the scores 
before and after training. The t-test assesses whether the means of two groups 
are statistically different from each other (Plitcha and Garzon 2009). 
 
Ethical approval   
As this project is a service evaluation it did not require ethical approval. Each 
participating practice gave written consent (appendix 12). The nurses were not 
required to sign a consent form. They were given an information sheet 
(appendix 13) making clear that consent is implied by filling out the 
questionnaire which is the usual practice for surveys undertaken in the UK.  
 
11.3.1 Other possible methods 
The method I used is recommended by Hennekens and Burning (1987) to 
measure the effect of an intervention. The risk of bias would have been reduced 
if I had been in the position to ask someone else to deliver the training or to 
carry out the evaluation. 
 
11.4 Results 
Six GP practices agreed to take part. There was considerable variation in the 
number of people with SMI registered with each one. The mean number of 
patients was 80 (range 13 to 123 – sd 45). The average percentage of SMI 
patients as a proportion of each practice population was just under one percent 
(range: 0.3% to 1.89% - sd 0.56).  
 Practices identified a mean of 1.3 nurses (range: 1 to 2); a total of eight 
nurses agreed to take part. They were all white British females who on average 
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had been working as a registered nurse for 23 years (range: 3 to 42). None of 
the nurses had any prior training in providing physical health checks for people 
with SMI but one had previously taken on the role.  
 The mean number of nurses answering correctly on the misconception 
questions was 2 (sd=3.17) pre-training and 6 (sd=0.92) post training [p=<.01, CI 
0.41 (0.63 to 0.19), t=3.93] (see Table 11.1). This suggests that training had 
been effective in modifying nurses’ misconceptions of SMI and physical health; 
for example, they virtually all agreed that people with SMI tended to die earlier 
and knew how to deal with sedation caused by antipsychotics.  
 The mean number of nurses answering correctly on the attitude 
questions was 5 (sd=1.55) pre-training and 6 (sd=1.49) post training [p=0.50, CI 
5.50 (-0.85 to 11.85), t=11.00] (see Table 11.2). Following training, the practice 
nurses’ attitudes towards a number of parameters were only slightly shifted in a 
positive direction; for example, they nearly all believed that when they are 
delivering a health check they can help patients with SMI identify triggers that 
cause worsening symptoms and that they can assist them to maintain 
meaningful activities. 
 The results from the motivation to work with CMHW questionnaire 
revealed that practice nurses would be much more likely to be motivated to 
work with CMHWs regarding patients and service developments (see table 
11.3)
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Table 11.1 The number of participants who disagreed with common misconceptions about physical health and SMI (n=8) 
 
1. Items Before  n  (%)          After    n (%) 
People with mental illness die five years earlier than the general population (F)   0 (0)   7 (87.5) 
2. Antipsychotic medication should be increased if the patient stops smoking (F) 
3.  
4. Psychotic symptoms can be improved in schizophrenic patients by using caffeine (F) 
  0 (0)       
       
     7 (87.5) 
6 (75) 
 
6 (75) 
5. If the patient is not under the care of the Community Mental Health team, then they do not need a care plan (F)       7 (87.5)   8 (100) 
6. Patients who take lithium need their lithium levels monitored every six months and their creatinine and thyroid 
levels measured every year (F) 
  0 (0)   5 (62.5) 
7. If the elevation of a patient’s prolactin levels is <2000 mIU/L, then it is reasonable to continue to monitor the 
level without any further action (F) 
   1 (12.5) 6 (75) 
8. It is important to encourage all patients with severe mental illness to drink lots of fluid (F)     0 (50) 6 (75) 
9. As a much smaller proportion of people with SMI are sexually active compared to the general population, they 
are at less risk of acquiring a sexually transmitted infection (F) 
    6 (75)    6 (75) 
Cannabis use is a contributing factor in 50% of schizophrenia cases (F)         0 (0)   5 (62.5) 
10. The side effect of sedation from taking an antipsychotic, cannot be dealt with by the patient taking their 
medication just before they go to bed (F) 
            1 (12.5)     7 (87.5) 
Mean total score                      (n=2, 25%, sd 3.17)   (n=6, 75%, sd 0.92)  
 
  
173 
 
Table 11.2 Trainee attitudes to the physical health of SMI patients (n=8)  
 
11. Items  Before  n  (%)        After    n (%) 
The diagnosis of a patient with severe mental illness affects whether recovery is possible 
You do not need to know the views of your patients with severe mental illness regarding their psychiatric 
medications (F) 
      7 (87.5)     
    6 (75) 
7 (87.5)      
8 (100)  
12. You are not in a position to help your patients with severe mental illness identify people who can assist them 
during a crisis (F) 
    6 (75)  7 (87.5) 
13. You are not in a position to  identify triggers that cause symptoms of your patients with severe mental illness to 
get worse and identify warning signs that come before they get symptoms (F) 
    6 (75)  8 (100) 
14. It is sometimes necessary to disregard the patients’ preferences regarding their physical health in order to 
provide the best treatment (F) 
    2 (25)  5 (62.5) 
15. Many patients with severe mental illness cannot learn how to make well-informed choices about their physical 
care (F) 
4 (50)  5 (62.5) 
16. When providing patients with SMI a health check, you should keep focused on their physical  health (F)    4 (50)  5 (62.5) 
17. You should invalidate the patient’s goal when it is unrealistic (F)      3 (37.5)  6 (75) 
A physical health check appointment does not need to include assisting patients with severe mental illness in 
maintaining activities that are meaningful to them (F) 
            5 (62.5) 8 (100)  
18. The physical health goals of “normal” people are often too stressful for patients with severe mental illness to 
reach (F) 
            5 (62.5)    4 (50) 
Mean total score                      (n=5, 62.5%, sd 1.55)   (n=6, 75%, sd 1.49)  
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Table 11.3 Practice nurse response to motivation to work with CMHW questionnaire 
 
 
Practice nurse motivation to work with CMHW questionnaire 
 
Number of nurses responding to each answer: 
 
 
Question: Would you: 
 
Much more likely 
(score 5) 
More likely 
(score 4) 
Likely 
(score 3) 
Less likely 
(score 2) 
Don’t know 
(score 1) 
Mean 
response (sd) 
 
Contact your own CMHW to inform them about changes in 
health or circumstances of a particular patient? 
 
 
      5 
 
      3 
 
      0 
 
      0 
 
      0 
 
4.62 (0.52) 
 
Contact your own CMHW to ask them about a particular patient? 
 
 
 
      5 
 
      3 
 
      0 
 
      0 
 
      0 
 
4.62 (0.52) 
 
Contact your own CMHW to inform them about new or changes 
in service developments? 
 
 
      4 
 
      3 
 
      0 
 
      0 
 
     1 
 
4.12 (1.36) 
 
Contact your own CMHW to ask them about new or changes in 
service developments? 
 
 
      4 
 
      3 
 
     0   
 
      0 
 
     1 
 
4.12 (1.36) 
 
Develop an individual system of communication between your 
own CMHW 
 
 
 
      5 
 
     3 
 
     0 
 
      0 
 
     0 
 
4.62 (0.52) 
Overall mean response (sd) 
 
 
                                                                                                                                                  4.42 (0.27) 
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11.5 Discussion 
It was disappointing that only six practices agreed to take part. I tried to find out 
the reasons by asking 120 GPs (from the 31 practices invited) at a local training 
event to complete a questionnaire. Only one person completed it, stating they 
had not heard of the project. Therefore I can only hypothesize as to reasons 
why they chose not to participate: e.g. too busy; no extra funding provided; no 
interest in SMI; feel proficient in providing care for this group already; think their 
practice nurses should not be dealing with this group; unaware of the project; 
lack of faith in the trainer. 
 The proportion of patients with SMI registered in each practice is slightly 
higher than the national average of 0.8% (NHS Information Centre 2011). The 
variation in the proportion of people with SMI registered with the participating 
practices may be explained by their location. As would be expected the 
practices with a high population of people with SMI are located in the town 
centre and those with the lower population are located in either a village or quiet 
suburb (McManus et al. 2009). 
 The aim of this study was to establish whether a training package to 
address common misconceptions about the physical health of people with SMI 
was effective in modifying practice nurses’ attitudes and increasing motivation 
to work with CMHWs. This is the first time that anyone has considered whether 
the misconceptions of practice nurses could be a barrier to providing physical 
health checks to people with SMI. Because training was effective in correcting 
misconceptions, these practice nurses might be more motivated to carry out 
health checks for this group of people in their place of work. This study has not 
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illustrated whether training had altered the nurses’ more general perceptions of 
the value of health checks 
 Practice nurses were not aware of the reduced life expectancy of people 
with SMI. This is a possible explanation of why they have not seen screening 
these patients for CVD as part of their role. There are a number of studies that 
have been carried out in primary care in the United Kingdom that are consistent 
with my observation that health checks are not being carried out routinely 
(Roberts et al. 2007, Reilly et al. 2012). In addition, a systematic review of 
primary care studies relating to somatic diseases in patients with schizophrenia 
revealed that healthcare professionals are not proactive in screening these 
patients (Oud & Meyboom-de Jong 2009).  
 A study in the United Kingdom determined that serious and enduring 
disorders such as schizophrenia made up 1.5% of the patients seen by practice 
nurses and an estimated 2% were taking antipsychotic medication (Gray et al. 
1999). This is without proactively inviting patients for a health check. Before any 
change in their motivation to work with patients with SMI can take place, 
practice nurses need to have an understanding of the problem. This is 
highlighted in two models of behaviour change (Prochaska & Di Clemente 1992, 
Rogers 1983). As a result, following training, practice nurses may be more likely 
to offer screening and appropriate interventions; either during a planned health 
check or if the patient presents themselves for another reason, e.g. helping 
them manage the side effects of their medication, such as sedation. 
 I do not know if the attitudes of the participants reflect those of other 
practice nurses. The fact they were asked by their employers to be involved in 
the study may have had some influence. A study to determine the abilities of 24 
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practice nurses to detect psychiatric morbidity concluded that one reason for the 
variation in their skills may be their interest in the subject (Plummer et al. 2000). 
The attitudes of the nurses in this study were fairly positive before training; 
though there appeared to be a small improvement after participation, I cannot 
claim this was due to my intervention. 
 The results show that practice nurses in my study already had an 
awareness of the high chance of contracting a sexually transmitted infection in a 
proportion of this group. This contrasts with mental health nurses who appear to 
underestimate this risk (Hughes & Gray 2008). My results highlight that the 
subject of sexual health may be less of a priority than some of the other issues 
when providing this programme to other practice nurses. 
 I established that following training more practice nurses agreed that 
finding out the views of their patients with SMI regarding their psychiatric 
medications was important. This means they could be more likely to actively 
promote adherence (Gray et al. 2006). The results also indicated, that despite 
the score relating to the recovery of people with SMI remaining unchanged, they 
showed a possibility that they may seek to develop a therapeutic relationship 
with this group of patients. The scores were higher post training for the 
questions relating to discovering the patients’ views and preferences and 
recognizing their own role in providing assistance with emotional or social 
issues. This demonstrates an acceptance to be supportive of the wellbeing of 
the client (Diorio 2001) and not exclusively follow a checklist of physical 
screening. This holistic approach embraces the process of recovery (Smith 
2000).  
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 After completing training, practice nurses displayed that they would be 
much more likely to communicate with their CMHW. This corresponds with a 
study to validate the readiness for interprofessional learning scale in the 
postgraduate context (Reid et al. 2006) which revealed that most participants 
agreed that learning with other healthcare workers would help them to 
communicate better with other professionals. In addition, because the whole 
concept of caring holistically for a patient with SMI is new to practice nurses, 
they may feel that they are supported by having contact with CMHWs. As very 
few Community Mental Health Teams have a clear strategy for communication 
with primary care (England and Lester 2005, Bindman et al. 1997) keeping up 
this contact maybe a challenge. 
 The design of the questionnaires was poor (see limitations). This reflects 
my lack of knowledge and experience when they were designed at the 
beginning of this PhD. I have since been successful in obtaining a bid to 
develop further training (see chapter 14). I wanted to measure how the practice 
nurses perceived their ability and role in carrying out physical health checks for 
people with SMI. I therefore used a likert rating scale which is a technique for 
measuring attitudes (Likert 1932).   The questions are written with a positive 
statement. 
 
11.6 Limitations 
There are limitations to this study. It was designed for a much larger group of 
participants and therefore the results cannot be generalisable. Given the small 
numbers participating, a qualitative approach to data collection could have 
provided more meaningful results. 
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 The correct answers for both the “misconception” and “attitudes” 
questionnaires are all false. This could have had an influence on the results if 
participants realized this after the training and answered the questions as false 
accordingly. 
 Some of the statements in the misconception questionnaire could have 
been confusing. In particular, question one, I have stated that people with SMI 
die five years earlier as a false statement when in fact they do die earlier but by 
12-20 years.  
 The questionnaires were repeated directly after training therefore it is 
possible that participants would remember the questions that were asked pre-
training and through strategic learning remembered the answers by rote. In 
order to discover the durability of any improvements a longer follow-up is 
needed. In retrospect, this could have been carried out electronically without the 
need to meet with the nurses physically. 
 There is potential bias as I delivered and evaluated the intervention. I do 
not know whether the participants were typical or atypical practice nurses. 
 
11.7 Summary of chapter 
In this chapter I have described how practice nurses who complete the physical 
health check for severe mental illness training package have fewer 
misconceptions about SMI and may be more likely to accept carrying out these 
health checks as part of their role; their motivation to work with the CMHW is 
enhanced.  
This paper was published as: 
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Hardy S. (2012) Training practices nurses to improve the health of patients with 
severe mental illness: the effect on beliefs and attitudes. International Journal of 
Mental Health Nursing. 21 (3) 259-265. 
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Chapter twelve: Does training practice nurses increase CVD 
screening  and lifestyle intervention?  
 
In this chapter I describe how training practice nurses increased the level of 
CVD screening and lifestyle intervention given to people with SMI in the five 
participating practices. As the practices varied in the number of patients that 
they serve (the smallest serving approximately 5,000 and the largest 13,000) 
and in their location (urban, surbuban and rural) they provided a reasonable 
national representation. 
  
12.1 Background 
As described previously in my thesis, experts have advocated the need to 
improve CVD monitoring and the provision of lifestyle advice in people with SMI 
(Osborn et al. 2011, De Hert et al. 2009a, Kilbourne et al. 2007, Barnett et al. 
2007). An EPOC (Cochrane Effective Practice and Organisation Care) review 
did not identify any randomised trials which assessed the effectiveness of 
physical health monitoring in this group (Tosh et al. 2010). In the general 
population, authors of a systematic review have concluded that general health 
checks did not reduce morbidity or mortality (Krogsbøll et al. 2012). All the 
fourteen studies included were carried out before 1999; therefore it is possible 
that recent advances in the prevention of CVD may have improved the benefits 
of these checks (Thompson and Tonelli 2012). In contrast to Krogsbøll et al.’s 
observations, a meta-analysis of nurse-provided or nurse-coordinated care 
management programmes for secondary prevention, shows that they are highly 
effective in reducing CVD morbidity and mortality in patients with coronary 
artery disease (Clark et al. 2005). Running nurse led secondary prevention 
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clinics in primary care incurs the cost of nurses' time (Campbell et al. 1998). 
Consequently GPs may view them as expensive and be reluctant to resource 
them (Raftery et al. 2005). In a randomised controlled trial of 1343 patients with 
coronary heart disease, the results showed that these costs were relatively low 
and were linked to health gains that were considerable in terms of deaths, life 
years, and QALYs (Raftery et al. 2005).  
 There is some literature from the 1990s which supports designated 
practice nurse clinics for people with SMI. Kendrick et al. (1994, 1995) tested 
the teaching to GPs of structured assessments of their long-term mentally ill 
patients. They concluded that this can increase their involvement in psychiatric 
care, but as regular structured assessments were not feasible in routine 
surgeries, special appointments with input from practice nurses might be more 
reliable. Burns et al. (1998) carried out a randomised controlled trial in which 
they provided training to practice nurses to carry out structured assessment of 
people with schizophrenia. They concluded that structured assessments by 
practice nurses are feasible with this patient group, but training, targeted at both 
nurses and GPs, is needed if this intervention is to translate into health gain. 
 Since the introduction of a new payment contract in 2004 in England, the 
emphasis of practice nurse clinics has been focussed on long term conditions 
rather than general health checks. Annual clinics to review patients with 
diabetes for example, have become routine (Hall 2008). A recent randomised 
control trial of these clinics run by practice nurses showed equivalent results to 
GPs in respect of lipids, glucose and blood pressure levels and increased 
patient satisfaction (Houweling et al. 2011).  
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 I have explained in previous chapters that the authors of national 
guidance in England recommend that patients with SMI should receive a 
physical health check at least once a year (NICE 2006, 2010a) and how GPs in 
primary care are paid to provide CVD screening for this group every fifteen 
months (BMA and NHS Employers 2012). It is important to repeat these details 
as the change in the way this imbursement is given took place during the period 
of this study. Between April 2004 and March 2011, payment was received if 
primary care practitioners documented that they had completed a review in 
people with SMI. There should have been evidence that the patient was offered 
screening, routine health promotion and prevention advice appropriate to their 
age, gender and health status, but these were not measured. Since April 2011, 
payment is given for recording patients’ alcohol consumption, body mass index 
(BMI), blood pressure, glucose and HDL cholesterol level (if over 40 years), and 
cervical screening within the last five years (if within national screening age).  
 Many GPs in primary care choose to screen people with SMI 
opportunistically for CVD risk when these patients attend the clinic for another 
reason, rather than inviting them for an annual health check by a practice nurse 
(Reilly et al. 2012, Hardy 2011). As the GPs’ usual consultation times are short, 
it is difficult for them to provide adequate lifestyle advice (Phelan et al. 2001). 
For example, a recent study revealed that health education was not a common 
feature of consultations with the SMI group of patients in primary care (Reilly et 
al. 2012). When in a busy clinic, professionals may make assumptions, such as 
a patient with a normal BMI is eating well. These do not necessarily hold true, 
my study examining the food diaries completed by people with schizophrenia 
found that the patient with the lowest BMI had the unhealthiest diet (Hardy and 
  
184 
 
Gray 2011). It is important to have discussions with patients about their lifestyle 
to either encourage a change in unhealthy routines or to motivate them to 
maintain a healthy way of life (Miller 2005, NICE 2012). I argue that creating a 
nurse led clinic for people with SMI would provide sufficient time to achieve this 
effectively, but there is presently no evidence to support this view (Hardy and 
Gray 2010).  
 The aim of this study is to establish whether training practice nurses 
increases the proportion of patients with SMI screened for CVD risk factors and 
given lifestyle advice in primary care 
 
12.2 Method 
Sample and procedures 
Audits are suggested as one method of evaluating a complex intervention 
(Craig et al. 2008). This is a repeat audit monitoring how well primary care 
practitioners are meeting their duty to screen people with SMI for CVD risk 
factors and give them lifestyle advice. This audit will provide information to 
decide how this might be improved. Practice nurses will take part in training to 
deliver health checks for people with SMI. The audit will be carried out pre and 
post training as described below.  
 
Audit Standards 
The standards for CVD screening and lifestyle advice were derived from 
published guidelines (NICE 2006, 2010a, De Hert et al. 2009a). These were 
that all patients with SMI should, as a minimum, have their blood pressure, BMI 
(or waist circumference), blood glucose (or HbA1c) and cholesterol measured at 
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least once a year. They should also be given advice about diet, exercise and 
smoking cessation annually.  
 
Data Collection 
This was an audit that took place between September 2009 and August 2010 
and was then repeated following the training of practice nurses between 
September 2010 and August 2011. Patients were identified from the SMI 
register of each of the five participating practices. Demographic information 
(age, gender) and evidence of whether screening and lifestyle advice had been 
given in the last year was extracted manually from the electronic patient 
records. 
 
Data Analysis 
Following advice from Allan Clarke, I used relative risk to calculate whether 
training made a difference to the level of screening and lifestyle advice given to 
people with SMI as a group. The t-test was employed to determine the 
difference between the mean number of interventions received by each 
individual patient with SMI before and after training. This analysis was done with 
SPSS, version18. 
 
12.2.1 Other possible methods 
An RCT would have provided a comparison and reduced confounders. Due to 
the difficulty in recruiting practices and the fact I was conducting the project 
alone, this was not possible. 
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12.3 Results  
I invited 31 primary care centres in Northampton to take part in this project, five 
agreed. From the computer records I identified 400 patients from the SMI 
register. The number of patients (n=400) in the first and second audit remained 
unchanged. However, I cannot assume that they were all the same patients as I 
did not record how many of them left or joined the practice during this time. That 
said, the turnover of patients in primary care in GP practices is generally very 
modest and therefore it is only likely to be a few patients who were different 
(Stokes et al. 2004). Table 12.1 shows that the demographic profile (age and 
gender) of the sample remained broadly similar between the two audits. Most of 
the participants were male and the majority of them were middle-aged.  
 Table 12.2 shows the proportion of patients that had each element of a 
health check completed in the year before and after Practice Nurse training. In 
terms of CVD screening factors, in the first audit the most commonly assessed 
element was blood pressure, more than half the patients that participated had 
this checked. BMI was recorded in the records of a little under half of patients. 
Around a third of patients had had a blood test for cholesterol and glucose 
levels. One in five patients had all four risk factors checked. Table 12.3 shows 
the elements of the health check delivered to each patient before and after 
training. The mean number of interventions received by each patient for 
screening was fewer than two from a possible four in the first audit. In the 
second audit following training, there was a significant increase in the proportion 
of patients receiving each health check element. Three quarters of the patients 
had their blood pressure checked and over half had their BMI recorded. Just 
under half were given blood tests for glucose and cholesterol levels. There was 
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no significant increase in the number of patients receiving all elements of CVD 
screening. The mean number of interventions received by each patient for 
screening was nearly two and a half from a possible four which was a significant 
increase. 
 Turning to lifestyle counselling, in the first audit just over one in ten 
patients with SMI received diet and exercise advice and over half received 
smoking advice. Around one in ten patients received all three elements of 
lifestyle guidance. From a possible three lifestyle interventions, patients 
received less than one. Following training there was a significant increase in the 
three elements of lifestyle advice giving. Just over a third of patients received 
diet and exercise advice and around two thirds were given information about 
smoking. From a possible three lifestyle interventions, patients received nearly 
one and a half.  
 In the first audit around one in twelve patients received a complete health 
check (all seven elements), this increased significantly following the training to 
more than one in seven. This is in fact, almost a doubling of patients receiving a 
comprehensive health check. The mean number of both screening and lifestyle 
advice elements from a possible seven received by each patient increased from 
just over two and a half to nearly four. 
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TABLE 12.1, age distribution of participants 
 
 
 
 
 
 
 
Age category  16-35   36-55 
    
   56+ 
 
 
 
 n   %   n    %   n    % 
 
First audit (n=400) 
 
96, 24 
 
176, 44  
 
128, 32 
 
Second audit (n=400) 
 
94, 23 
 
179, 45 
 
 
127, 32 
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TABLE 12.2, proportion of patients that had each element of a health check completed in the year before and after 
Practice Nurse training 
 
 
 
                                Completed at health check    
Component of health check 
Pre-training  year   
(n=400) 
Post-training year  
(n=400) 
Relative risk (95% CI) 
  n,  %  (95% CI)   n,  %  (95% CI)  
CVD risk factors    
Glucose 125, 31 (27,36) 179, 45 (40-50) 1.43 (1.19, 1.72, p<.01) 
Blood pressure 245, 61 (56, 66) 300, 75 (70-79) 1.22 (1.11, 1.35, p<.01) 
Cholesterol 144, 36 (31, 41) 177, 44 (39, 49) 1.23 (1.04, 1.46, p=.02)  
Body mass index (BMI) 186, 47 (42, 51) 219, 55 (50, 60) 1.18 (1.03, 1.36, p=.02) 
All risk factors 79,   20 (16-24) 91,   23 (19-27) 1.15 (0.88, 1.51, ns) 
Lifestyle advice    
Diet 50,   13 (10, 16) 136, 34 (30, 39) 3.06 (2.03, 3.65, p<.01) 
Exercise 56,   14 (11, 18) 138, 35 (30, 39) 2.46 (1.87, 3.25, p<.01) 
Smoking 219, 55 (50, 60) 279, 70 (65, 74) 1.27 (1.14, 1.42, p<.01) 
All three elements 43,   11 (8, 14) 112, 28 (24, 33) 2.60 (1.89, 3.60, p<.01) 
All elements of health check 33,    8  (6, 11) 60,   15 (12-19) 1.82 (1.22, 2.72, p=.01) 
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TABLE 12.3, elements of the health check delivered to each patient with SMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Elements Before After 
 
Significance   
   
 Mean  (sd     95% CI) Mean  (sd     95% CI) 
 
 
CVD screening (out of 4) 1.83   (1.53, 1.68 to 1.98) 2.41    (0.47, 2.36 to 2.46) 
 
t=-6.99, p<.05 
 
Lifestyle (out of 3) 0.85   (0.95, 0.76 to 0.94) 1.41    (1.41, 1.27 to 1.55) 
 
t=-6.98, p<.05 
 
Screening and lifestyle (out of 7) 2.69   (2.22, 2.47 to 2.91) 3.85    (1.37, 3.72 to 3.98) 
 
t=-8.22, p<.05 
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12.4 Discussion 
The aim of this study was to establish whether training practice nurses 
increases the proportion of the patients in their practice with SMI being 
screened for CVD risk factors and given lifestyle advice. Following training, all 
elements of CVD screening and lifestyle advice increased. Importantly, there 
was no decrease in any of the interventions.   
 The proportion of patients receiving cholesterol and glucose 
measurements increased from a third in the first audit to just under half in the 
second. Though this is a large increase, the actual numbers are low in 
comparison to the blood pressure and BMI measures. This is consistent with 
other studies (Eldridge et al. 2011, Smith et al. 2007a, b). Only a quarter of 
patients had glucose and cholesterol tested in the study by Eldridge et al. 
despite a hundred percent having BMI and blood pressure recorded. Smith et 
al. measured glucose in approximately 75% of participants but only recorded 
HDL cholesterol in 22%. They report obtaining fasting samples was not possible 
easily in an outpatient SMI cohort with the various limitations including timing of 
appointments and laboratory schedules. The nurses in my study may have 
experienced similar difficulties, as although unnecessary to fast for total 
cholesterol and HDL (Lab Tests Online 2012, Birtcher and Ballantyne 2004), the 
laboratory in Northampton requires it for HDL. My training suggested recording 
blood pressure and BMI, and testing random glucose or HbA1c and total 
cholesterol in everyone. However six months later there were changes to the 
targets for people with SMI in the GPs’ payment contract; these included 
measuring blood pressure and BMI to all but only offering blood tests to patients 
over forty years old and measuring HDL, rather than total cholesterol (BMA and 
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NHS Employers 2012). This may explain the fact that fewer patients had blood 
tests done than the other screening measures.  
 More patients were given diet and exercise advice following training and 
these interventions were not targets of the payment contract. The level of 
smoking advice increased significantly despite this being a payment target 
when the first audit took place. These findings are consistent with those of 
Bernard et al. (2009) who reported that the training and education of nurses in 
primary care centres promotes the use of prevention practices. This is important 
as the high prevalence of obesity and dyslipidemia in patients with SMI 
suggests that these patients may benefit from interventions that are focused 
more specifically on changing health behaviours (Graves and Miller 2003, Brar 
et al. 2005). As only half of the patients taking long-term primary prevention 
medications following screening adhere to their treatment (Morisky et al. 2008, 
Vrijens 2008), promoting a healthy lifestyle is essential.  
 It is encouraging to observe that in the second audit there was a 
significant increase in the mean number of elements of the health check 
received by each individual patient, both for screening and lifestyle advice. 
However, more research is required to examine whether this has an effect on 
patient outcomes. Unfortunately it was not possible to ascertain whether the 
effect was sustainable with time by examining records after 2011. This was due 
to the project only having two years of funding. It had been hoped at the start of 
the study that a further year may be funded and a third audit could have been 
carried out. However organisational change at the primary care trust level 
prevented this. 
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 Although the training in my study incorporated the suggestion of 
developing a specific nurse led clinic, I had no control of whether the five 
practices participating developed this as a service. As described in the previous 
chapter, practice nurses who have completed training have fewer 
misconceptions about SMI and might be more likely to accept carrying out these 
health checks as part of their role (Hardy 2012), but the organization of their 
overall workload is usually controlled by the GPs (McGregor et al. 2008).  
 
12.5 Limitations 
The research activity around the training may have increased the awareness of 
the increased CVD risk in people with SMI and encouraged healthcare 
professionals in the practices to offer patients screening, rather than it being the 
effect of the training itself (the Hawthorne effect – Mayo 1933).  
 Due to the change in the GP contract, I cannot claim the increases in 
blood pressure and BMI in the second audit were fully due to my intervention. 
 
12.6 Summary of chapter 
Training practice nurses to deliver health checks for people with SMI increases 
the level of screening and lifestyle advice given to this group of patients. More 
research is needed to assess whether the organization of the practice nurse 
workload to include annual health checks for patients with SMI in addition to 
training, will enhance this progress. 
This study has been published as: 
Hardy S, Hinks P and Gray R. (2013) Does training practice nurses to carry out 
physical health checks for people with severe mental illness increase the level 
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of screening for cardiovascular risk? International Journal of Social Psychiatry. 
(in press) 
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Chapter thirteen: What are the views of patients regarding their 
physical health check? 
  
Craig et al. (2008) recommend that appropriate ‘users’ should be involved at all 
stages of the development, process and outcome analysis of a complex 
intervention, as this is likely to result in better, more relevant science and a 
higher chance of producing implementable data. The purpose of this chapter is 
to portray the views of patients with SMI regarding the physical health check 
that was delivered to them by a practice nurse who had received the PhyHWell 
training. These observations will be employed to refine and enhance the 
intervention 
 
13.1 Background 
As described in previous chapters, there is little evidence to show that health 
checks are for people with SMI are routinely taking place (Roberts et al. 2007) 
or that health education is a common feature of consultations with this group of 
patients in primary care (Reilly et al. 2012). This may be because people with 
SMI do not consider themselves at risk of physical health problems and 
therefore do not attend for screening (Campion et al. 2005). However, my audit 
described in chapter 5 demonstrated that they will attend for a physical health 
check when invited to an appointment at a specific time and date with a named 
person (Hardy and Gray 2012).  Additionally, a qualitative study from the 
perspectives of individuals with a mental illness, established that this group of 
patients thought it would be advantageous if primary health care providers 
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focused on preventative health and early detection of physical health problems 
(McCabe and Leas 2008). 
 Two studies concluded that people with SMI give less attention to their 
lifestyle and physical health needs due lack of knowledge rather than poor 
motivation (Buhagiar et al. 2011, Campion et al. 2005). In fact, other research 
has shown that people with SMI possessed a high positive attitude towards their 
physical health care but it is the lack of support and negative staff attitudes that 
are possible barriers to their participation in lifestyle interventions (Roberts and 
Bailey 2011, Brunero and Lamont 2010). People with schizophrenia consider it 
important that the healthcare professionals have the ability to inspire their 
confidence and that they are kind and patient (Lester et al. 2003). They also 
want to know what services are available to assist them to make informed 
decisions and adopt proactive health choices (McCabe and Leas 2008). 
Additionally, peer and staff support, knowledge, personal attributes and 
participation of staff have been identified as possible incentives for improving 
the health of this group (Roberts and Bailey 2011).  For example, Campion et al. 
(2005) reported that one third of patients with SMI in their study said they would 
increase their physical activity following advice from a doctor. 
 A qualitative study examining personal (or holistic) care of all patients in 
general practice reported that patients regardless of diagnosis wanted to be 
treated as a “whole person” rather than just treating the presenting illness 
(Tarrant et al. 2003). The patients referred to the importance of professionals 
knowing about them and their family history. The nurses in this study described 
themselves as specialists in this respect. A mental health service user with a 
diagnosis of schizophrenia responded to this study (Antoniou 2003). She 
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emphasized that personal care is very important to mental health service users 
who are trying to survive in the community. Understanding the relationship from 
the perspective of persons with SMI may provide insight into how this 
relationship can be formed into a long-term working partnership with positive 
health outcomes (Galon and Graor 2012). 
 In this study my primary objective was to examine the patients’ view of 
the physical health check that was delivered to them by a practice nurse who 
had received PhyHWell training. I hoped to employ these observations to refine 
and enhance the intervention. 
 
13.2 Method 
I have used a qualitative method of research for this study. I chose to interview 
patients as this allowed for some flexibility in administration, clarification of 
questions and the use of follow up questions (Adler and Clark 2011).  The 
advantage of interviewing is the use of open-ended questions and probing. This 
gives participants the opportunity to respond in their own words, rather than 
forcing them to choose from fixed responses. Open-ended questions can evoke 
responses that are meaningful to the participant, explanatory in nature and 
unanticipated by the researcher. Probing allows the researcher to ask why or 
how after the initial participant responses (encouraging them to elaborate on 
their answers) and engage with them according to their individual personalities 
and styles, 
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Recruitment  
I intended to interview twelve patients from three of the participating practices 
who had had a health check by a nurse trained in the PhyHWell project. I aimed 
to to build a sample representative of the population who have had a health 
check. It was planned that this would be achieved by using purposive non-
random sampling by selecting a distribution of gender and diagnosis (three men 
and three women with bipolar disorder and three men and three women with 
schizophrenia), age (three patients from each age group 18-28 years, 29-39 
years, 39-49 years and over 50 years) and ethnicity (one patient who belongs to 
the black minority ethnic sector diagnosed with bipolar and one with the 
diagnosis of schizophrenia). These characteristics would reflect the diversity 
and breadth of the sample population. 
 Each practice was asked to identify one male and one female patient 
with schizophrenia and the same for bipolar disorder. They were asked to 
include one patient from each age group. The practice that had the highest 
percentage of patients belonging to the black minority ethnic sector was 
requested to include a patient of either sex from this group. A member of the 
administrative team from each participating practice generated a list of eligible 
patients using these criteria. The first patient listed in each category was then 
selected. The names of the identified patients were checked by one of the 
healthcare professionals to ensure they had mental capacity to consent. As I 
recognized that it was unlikely that everyone invited would attend, I aimed to 
invite eight people from each of the three identified practices. 
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Conduct of Interviews 
I followed this topic guide:  
 How do you think you look after your physical health? 
 How would you describe your physical health (e.g. good, poor)? 
 Have you got any concerns about your physical health? 
 Where would you go if you had a physical illness? 
 How often do you visit your GP? 
 What did you think about the health check you had (interventions, nurse 
delivering health check)? 
 Has the health check encouraged you to make any lifestyle changes? If 
so, what are they? 
Open ended questions were asked in order not to lead the patient. A tape 
recorder was not used. After consultation with people with schizophrenia, I 
determined that this could be unacceptable to some participants because of 
paranoid symptoms and therefore may restrict involvement. An assistant was 
used to take notes. This afforded a lack of distraction for me by having to write. I 
was able to keep eye contact with the patient and maintain the flow of 
conversation. However, the patient may have felt uncomfortable talking in front 
of another person or have been distracted by their presence. 
 
Data Analysis 
Thematic analysis was conducted on the notes from the interviews. I followed 
guidance from Howitt and Cramer (2010) as described in chapter six. I have 
driven some of the themes by using a topic guide. An example of one theme 
was the patients’ concerns about their physical health which emerged from 
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asking them about this directly. I discussed these with my supervisor Dr 
Katherine Deane. 
 
Ethical approval 
The Regional Ethics Committee (through proportionate review) gave approval 
on the condition there was an assistant to take notes (appendix 14 and 15). 
Additionally, I made my own notes immediately following the interviews in order 
to record some of my observations about the patients. 
 
13.2.1 Other possible methods 
The use of questionnaires rather than interviews may have provided me with 
the views of more patients. 
 
13.3 Results 
From a total of 29 invited patients, five attended. The first practice identified 
eight patients using the criteria and one turned up. As they had many eligible 
patients they were able to invite a further eight and again one attended. The 
second practice was very small and only had five eligible patients. They were all 
invited and one came to the interview. The third practice invited eight patients 
and two of them attended. 
 Table 13.1 illustrates the demographic information of the participants. 
None of them were working and the majority had no regular support from 
secondary care services. 
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13.3.1 Observations 
Though all the patients were willing to take part in the interviews, their answers 
were in the main, very brief. It was difficult to get them to elaborate on the points 
they had made. 
 All the patients arrived on time for their interview without exception. Most 
appeared clean and well kempt. The majority of patients were initially a little 
guarded until they listened to the verbal explanation of the study. Finding out 
that the interviewer (me) was a nurse seemed to be a reassuring factor.  
 One patient lived with her husband who was present during the interview. 
She responded to all her questions but looked to her husband for confirmation 
of her answers. This patient stated that she was very happy with all the care 
received now and in the past. Only one patient declared the opposite. 
 The other four patients who all lived alone indicated that life could often 
be rather difficult. 
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Table 13. 1 Demographic information of participants 
 
 
Patient 
number 
Ethnicity Gender Age Diagnosis 
Year of 
diagnosis 
Living 
arrangements 
Occupational 
status 
 
Social support 
 
 
1 
 
White 
British 
 
 
 
Female 
 
52 
 
Bipolar disorder 
 
2005 
 
Lives alone 
 
Unemployed 
 
None 
2 White 
British 
 
 
Male 48 Schizophrenia 2002 Lives alone Unemployed CPN for injection 
3 White 
British 
 
 
Female 47 Psychotic 
episode 
2002 Lives alone Unemployed 
(carer for son) 
None 
4 White 
British 
 
 
Female 76 Bipolar disorder 2010 Lives with 
husband 
Retired CPN annually 
5 White  
British 
 
Male 25 Paranoid 
schizophrenia 
2002 Lives alone Unemployed Weekly visit from 
support agency 
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13.3.2 Patients’ understanding of physical health 
All of the patients appeared to have a good understanding of the importance of 
a healthy diet and taking regular exercise. Some were managing to do regular 
activity and eat well but others reported that it was not so easy. Two patients 
reported that their lifestyle had improved now that their mental state was better. 
Only one patient smoked but he was trying to give up. None of the patients 
were currently drinking alcohol or taking illicit drugs, though one reported a past 
habit. 
 Patients gave very little detail regarding whether they thought they were 
healthy or not. Two patients described joint problems or stiffness caused by the 
medication they were taking. One said the medication had made her gain 
weight. Another was unaware that his medication may increase weight or cause 
problems. 
 
 ‘Sometimes I comfort eat though it doesn’t help me feel better.’ 
 Patient 1 (52 year old female) 
 
 ‘I try to exercise (cycle), sometimes I’m a bit lazy’ 
 Patient 2 (48 year old male) 
 
 ‘Look after health better now – didn’t give a t**s before when ill as  
 didn’t care whether I lived or died’ 
      Patient 3 (47 year old female) 
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 ‘My health is better since I started to look after myself’ 
 Patient 4 (76 year old female) 
 
 ‘My health is bad. I’m not a healthy eater, I smoke…’ 
 Patient 5 (25 year old male) 
 
13.3.3 Patients’ concerns about their physical health 
The patients voiced some concern regarding their physical health though they 
did not display an awareness of the risk of CVD. One patient felt that everything 
that could be done in regard to keeping her healthy was in place. Another said 
they were not worried at the moment but probably would need to consider their 
health in the future. Two patients mentioned side effects of medication. 
 
 ‘My health could be better. I haven’t looked after myself so well  
 since my mental illness. I would rather have side effects (from the  
 medication) than symptoms of bipolar disorder.’ 
 Patient 1 (52 year old female) 
 
 ‘I worry about the stiffness.’ 
 Patient 2 (48 year old male) 
 
Seeking help with a physical illness 
The majority of patients said they would attempt to sort out minor ailments 
themselves and only attend the surgery because they have to, e.g. reviews for 
medication and diabetes or more severe illness. One said this was because she 
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was brought up not go but when her mental health was poor it was because she 
didn’t trust anyone. She thought seeing the same person each time she came to 
surgery would help. Two other patients said they had no confidence in doctors. 
One said he found it easier to talk to the community mental health nurse but she 
didn’t know about physical health and another said she might be happier seeing 
a nurse. A different patient said seeing a nurse would be ok if they were not too 
young and had some understanding of the patient’s situation. 
 
 ‘System at this doctor means you see different doctor or   
 nurse each time. Not good when you have mental illness   
 and cannot trust people.’ 
 Patient 3 (47 year old female) 
 
 ‘I stopped coming (to GP surgery) because doctors would just read notes 
 and say will write to CPN. My physical illness is overlooked because I 
 have a mental health problem. They treat me like a child. I would be 
 more willing to come if this changed.’ 
 Patient 5 (25 year old male) 
 
13.3.4 Patients’ thoughts about the health check  
Most of the patients expressed that they were pleased to be invited and thought 
the health check was worthwhile.  They were glad to be offered advice about 
diet and exercise. Only one said he thought it didn’t matter but he was unaware 
that he had had a health check. The majority of patients said that they had not 
been told what the blood tests were for and would have liked an explanation.  
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Four patients wished that they could have discussed medication and its effects 
on their health. Generally patients wanted more information, both verbal and 
written. 
 
 ‘I don’t know what to ask for, so would like to be offered more information 
 about  services available to me.’  
 Patient 3 (47 year old female) 
 
13.3.5 Patients’ thoughts on the effect of the health check  
All of the patients reported since the health check they had started to make 
changes to their lifestyle, three reporting an increase in regular exercise and 
making changes to their diet. The fourth patient was improving her eating and 
the fifth (who thought he had not had a health check) was working with the 
nurse to decrease his smoking. 
 
 ‘It made me focus on my weight problem. I would like to see nurse 
 weekly but they can only do once a month so my parents are paying for a 
 diet class.’  
 Patient 1 (52 year old female) 
 
 ‘I’m seeing the nurse every six weeks for my diet. I’ve lost 2 stone!’ 
 Patient 4 (76 year old female) 
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13.4 Discussion 
The purpose of this study was to examine the patients’ views regarding the 
physical health check delivered by a nurse trained in the PhyHWell project. 
 It was disappointing that I only managed to recruit five patients to the 
study. It is recognized that recruitment can be the most challenging part of a 
clinical research study and our potential participants shared most of the 
characteristics often associated with poor response (Patel et al. 2003, 
Armstrong et al. 1992). Given this, and the fact that patients with SMI are often 
not forthcoming in presenting themselves with physical ailments, the response 
rate is not surprising (Saha et al. 2007, Andreasen 1995). However, despite the 
small number of participants, I still managed to get a cross section of gender, 
age and diagnosis. I may have recruited more patients had I been in a position 
to invite more. I was limited by the need for room space in the practices and the 
goodwill of the staff to carry out the administration needed.  
 All the patients arrived on time for their interview without exception. It 
could be argued that this exhibits a picture of good organization which is a 
characteristic often described as lacking in people with SMI (Martinez-Arán et 
al. 2004, Andreasen 1995). However we should take into account that of the 
people who did not attend, only a small number telephoned to say they were not 
coming. We do not know if those who did not inform us of their non-attendance 
made a conscious choice not to participate, or if they were too disorganised to 
come. 
 Most of the participants appeared clean and well kempt. This could 
demonstrate that they want to look after themselves and were therefore 
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responsive to advice given by the nurse during the health check. These 
participants may not be typical of the SMI group as a whole. 
 The majority of patients were initially a little guarded until they listened to 
the verbal explanation of the study. This may have been due to concerns about 
confidentiality which any person being interviewed may be worried about (Lavin 
and Maynard 2001). These anxieties are usually allayed following assurance 
that their privacy will be respected (Sekaran 2003). Additionally, some people 
with SMI have an element of suspicion related to their diagnosis which could 
increase their apprehension in this situation (Freeman and Garety 2000). They 
could have been reassured by the knowledge of the interviewer (SH) being a 
nurse because they expected to be approached from a perspective of 
understanding (Freeman and Garety 2006). 
 The majority of patients who attended had no regular support from 
secondary care. This may be because they are well and so were able to make 
the decision to participate. Perhaps the people who were receiving support 
were less well and this is one reason why they did not attend.  
 Most participants answered the questions during the interviews very 
succinctly. This may be characteristic of the cognitive problems of SMI rather 
than indifference (Martinez-Arán et al. 2004, Andreasen 1995).  
 The patients did not display an awareness of CVD risk. I cannot be sure 
whether they were told about this during the health check and did not remember 
or were not given this education. Providing relevant written information could be 
helpful and was suggested by some of the participants.  
 A number of the patients said they would delay seeking help with a 
physical illness due to their lack of confidence in their doctors and having to see 
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a different person each visit. One of them illustrated his reluctance to attend due 
to the negative attitude of his GP. This concurs with the findings of Roberts and 
Bailey (2011) regarding possible barriers. However, the patients were willing to 
see a nurse. The reason may be because generally nurses have more time 
than doctors and therefore appear more patient; a trait considered important by 
people with schizophrenia (Lester et al. 2003). Having one nurse in the practice 
responsible for providing these health checks offers the opportunity to build 
ongoing relationships. However, as expressed by one of the participants, this 
nurse would need to have a positive manner and relevant skills. Training nurses 
will assist in this outcome (Hardy 2012).  
 Most of the patients expressed that they were pleased to be invited for a 
health check and thought it was worthwhile. Their views coincide with the 
participants of the study by McCabe and Leas (2008) who thought that it would 
be beneficial if primary health care providers focused on preventative health. 
The patients in our sample wanted to know more about what blood tests they 
were having and the effects of their medication. This demonstrates a high 
positive attitude towards their physical health care which concurs with the 
results of the study by Brunero and Lamont (2010). People with SMI may give 
more attention to their lifestyle and physical health needs if they have this 
knowledge (Buhagiar et al. 2011, Campion et al. 2005). 
 Despite the apparent lack of knowledge of CVD risk factors, the patients 
were making lifestyle changes. In fact, one patient was unaware that he had a 
health check. It could be argued that this is not important if the consequences 
are achieved i.e. he was tackling the toughest lifestyle change (smoking). It 
appears from the interviews that lifestyle changes were implemented following 
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the health check. This is synonymous with the findings of Campion et al. (2005). 
However, as I do not have an awareness of the participants’ previous 
behaviour, I cannot claim this to be the case.  
 The Kings Fund report for long term conditions and mental health (Kings 
Fund and Centre for Mental Health 2012) suggests that developing more 
integrated support for people with mental and physical health problems could 
improve outcomes. Providing education based on the views of the patients with 
SMI is only one but very important step to meeting this challenge and improving 
the service received by this group with regard to their physical health needs.  
 Training for practices nurses to provide physical health checks for people 
with SMI should emphasize the patients’ views of what will make them effective.   
 
13.6 Limitations 
There is a risk of potential bias as I carried out the interviews and analysis. 
There were only five patients in the study. 
 
13.6 Summary of chapter 
In this chapter I have described the views of five patients with SMI regarding 
their physical health check.  These include: the importance of explaining why 
the health check has been offered; describing what each blood test is for; 
relating the potential side effects of antipsychotic medication; providing relevant 
verbal and written information; and the opportunity to see the same healthcare 
professional where possible. This study was published as: 
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Hardy S, Deane K and Gray R. (2013) The Northampton Physical Health and 
Wellbeing Project: The views of patients with severe mental illness regarding 
their physical health check. Mental Health in Family Medicine. (in press). 
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Chapter fourteen: Impact case study 
 
 
Craig et al. (2008) explain that publication in the research literature is essential 
but it is only part of an effective implementation strategy. In this chapter I have 
described how I have disseminated my research in order to make an impact. 
 
14.1 Background 
Nurses are taught to practice evidence based nursing (EBN) which is the 
conscientious, explicit, and judicious use of current best evidence in making 
decisions about the care of individual patients or groups (DiCenso et al. 2005). 
It requires integration of individual clinical expertise and patient preferences with 
the best available external clinical evidence from systematic research, and 
consideration of available resources (DiCenso et al. 2005).  The purpose of this 
research was to create an evidence based pathway as there have been no 
previous studies regarding practice nurses and the physical health of people 
with SMI in primary care. However, evidence suggests that research findings 
may take one to two decades to be translated into standard health care practice 
(Sussman et al. 2006). The Promoting Action on Research Implementation in 
Health Services or PARIHS framework (Rycroft-Malone 2004) suggests that 
successful use of implementation of evidence into clinical practice is a function 
of three elements: the evidence to be put into practice, the environment where 
the research is going to be implemented and the type and extent of facilitation 
used to help the implementation process. Scott (2008) explains that there are 
many different strategies to get research into clinical practice, such as financial 
incentives, written information, educational materials, conferences and 
workshops. However, as there are differences in the way the doctors and 
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nurses work this may affect the way that research is introduced into their 
practice (Scott 2008) (in the case of this research, practice nurses work as 
salaried employees and GPs are usually the employers). Additionally, there is 
often a cultural divide between researchers, practitioners, and administrators 
which can prevent research becoming standard clinical practice (Eccles et al. 
2005). Communicating the findings and practice implications of research occurs 
most effectively between people who share important attributes such as 
educational level, beliefs, social status, and networks (Haines and Jones 1994). 
My being a practicing clinician in primary care may therefore aid in this process.  
 
14.2 Financial incentives 
Funders and policy makers worldwide have experimented with initiatives to 
change physicians’ behaviour and improve the quality and efficiency of medical 
care (Tsai et al. 2005). Financial incentive schemes in healthcare can lead to 
improvements in the quality of care for rewarded activities but they could also 
lead to neglect of the non-incentivised aspects of patient care (Doran et al. 
2011). 
 
14.2.1 Commissioning for Quality and Innovation (CQUIN) payment 
framework 
The Commissioning for Quality and Innovation (CQUIN) payment framework 
was developed in 2009 to enable commissioners to reward excellence by 
linking a proportion of English healthcare providers' income to the achievement 
of local quality improvement goals (NHS Institute for Innovation and 
Improvement 2012). This is a developmental process and participants are 
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encouraged to share their schemes to meet the requirement for transparency 
and support improvement in schemes over time.  
 
The Northamptonshire CQUIN 
Following the completion of the PhyHWell project I was asked to participate in 
the development of a CQUIN for physical health in SMI and work as a 
consultant on this project for Northamptonshire Healthcare Foundation Trust 
(NHFT) (see appendix 16). The commissioner for mental health reported that 
the GPs in primary care wish to improve their confidence, skills and practice 
when working with people with SMI. Her opinion was that the most effective 
source of this support would be from the specialist mental health clinicians.  
 The goal of the Northamptonshire CQUIN is to improve implementation 
of NICE Guidance regarding health checks for people with SMI in Primary Care 
(NICE 2006, 2010). The key outcome of undertaking this work will be:   
1. NHFT supporting the development of Primary Care Clinicians to enable 
their undertaking of appropriate annual physical health checks of patients 
with SMI in line with Mental Health QOF indicators.  
2. Clinicians in NHFT will provide CVD screening and lifestyle advice at 
baseline, six weeks and 12 weeks when prescribing a new or increased 
dose of antipsychotic medication. 
 To help meet the first outcome I have developed training for practice 
nurses through a Health Innovation Education Cluster (described in 14.4.1). 
Present at each training session are mental health nurses whose time is 
backfilled with payment from the CQUIN. The participating practice nurses are 
given the name and contact details of the community mental health worker 
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linked with their particular practice. They are advised to contact them for help 
and advice. 
 In order to meet the second outcome the clinical managers of NHfT have 
set up clinics to carry out the baseline, six and twelve week screening and 
lifestyle advice. Workers have been trained to perform electrocardiograms. I 
have written the protocol and guidelines for these checks (see appendices 17 
and 18). I have also advised managers during this process and talked to various 
clinical teams to answer their queries. 
  
14.2.2 Quality and Outcomes Framework 
The Quality and Outcomes Framework (QOF) was introduced in 2004 in the 
UK. This is a mechanism intended to improve quality by linking up to 25% of 
general practitioners’ income to achievement of publicly reported quality targets 
for a number of long term conditions (Roland 2004). It contains groups of 
indicators, against which practices score points according to their level of 
achievement (British Medical Association and NHS Employers, 2011). This 
payment system has been criticised as the primary care doctors can decide to 
exclude patients they consider as unsuitable for a particular target, and the 
quality of the consultation is not measured (Ashworth and Jones, 2008). Since 
2009, NICE has been responsible for managing the development of the QOF 
clinical and health improvement indicators. Evidence for changes to the QOF is 
provided by an expert committee, which includes representatives from the 
Universities of Birmingham and Manchester, NHS Employers and the General 
Practitioners Committee. The last indicator changes for severe mental illness (at 
the time of writing) were made by this panel in June 2010 for the QOF 2011/12 
  
216 
 
(NICE 2010b). The authors of the new guidance make the point that the 
indicators in the QOF are not intended to cover all the process outcomes or 
disease issues for each category and in some areas the indicators cover only a 
small part of the care for those conditions. This makes the assumption that 
primary care staff will be carrying out the care not included in the QOF. 
 The changes to the mental health QOF 2011/12 could mean that people 
with SMI will not be offered an annual review, which allows time for them to be 
given diet and exercise advice and adequate smoking counselling. When 
training the practice nurses, I advocate providing care using the best practice 
manual but also include the QOF requirements and how they have been 
developed. Additionally I encourage discussion about overcoming some of the 
difficulties they may have in practice when carrying out these health checks, 
such as time constraints and employers’ expectations.  
 When presenting this research to GPs and commissioners I have used 
the QOF requirements as one incentive to persuade them that training practice 
nurses to carry out health checks for people with SMI is a good idea. 
 
14.3 Written information 
Written information regarding research and good practice can take the form of 
journal publications written by the researchers, guidelines, website content 
(newly created or hosted by another party) and reports by journalists following 
interviews. 
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14.3.1 Publications 
A study of 768 nursing journal papers documented that they disseminated not 
only information about clinical practice, but also informed readers about 
research of potential value to the nurse's practice (Oermann et al. 2008). 
Therefore I have submitted my research to two different types of publication: the 
reports of each study and the development of the intervention to relevant 
academic journals that report health outcomes-related research and/or with an 
impact factor or h-index (the impact factor reflects the frequency with which the 
journal's articles are cited in the scientific literature - Saha et al. 2003; the h-
index attempts to measure both the productivity and impact of the published 
work – Hirsch 2005); and best practice articles to clinical journals. 
 Deciding on which academic journal to submit each study paper was 
dependant on the readership and relevance of the topic. For example, the 
paper: ‘Is the use of an invitation letter effective in prompting patients with 
severe mental illness to attend a primary care physical health check?’ is of 
interest to nurses, GPs, primary care researchers and commissioners, so a 
journal solely focused on nursing was not selected; instead this article was 
published in the Primary Health Care Research and Development journal which 
has a relevant multidisciplinary audience. 
 Research only published in academic journals is not seen by the nurses 
who could use it (Shuttleworth 2011) because they confine their reading to a 
narrower set of journals within their clinical field (McKibbon et al. 2007). With 
this in mind, to ensure that the information reaches the clinicians whose practice 
needs to change, I have published educational and best practice articles in 
clinical journals which are regularly accessed by practice nurses (Practice 
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Nursing, Nursing Standard and Independent Nurse) and mental health workers 
(Mental Health Nursing, British Journal of Wellbeing and Nursing Standard). 
This action meets with the recommendations of Goldsack et al. (2011). 
Following their study examining the distribution of health outcomes research of 
12 clinical specialties in 535 journals, they suggest communicating the results to 
healthcare professionals as well as publishing in health outcomes-related 
research journals.  
 
Reports of studies and development of the intervention: 
1. Hardy S and Gray R. (2012) Is the use of an invitation letter effective in 
prompting patients with severe mental illness to attend a primary care 
physical health check? Primary Health Care Research & Development. 
doi:10.1017/S1463423612000023 (appendix 19) 
Cited by 1 
 
2. Hardy S and Gray R. (2011) The secret food diary of a person diagnosed 
with schizophrenia. Journal of Psychiatric and Mental Health Nursing. 
doi: 10.1111/j.1365-2850.2011.01826.x 
Impact factor – 0.799 (appendix 20) 
Cited by 2 
 
3. Hardy S, White J, Deane K, Gray R. (2011) Educating healthcare 
professionals to act on the physical health needs of people with serious 
mental illness: a systematic search for evidence. Journal of Psychiatric 
and Mental Health Nursing. 18 (8) 721-727. 
Impact factor – 0.799 (appendix 21) 
Cited by 10 
 
4. Hardy S and Gray R. (2010) Adapting the severe mental illness physical 
Health Improvement Profile for use in Primary Care. International Journal 
of Mental Health Nursing. 19 350–355. doi: 10.1111/j.1447-
0349.2010.00686.x 
Impact factor – 1.071 (appendix 22) 
Cited by 12 
 
5. Hardy S, Hinks P and Gray R. (2013a) Screening for cardiovascular risk 
in patients with severe mental illness in primary care: a comparison with 
patients with diabetes. Journal of Mental Health.  22 (1) 42-50. 
Impact factor – 1.101 (appendix 23) 
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6. Mitchell A and Hardy S. (2013) Surveillance for metabolic risk factors in 
patients with severe mental illness vs diabetes: National Comparison of 
Screening Practices. Psychiatric Services. (in press) 
Impact factor – 2.388 
 
7. Hardy S. (2012) Training practices nurses to improve the health of 
patients with severe mental illness: the effect on beliefs and attitudes. 
International Journal of Mental Health Nursing. 21 (3) 259-265. 
Impact factor – 1.071 (appendix 24) 
Cited by 2 
 
8. Hardy S, Hinks P and Gray R. (2013b) Does training practice nurses to 
carry out physical health checks for people with severe mental illness 
increase the level of screening for cardiovascular risk? International 
Journal of Social Psychiatry. (in press)   
Impact factor – 1.147  
 
9. Hardy S, Deane K and Gray R. (2013c) The Northampton Physical 
Health and Wellbeing Project: The views of patients with severe mental 
illness regarding their physical health check. Mental Health in Family 
Medicine. (in press) 
H Index: 6  
 
 
Clinical articles: 
 
1. Hardy S and White J. (2013) Why are people with serious mental illness 
still not getting their physical health checked? Mental Health Nursing. 33 
(1) 14-18. (appendix 25) 
 
2. Hardy S and Gray R. (2012) Learning Zone: Reducing cardiovascular 
disease risk in patients with severe mental illness. Nursing Standard. 26 
(45) 41-48. (appendix 26) 
 
3. Hardy S. (2012) The increased risk of diabetes in people with severe 
mental illness. Practice Nursing. 23 (9) 430-433.(appendix 27) 
 
4. Hardy S. (2011) Will the changes to the QOF mental health indicators 
improve care for people with severe mental illness? British Journal of 
Wellbeing. 2 (5) 18-21. (appendix 28) 
Cited by 1 
 
5. Hardy S. (2011) Improving the physical health of people with severe 
mental illness. The British Journal of Wellbeing. 2 (1) 32-35. (appendix 
29) 
 
6. White J and Hardy S. (2010) Managing medications in schizophrenia. 
Practice Nursing. 21 (8) 393 -396.(appendix 30) 
Cited by 1 
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14.3.2 The Health Improvement Profile for Primary Care (HIP-PC) Manual 
Clinical guidelines are recommendations based on the best available evidence 
regarding the appropriate treatment and care of people with specific diseases 
and conditions (NICE 2012). They help health professionals in their work, but do 
not replace their knowledge and skills. Citrome and Yeomans (2005) 
recommend clear and consistent recommendations for people with SMI, on how 
and when to monitor weight, cardiovascular function, and metabolic parameters 
and, importantly, what to do with the results. This, they say, would support 
clinicians wishing to integrate physical and mental healthcare. A systematic 
search and meta-analysis identified seven studies which examined any change 
in the screening of people with SMI before and after guideline implementation 
(Mitchell et al. 2012a). From these studies, only glucose data were sufficient for 
analysis and showed a small but significant increase in monitoring post 
guidance. Despite the presence of eighteen sets of guidelines for physical 
healthcare in people with SMI, implementation is incomplete (Mitchell et al. 
2012b). This may be because guidelines are not matched with resources 
(Mitchell et al. 2012b) and there is no evidence to suggest that the healthcare 
providers are given any training to use them. The Health Improvement Profile 
for Primary Care (HIP-PC) is an evidence based physical health manual 
specifically written for practice nurses. It is easily accessible by downloading 
from the website http://physicalsmi.webeden.co.uk/. Additionally, the practice 
nurses are offered training with regard to its use and it is updated according to 
any changes in recommended practice. As stated in chapter eight, the manual 
is being used in many areas and therefore may have improved the care of 
thousands of patients. 
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14.3.3 Website 
I decided to create a website (http://physicalsmi.webeden.co.uk/) in order to 
make information regarding carrying out a health check for people with SMI in 
primary care accessible to any interested party. This is described in chapter 
eight. The website is listed on the Royal College of Psychiatrists’ National Audit 
of Schizophrenia (NAS) website as a useful resource for primary care 
(http://www.rcpsych.ac.uk/quality/nationalclinicalaudits/schizophrenia/nationalsc
hizophreniaaudit/nasresources.aspx - see appendix 31). The author (Professor 
Mike Crawford) of the NAS is including it in his presentations about the audit. 
 
14.3.4 Rethink 
After presenting my research at the Improving Physical Health for people with 
Mental Health Conditions held in London on 4th July 2012 I was approached by 
Paula Reid from the charity, Rethink Mental Illness. She and her colleagues 
were due to hold a workshop to discuss some of the key challenges to better 
physical health outcomes for people affected by mental illness later that month. 
They were hoping to design a resource that might support professionals in 
addressing these challenges and invited me to attend to share my research as 
a best practice example. During this meeting I took an active role in the 
roundtable discussions and offered expertise from a primary care perspective.  
 Following the workshop, Rethink Mental Illness worked with a range of 
stakeholders to develop a document that outlined where physical health 
monitoring should be taking place along the care pathway. This document also 
clarifies whether this monitoring should be overseen by primary or secondary 
care. I offered constructive feedback on a number of iterations of this document, 
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particularly regarding the SMI register and the annual physical health check 
(see appendix 32).  
 Rethink have shared my resources as an example of best practice on the 
web pages they have designed for health professionals: 
http://www.rethink.org/how_we_can_help/physical_health/physical_health_reso
urces/annual_health_checks.html  
 
14.3.5 Reports by journalists following interviews 
Health and medical research is one of the most widely reported sources of 
news (PHCRIS 2012). I was invited to take part in a telephone interview on 
three occasions which was then reported in each journal. I saw this as an 
opportunity to publicize my research and encourage best practice in this area.  
1. Stephen Robinson a journalist from General Practice magazine 
contacted me following the publication of my paper regarding inviting 
patients for a health check. He asked me a few very short quick 
questions. Though his article was not inaccurate, he focused mainly on 
the increase in payment GPs could receive if they followed my 
recommendations (Robinson 2012 – appendix 33).  
2. Following an interview lasting nearly and hour and a half in which we 
discussed my research at length, the journalist Alison Moore from the 
Health Service Journal wrote a very short paragraph about the practice 
nurse training I have developed for people with SMI. Her report was not 
accurate and she did not provide links to my website or training even 
though she discussed them (Moore 2012 – appendix 34).  
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3. Ian Hullatt, the mental health advisor for the Royal College of Nursing 
(RCN) arranged for me to have an interview with one of the writers of 
their Bulletin. As this is sent out free to all RCN members I considered 
this to be a good opportunity. The article was accurate and sensitive 
(Palfrey 2012 – appendix 35). Following its publication I received a 
number of emails and have provided one example (permission given 
from author to publish his name and details): 
 date: 2012-12-09 time: 22:19:48 UTC 
Your email address: andrew.lane@leicspart.nhs.uk 
Subject: SMI 
Message: 
Our team of Mental Health Facilitators commence working in 
primary care tomorrow working to enhance people with SMI 
holistic needs.  How fortunate that I read the recent RCN article 
that led to your website which will aid our service delivery.  
Many thanks Andrew Lane Mental Health Facilitator. 
 
14.4 Educational materials and workshops 
I have adapted the educational materials originally developed for the 
Northampton Physical Health and Wellbeing project for two new projects, the 
East Midlands Health Innovation Education Cluster (EM HIEC) and the NHS 
London project.  
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14.4.1 East Midlands Health Innovation Education Cluster (EM HIEC)  
The aim of the East Midlands Health Innovation and Education Cluster is to 
enable high quality patient care and services. They strengthen the co-ordination 
of education and training so that the benefits of research and innovation directly 
reach patients. Presently the EM HIEC is a formal cross sector partnership 
between NHS/Social Care organizations, higher education, and private and 
third sector organizations. It is anticipated that these collaborations will assure 
the creation of high quality education, a well equipped workforce, measurable 
service improvements and enhanced patient outcomes. The EM HIEC focuses 
on an ‘engine room’ approach to bring together partners for the rapid adoption 
and diffusion of ideas from education to service. 
 I completed an ‘expression of interests’ application to deliver a Physical 
Health in Severe Mental Illness for practice nurses, and was one of the five 
successful applicants from the original thirty-five. I was given a grant of 
£24,101.75. The project is explained in detail on the EM HIEC website 
http://emhiec.co.uk/projects-2012-2013/em22-physical-health-in-severe-mental-
illness/. There is also a short video presentation.  
 The course has been accredited by the Royal College of Nursing (see 
appendix 36). Nine four hour sessions have been arranged for up to sixteen 
practice nurses each, over a period of six months. In an attempt to improve links 
between both disciplines, four mental health nurses can also attend each 
session. I teach the course myself. The practice nurses complete a pre and post 
self evaluation and all nurses give feedback about the course. The practice 
nurses will also be asked to complete a survey six months after their attendance 
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to see if there is any change in practice. The evaluation will be carried out by 
Professor Huber, the University of Northampton. 
 
14.4.2 NHS London project 
Under the Mental Health Payment by Results tariff patients assessed as having 
a history of psychotic symptoms (SMI) that are currently controlled and causing 
minor problems are eligible for discharge to primary care. However, one study 
has indicated that GPs and practice nurses feel that the care of such people is 
beyond their remit (Lester et al. 2005). The medical directors of NHS London 
were aware that the Clinical Commissioning Groups (CCGs) in London 
recognise that the safe discharge of some patients with SMI from secondary to 
primary care is a clinical and financial priority. They were also aware of the 
need for training primary care staff to promote this safe discharge and increase 
the opportunities to address the physical health needs of this group. At their 
request, I developed a one-off training package in mental health (including 
physical health in SMI) for practice nurses in London to be delivered by mental 
health nurses. The project was facilitated by Dr Fiona Nolan of Camden and 
Islington NHS foundation trust.  
 Twenty mental health nurses attended one of two train the trainer 
sessions delivered by myself. One hundred and ninety-four practice nurses 
attended one of 22 three hour training sessions throughout London. Using a 
questionnaire developed specifically for the study, the attendees rated their 
levels of confidence and knowledge significantly more positively in all of the ten 
areas identified (CI -1.10 to -0.96, t = 27.98 p<.0001). 
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 This project provided good initial evidence that brief training in mental 
health can effectively be delivered by mental health professionals to practice 
nurses with a positive impact on their confidence and knowledge. A more 
extensive programme of training using this method is planned, alongside 
evaluation of the impact on practice and patient outcomes. At the time of writing 
294 practice nurses have booked for the second round. A third round is 
planned. We intend to publish our findings when these have been completed. 
 
14.4.3 Royal College of General Practitioners’ (RCGP) workshop 
I was asked to talk about my research at a RCGP workshop to describe the role 
of practice nurses in the care of people with severe and enduring mental illness. 
At this seminal workshop, I presented to an audience of 40 GPs. The feedback 
was that the GPs found my presentation to be excellent and my ideas on the 
role of the practice nurse very useful for their own practices and care offering 
(see appendix 37).  
 
14.4.4 NHS London Primary Care Mental Health Leadership Development 
Programme 
I am a member of the expert reference group for the NHS London Primary Care 
Mental Health Leadership Development Programme. The programme has been 
designed specifically for those working in primary care (in particular GPs) who 
would like to develop their leadership potential in the delivery of mental health 
services, or planning and commissioning of mental health services, through 
CCGs. As part of this programme I presented some of my research to 21 of the 
GP participants and explained how practice nurses can deliver health checks 
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for people with SMI. The session was evaluated as good/excellent. The GPs 
recorded how they would apply their learning and future needs: 
o Practice nurses are the way forward in General Practice. 
o Get practice nurse to start doing physical health checks. 
o Get templates up to date and care plans to focus on recovery. 
o Engage with practice nurses and do health checks differently. 
o Awareness of HIP-PC. 
o Consider using the GASS in our SMI LES check, changing the 
template. 
o Ensure Bexley will have trained practice nurses for this. 
o Speak to my practice about having a template for physical health 
checks. Better education of colleagues about why we are doing 
this. 
o Speak to our own practice nurse and get onto local course at end 
of February. Look at website physical SMI – 
http://physicalsmi.webeden.co.uk/  
o Talk to practice nurse in my practice. Eventually audit SMI cares 
in my practice. 
o Use resources for physical health reviews (HIP-PC and website) 
in our practice and include within plans for primary care MH LES. 
o Health checks in supported housing in Islington. Train our practice 
nurses re: SMI check. 
o Encourage local GP nurses to do the training to still them and 
inspire them. Think about how we extend local LES to use nurses 
more in this. 
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14.5 Conferences 
Presenting at conferences has provided me with an opportunity to engage in 
academic dialogue and share, discuss and disseminate my research (Williams 
2009). I have attained some recognition in my field which has led to future 
collaborations. Facing challenging questions and remarks has helped me to 
identify the strengths and weaknesses of my research. 
 
Conference presentations 
 Physical and Mental Health Conference. 7.11.12. Northampton.  
 Commissioning Mental Health Conference. 6.11.12. London.  
 Physical and Mental Heath Conference. 16.10.12. Northampton. 
 Research and Development Conference (keynote speaker). 27.9.12. 
Northampton.  
 Improving Physical Health for people with Long Term Conditions 
Conference. 4.7.12. London.  
 Bipolar Disorder Conference. 12.7.12. London.  
 Bipolar Disorder Conference. 28.6.12. Manchester  
 Advancing Psychiatry in a changing NHS. 14.6.12. Waltham Abbey.  
 Bipolar Disorder Conference. 20.2.12. Norwich. 
 Physical Health/Mental Health Interface for SMI Conference. 16.1.12. 
Northampton. 
 Health Service Journal Mental Health Congress. 1.12.11. London.  
 Physical health and SMI: Medic away day. 8.9.11. Northampton. 
 Physical health and SMI. 29.8.11. Universitäre Psychiatrische Dienste. 
Bern, Switzerland.  
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 University of East Anglia PGR Conference. 22.6.11. Norwich.  
 RCN 16th International Network for Psychiatric Nursing Research 
Conference. 22.9.10. Oxford. 
 RCN Mental Health Conference. 5.3.10. Liverpool.  
 
Planned conference presentations 
 Commissioning Mental Health Services 18.6.13 London. 
 International Network for Psychiatric Nursing Research Conference 5-
6.09.13 Warwick (awaiting notification of acceptance of abstract). 
 Breaking Barriers 11-13.09.13 Reykjavik (awaiting notification of 
acceptance of abstract). 
 RCN Safer Mental Health Services 5.10.13 London. 
 
14.6 Awards 
Winning an award highlights the quality and innovation of a person’s work. I 
have won two awards for the PhyHWell project. The first was for best practice in 
primary care, the Nursing in Practice Award for Mental Health 2010 (appendix 
38). More recently I was runner up in the RCN Marjorie Simpson New 
Researcher Award 2013 where my research was highly commended (appendix 
39).  
 
14.7 Summary of Chapter 
In this chapter I have described how I have attempted to increase the impact of 
my research by using various methods. These include: financial incentives 
(CQUIN and Quality and Outcomes Framework); written information 
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(publications, HIP-PC Manual, website, Rethink, reports by journalists following 
interviews); educational materials and workshops (Health Innovation Education 
Cluster, NHS London project, Royal College of General Practitioners’ 
workshops, London Primary Care Mental Health Leadership Development 
Programme); conferences and awards. Using these methods I have become 
recognised as an expert in the field of physical health in patients with SMI, 
particularly in regard to nursing and primary care. 
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Chapter fifteen: Conclusions 
In this chapter I provide a summary of the thesis including a table (15.1) and 
offer my views on implications for policy and the service context, workforce 
competencies and training and further research. 
 
15.1 Summary of thesis  
A number of recent studies show that life expectancy in patients with SMI is 
reduced (Chang et al. 2011, Laursen 2011, Wahlbeck et al. 2011). Research 
has established that people in this group have a higher risk than the rest of the 
population of developing physical conditions including CVD (Leucht et al. 2007). 
People with long term physical conditions such as diabetes are screened for 
CVD by practice nurses in primary care (Hall 2008). However, despite GPs also 
receiving payment to screen patients with SMI (BMA and NHS Employers 
2012), practice nurse contact with this group is low (Reilly et al. 2012). This may 
be explained by a number of factors. Healthcare professionals believe that 
patients with SMI will not attend for a health check if they are invited (Lester et 
al. 2005), despite there being only one study to demonstrate that they are poor 
at attending in response to an invitation (Harvey et al. 2005). They are also 
concerned that if they do attend, the tools used to help people improve lifestyle 
will be less effective than in the general population (Wright et al. 2006). 
Additionally, there is no appropriate training regarding the physical health of 
people with SMI universally available for primary care healthcare professionals 
(Hardy et al. 2011).  
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To address the physical health needs of people with SMI, healthcare 
professionals in primary care need access to training to improve their 
knowledge. In this thesis I have described how I have developed a training 
package and a programme of research. This was designed in an attempt to 
provide evidence that training practice nurses to deliver health checks for 
people with SMI will increase the quality of care in this group. 
 
I carried out a retrospective audit to find out whether patients will attend for a 
health check if they are invited (Hardy and Gray 2012). I found that sending 
patients with SMI in primary care an invitation appointment letter with a 
predetermined time and date for a health check was effective in getting the to 
attend.  
 
In order to find out whether a tool used for people with physical illnesses to 
improve their lifestyle is effective when used with the SMI population, I 
completed a prospective audit. This demonstrated that food diaries are one 
example of a tool being employed successfully in patients with SMI (Hardy and 
Gray 2011). 
 
A systematic search to find out what evidence there is for the efficacy of 
healthcare professional educational outcomes in studies of physical health in 
SMI identified no studies (Hardy et al. 2011). 
 
I developed a training package for practice nurses to teach them how to carry 
out physical health checks for people with SMI. This included a best practice 
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manual and a website (Hardy and Gray 2010). The learning outcomes were for 
the participants to: 
 Understand the definition of SMI. 
 Know the signs and symptoms of SMI. 
 Be familiar with the epidemiology of SMI. 
 Be aware of the impact of SMI on physical health particularly the 
increased risk of CVD. 
 Be confident in navigating and using the website. 
 Be confident in carrying out a health check using the HIP-PC manual as 
a guide. 
 Be competent in entering data onto the computer template. 
 Feel confident in providing this role within their practice. 
 Liaise with relevant healthcare professionals and agencies.  
 
To establish whether as many people with SMI are being screened for 
cardiovascular disease as people with physical conditions in Northampton, I 
carried out a retrospective audit (Hardy et al. 2013a). In the five Northampton 
practices, the proportion of patients with SMI being screened for CVD risk 
factors was much lower compared to those with diabetes.  The number of 
people with SMI receiving lifestyle advice was also very low. 
 
The GP’s payment contract changed in 2011, meaning that data regarding 
screening in SMI could be collected nationally. I completed a retrospective audit 
to establish whether as many people with SMI are being screened for CVD as 
people with physical conditions in England (Mitchell and Hardy 2013). Patients 
  
234 
 
with diabetes received higher levels of screening across all four parameters 
(body mass index, blood pressure, blood glucose and cholesterol) in the 
previous 15 months than those with SMI. 
 
A before and after study to measure the effect of the physical health and SMI 
training on the practice nurses’ motivation to carry out physical health checks 
for people with SMI showed a positive effect (Hardy 2012). 
 
I carried out a before and after study to establish whether training practice 
nurses to carry out physical health checks for people with SMI increases the 
level of screening for cardiovascular risk in this group (Hardy et al. 2013b). This 
confirmed that training practice nurses improves the quality of the health checks 
but still not to the levels received by other patient groups. 
 
I interviewed patients with SMI to find out what they think about the physical 
health checks (Hardy et al. 2013c). They wanted: an explanation of why the 
health check had been offered; a description of what each blood test was for 
and the potential side effects of antipsychotic medication; relevant verbal and 
written information; and the opportunity to see the same healthcare professional 
where possible 
 
15.2 Discussion 
Following an invitation letter for a health check, attendance rates were lower 
than in patients with diabetes (Hardy and Gray 2012). However, they were 
higher than expected from the SMI group and comparable with the general 
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population (Norman and Connor 1993). My audit may not reflect the wider 
population as health checks for people with SMI had been offered for the past 
six years in this practice by the same practitioner. Therefore the response rate 
to invitation letters is likely to be higher than that of a practice offering a new 
service. This study highlights what can be achieved over time at a practice 
level. Clinicians should consider other ways in addition to an invitation letter for 
those patients who have not attended. This may include reminders by telephone 
or text directly to the patient or carer. For patients who are under the care of the 
mental health team, it would be pertinent to contact their Community Mental 
Health Worker (CMHW). The CMHW can provide the patient with information 
about the importance of the health check and may even accompany the patient 
to the appointment. 
 My study did not address how to engage with patients who are homeless 
or not registered with a GP practice. At least one in five homeless people suffer 
from a severe mental health problem (Crisis 1999). In a survey by Crisis in 
2002, the homeless people that were interviewed were almost 40 times more 
likely not to be registered with a GP than members of the general public. CCGs 
and local authorities should work closely together to ensure they tackle the 
health needs of homeless people with SMI in an integrated way. There is a 
need to develop competent outreach workers who work differently and build up 
trusting relationships. This could be provided through a Local or Direct 
Enhanced Service. Homeless people with SMI can then be gently encouraged 
to attend GP surgeries but those who won’t attend should be offered tests and 
advice in the street. Staff in primary care practices should be trained how to 
provide a welcoming environment for this group. Communicating across sectors 
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and creating clear points of access for the agencies working with the homeless 
is also a priority.  
 The patients with schizophrenia who were asked to complete food diaries 
all managed to complete the task (Hardy and Gray 2011). This may be 
evidence of motivation to improve their health and demonstrates the utility of 
food diaries in educating this population. There is a need to educate practice 
nurses in how to help patients with all long term conditions (including SMI) to 
become effect managers of their disease. This education should include using a 
motivational approach, empowerment and problem solving. 
 A systematic search for evidence based education available for qualified 
nurses to monitor the physical health of people with SMI yielded no studies 
(Hardy et al. 2011). This lack of evidence adds to the view that carrying out 
physical health checks for people with SMI is not the responsibility of nurses 
(Blythe and White 2012, Robson et al. 2012). The lack of specific evidence to 
demonstrate that education of the nurses will improve patients’ health makes 
advocating any education (should it be available) a difficult task.  I hope that this 
thesis and the outcomes of the training that I have delivered through the NHS 
London project and the HIEC project will have some influence in shaping the 
provision of education for practice nurses by providing specific evidence. 
 In the audit of the five practices in Northampton before training, the NHS 
information database had a much higher percentage of patients with SMI 
recorded as having a review compared with the actual level of screening and 
advice given Hardy et al. 2013a). This suggests that there was a lack of 
awareness of the screening, health promotion and prevention advice that is 
appropriate for this group of patients, but it was carried out before specific 
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payment indicators were imposed. The findings of the audit of England 
practices (Mitchell and Hardy 2013) show that the financial incentives given to 
primary care practices might have improved monitoring in line with the 
observation that most targets are achieved. In the repeat audit of the five 
Northampton practices following training all screening measures and lifestyle 
advice increased (Hardy et al. 2013b). These findings are consistent with those 
of Bernard et al. (2009) who reported that the training and education of nurses 
in primary care centres promotes the use of prevention practices. However the 
increases in screening following training were not as remarkable as those 
following the introduction of financial incentives. This suggests a need for 
payment to motivate the organisation to provide the service. As an example, 
payments through QOF could be made to provide lifestyle advice to people with 
SMI until it becomes usual practice. There is a need for good quality research 
and evidence based education to ensure that these interventions are effective. I 
am involved in developing and delivering the training for one such study 
(PRIMROSE  - University College London). 
 I do not know whether the nurses in the study delivered their screening in 
designated clinics for people with SMI. The concern about patients not 
attending and leaving the practice nurse without patients to see could be 
addressed by having one such appointment at the end of the morning clinic. 
Offering a later appointment could increase attendance by patients with SMI 
who may have difficulty in getting up due to their illness. Additionally, the nurse 
would then be able to use the time if patients did not attend to follow them up 
and then carry on with non clinical duties. Practice nurses work for GPs who 
provide general care, yet most practices now offer specialised clinics for 
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different specific conditions such as COPD, asthma and diabetes. These clinics 
are cost effective at a practice level as there is a payment provided through 
QOF. At a population level they are also likely to be cost effective as much of 
the work is around self management and prevention of complictions and/or 
exacerbation. It can therefore be argued that providing a specialised clinic for 
people with SMI would have the same benefits, However as many people have 
more than one long term condition, perhaps providing generic clinics 
encompassing all conditions may be be more cost effective and holistic. The 
RCGP (2012) promote medical generalism which they define as an approach to 
the delivery of health care that routinely applies a broad and holistic perspective 
to the patient’s problems. They advocate that these principles will be needed 
wherever and whenever people receive care and advice about their health and 
wellbeing, and all healthcare professionals need to value and be able to draw 
on this approach when appropriate. This suggests that the medical generalist 
approach can, and should be used by a practice nurse during any type of clinic. 
However, the RCGP do acknowledge that the ability to practise as a generalist 
depends on one’s training, and on the routine use of skills that helps people to 
understand and live with their illnesses and disabilities, as well as helping them 
to get the best out of the healthcare options that are available and appropriate 
for their needs. Many practice nurses do not have the skills and competencies 
to help patients manage a range of long term conditions. This may result in the 
patient attending the practice on a number of occasions to see different 
practitioners. There are pros and cons for this approach. On the positive side, 
messages can be reinforced by the practitioners at each visit and the emphasis 
of the consultation can focus on one specific area allowing the patient to 
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concentrate on one issue at a time. This is particularly useful for someone with 
schizophrenia where concentration and planning may be a problem. Additionally 
if the nurse is providing a clinic in just one field, she is more likely to be an 
expert in that area. Patients who are isolated and lonely may welcome 
additional visits. Conversely, busy patients may resent numerous visits and 
tests and advice may be duplicated.  Most education is expensive and offered 
as disease specific. Therefore practice nurses (and/or their GP employers) may 
choose to access only those that they see as relevant to their role.  Presently, 
for practice nurses to provide generic clinics that allow them to work according 
to their professional code of conduct, they would need to access a range of 
courses.  A generic course encompassing all long term conditions could include 
the disease specific information as well as the psychological issues relevant to 
them all. This approach would meet with the recommendations of the Royal 
College of Psychiatrists’ mission statement (2010), ‘no health without public 
mental health’. 
 It appeared from the interviews with patients that they were making 
lifestyle changes following their health check, despite the apparent lack of 
knowledge of CVD risk factors (Hardy et al. 2013c). This is consistent with the 
findings of Campion et al. (2005). However, as we do not have knowledge of 
the participants’ previous behaviour, we cannot claim conclusively that this was 
the case. The patients’ views of what will make physical health checks for 
people with SMI effective were considered when modifying the HIEC training for 
practice nurses (explained in chapter 14). 
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In order to encourage a change in clinical practice, I have used a number of 
methods to promote my research. These include: financial incentives; written 
information; educational materials and workshops; and conferences and 
awards. All of these methods (described in chapter 14) could be employed on a 
wider scale by other organisations. 
 
In summary, I have shown that patients with SMI will attend for a health check 
in primary care when invited by letter providing the date and time of 
appointment and the name of the practitioner. Training practice nurses to 
deliver these checks increases the level of screening and lifestyle advice given 
to this group of patients. 
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Table 15.1 Objectives, samples, design, analysis and outcomes of the studies 
 
 
Objectives 
 
Study Sample Design Analysis 
 
Outcomes 
P
h
a
s
e
 o
n
e
 
To explore whether an 
invitation appointment 
letter is effective in 
prompting patients with 
SMI to attend a physical 
health check in primary 
care compared with 
those with diabetes. 
 
 
 
Study 1 
 
 
92 patients 
with SMI and 
416 with 
diabetes 
 
 
Retrospective 
audit 
Descriptive statistics:  
Odds ratio to explore 
whether the patient’s 
diagnosis made a 
difference to the 
numbers responding 
to an invitation for a 
health check. 
 
An invitation appointment 
letter is an effective way of 
ensuring that patients with 
SMI have a physical health 
check. 
To consider the 
feasibility of food diaries 
as a method of 
understanding the 
dietary behaviour of 
people with 
schizophrenia. 
 
Study 2 
 
 
8 patients with 
schizophrenia 
 
Prospective 
audit 
 
Identification of 
themes 
The food diary is a useful 
clinical tool for patients with 
schizophrenia. 
Contrary to public belief, 
patients with schizophrenia 
are capable of completing 
homework tasks. 
To identify the evidence 
of efficacy of the 
education of qualified 
health care 
professionals to deliver 
interventions aimed at 
improving the physical 
health of adults with 
SMI. 
 
 
 
 
Study 3 
 
 
 
 
147 papers 
 
 
 
 
Systematic 
search 
Summary of 
characteristics of 
studies, their 
methodological 
quality, a summary of 
the results, synthesis 
of results in light of 
risk of bias. 
 
 
 
No studies were identified as 
suitable for a systematic 
review 
P
h
a
s
e
 tw
o
 
 
 
To establish the 
proportion of patients 
with SMI being 
screened for CVD risk 
factors in their GP 
practice compared to 
those with diabetes and 
determine whether 
people with SMI receive 
lifestyle advice. 
 
 
 
 
 
Study 4 
 
 
386 people 
with SMI and 
1875 people 
with diabetes 
 
 
 
 
Retrospective 
audit 
Descriptive statistics: 
Odds ratio to see 
whether diagnosis 
made a difference to 
level of screening. 
Mean number of 
interventions 
And standard 
deviation 
Chi-square test to 
see if age was 
associated with the 
number of 
interventions 
received. 
 
Just over a fifth of patients 
with SMI received a full CVD 
screen compared to the 96% 
of those with diabetes 
(OR=90.37; 95% CI=64.53 to 
126.55: p<.01). Fifty-seven 
per cent of the SMI patients 
were given smoking advice 
but only thirteen and fourteen 
percent received guidance 
regarding diet and exercise 
respectively. 
 
To establish the 
proportion of patients 
with SMI being 
screened for CVD risk 
factors in England 
compared to those with 
diabetes 
 
 
Study 5 
 
2,488,948 
people with 
diabetes and 
422,966 with 
SMI 
 
 
Retrospective 
audit 
 
Chi-square test to 
see whether 
diagnosis made a 
difference to level of 
screening 
 
Patients with diabetes 
received higher levels of 
screening across all four 
parameters in the previous 15 
months than those with SMI 
(97.3% vs 74.7%; p<0.0001).  
 
 
To address common 
misconceptions about 
the physical health of 
people with SMI. 
 
 
 
Study 6 
 
 
 
8 practice 
nurses 
 
 
Before and 
after study 
Descriptive statistics:  
Mean of nurses’ 
scores. 
Unpaired t-test to 
measure the 
difference in the 
scores before and 
after training. 
 
 
The training was effective in 
modifying practice nurses’ 
misconceptions about physical 
health in people with SMI. 
 
 
 
 
To establish whether 
training practice nurses 
increases the proportion 
of patients with SMI 
being screened for CVD 
risk factors and given 
lifestyle advice in their 
GP practice.  
 
 
 
 
 
 
 
Study 7 
 
 
 
 
 
 
400 patients 
with SMI  
 
 
 
 
 
 
A before and 
after audit. 
Relative risk to 
calculate whether 
training made a 
difference to the level 
of screening and 
lifestyle advice given 
to people with SMI as 
a group. T -test to 
determine the 
difference between 
the mean number of 
interventions 
received by each 
individual patient with 
SMI before and after 
training.  
 
 
 
 
Training practice nurses about 
CVD prevention in people with 
SMI may be effective in 
increasing the proportion of 
patients in this group who 
receive a comprehensive health 
check. 
 
 
To examine the 
patients’ views 
regarding the physical 
health check delivered 
by a nurse trained to 
deliver the intervention. 
 
 
 
Study 8 
 
 
 
5 patients with 
SMI 
 
 
Interviews 
using a topic 
guide. 
 
 
Thematic analysis. 
Patients’ views include: 
explaining why the health 
check has been offered; 
describing blood tests and 
side effects of antipsychotic 
medication; providing verbal 
and written information; seeing 
the same healthcare 
professional where possible. 
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Mrs Sheila Hardy 
22 Bridle Path 
Brafield 
Northampton 
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Dear Mrs Hardy 
 
Study Title: An evaluation of the Northampton Physical Health and 
Wellbeing (PhyHWell) program on the impact of 
cardiovascular risk in patients with Severe Mental Illness 
REC reference number: 10/H0403/38 
Protocol number:  
 
The Research Ethics Committee reviewed the above application at the meeting held on 
11 May 2010. Thank you for attending to discuss the study. 
 
Ethical opinion 
Discussion 
 
 The Committee asked you how the methodology will answer the primary 
outcome measure for the study as outlined in section A57. of the Application 
Form. You outlined that the outcome measure was Patients (with Mental 
Health problems) rate of cardiovascular disease, and whether the health 
improvement profile helps to influence this by incorporating lifestyle changes 
etc. 
 
 The Committee asked you to outline the Health Improvement Programme.  You 
stated that you, the Chief Investigator (who has designed a Health Programme) 
has been commissioned to undertake this by the PCT.  This programme 
requires Practice Nurses and Mental Health Nurses attending training in 
relation to the Health Improvement Profile (HIP). It then requires these Nurses 
to discuss the findings of the HIP with the patients, who are accessing the 
service throughout the year.  The Health Improvement Profile is over and 
above what is current practice.  This is a new service development but there is 
no randomisation.   
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 The Committee asked for clarification of the training.  You stated that it is being 
imparted to Community Mental Health staff and Practice Nurses, and will 
consist of one days training. There is no requirement for these Nurses to then 
cascade this training to others. The Committee asked whether the Nurses are 
competent to deliver the profile and would there be any overlap with HONOS – 
Mental Health? You stated that there will be no overlap with HONOS, as you 
will be measuring an intervention on the health check. 
 
 You were asked if relevant data is being collected, and referred to in the 
QRISK®2.  The Committee questioned whether this is patient data and whether 
it is correlated to patient medication.  You acknowledged that this was a 
limitation of the study as it was not being envisaged that influencing factors 
(such as medication interactions) would not be correlated with the outcomes.  
You felt that the HIP should take these interactions into account. 
 
 You were asked if there is a Community Mental Health Nurse attached to each 
GP practice, and you confirmed that there is in the Northamptonshire area. 
 
 The Committee mentioned that some patients will be needle phobic.  You 
stated that you are aware that some may not have blood tests etc. and you 
hope that this will be identified in the interviews. 
 
 The Committee relayed their concerns over the Focus Groups and the sample 
size of 10.  They questioned whether 10 will be enough for the Focus Groups; 
whether there is potential for bias in the interviews being a purposive sample.  
You stated that you will make it clear to the Nurses that you are not evaluating 
the Nurses themselves, but the intervention.    
 
The members of the Committee present decided that it was unable to give a 
favourable ethical opinion of the research, for the following reasons.  The following 
should be considered if a further application for ethical review is made: 
 
 The Application needs splitting to give greater clarity of the research 
component as currently it is lacking this.  The audit/service evaluation that is 
not part of the research, should be removed from the application and the 
research element specifically outlined.  It should however, state how the 
research fits in with the audit/evaluation.  Attention should be made to the 
methodology as it is difficult to understand (as it is currently described). 
 
 The Application should be clear what the Researchers role is within the study 
e.g. delivering the training, what the training is intended to do etc.  At present 
details within the application are obscure. 
 
 The methodology is somewhat limited and it is very unclear what the primary 
outcome measure is as detailed in section A57. of the Application Form.  This 
requires attention. 
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 An application should state what relevant data is being collected, and referred 
to in the QRISK®2.  It should be made clear whether this is patient data and 
whether it is correlated to patient medication. 
 
 Section A31. of the Application Form states that Healthcare Professionals will 
have up to a year to decide to take part.  Clarification is required, and as to how 
this fits in with the 5 – 13 month schedule. 
 
 Greater clarity should be given as to how the 10 (out of the 31 practices) will be 
selected?  It mentions ‘appropriate’ patients will be asked by the GP or Nurse 
whether they wish to take part in an interview.  It is unclear what this means 
and there may be potential for bias.   
 
 It should be clear throughout the application what kind of ‘Nurse’ the 
application refer to e.g. Community Mental Health Nurse etc. 
 
 It should be made clear in the Participant Information Sheets what the 
mechanism is should any bad practice be identified whilst undertaking the 
research e.g. it should detail the bounderies of confidentiality etc. 
 
 The baseline assessment does not address that Mental Health patients may be 
needle phobic and whether this is likely to affect the study? 
 
I regret to inform you therefore that the application is not approved.  
 
Options for further ethical review 
 
You may submit a new application for ethical review, taking into account the 
Committee’s concerns.  You should enter details of this application on the application 
form and include a copy of this letter, together with a covering letter explaining what 
changes have been made from the previous application.  We recommend that the 
application is submitted again to this Committee, but you may opt to submit to any 
another Research Ethics Committee within this domain. 
 
Alternatively, you may appeal against the decision of the Committee by seeking a 
second opinion on this application from another Research Ethics Committee.  The 
appeal would be based on the application form and supporting documentation 
reviewed by this Committee, without amendment.  If you wish to appeal, you should 
notify the relevant Research Ethics Service manager (see below) in writing within 90 
days of the date of this letter.  If the appeal is allowed, another REC will be appointed 
to give a second opinion within 60 days and the second REC will be provided with a 
copy of the application, together with this letter and other relevant correspondence on 
the application.  You will be notified of the arrangements for the meeting of the 
second REC and will be able to attend and/or make written representations if you wish 
to do so. 
 
The contact point for appeals is: 
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Joan Kirkbride 
Head of Operations  
National Research Ethics Service 
C/o Janet Kelly 
Darlington Primary Care Trust 
Dr. Piper House 
King Street 
Darlington 
Co. Durham 
DL3 6JL 
 
Tel: 01325 746167 
Mobile: 07979 806425 
Email: joan.kirkbride@nres.npsa.nhs.uk 
 
Documents reviewed 
 
The documents reviewed at the meeting were: 
   
Document    Version    Date    
Covering Letter  1  01 April 2010  
REC application  53425/114957/1/454  19 April 2010  
Protocol  5  01 April 2010  
Investigator CV  Chief Investigator x2     
Participant Information Sheet  3 Patient  01 April 2010  
Participant Consent Form  1 Patient  01 January 2010  
Letter of invitation to participant  3  01 April 2010  
GP/Consultant Information Sheets  3  01 April 2010  
GP Consent Form  1  01 January 2010  
Letter to GP/Consultant  3  01 April 2010  
Primary Care Nurse Information Sheet  1  01 April 2010  
Secondary Care Nurse Information Sheet  1  01 April 2010  
Primary Care Nurse Information Sheet  1  01 April 2010  
Secondary Care Nurse Information Sheet  1  01 April 2010  
Investigator CV  Academic Supervisor  01 January 2008  
Evidence of insurance or indemnity    20 April 2010  
Referees or other scientific critique report    15 April 2010  
Interview Schedules/Topic Guides  2  01 April 2010  
Questionnaire: Attitudes Quiz - Post Training  2  01 April 2010  
Questionnaire: Attitudes Quiz - Pre Training  2  01 April 2010  
Questionnaire: Knowledge Quiz - Pre Training  2  01 April 2010  
Questionnaire: Knowledge Quiz - Post Training  2  01 April 2010  
Unfavourable Opinion Letter    02 March 2010  
Letter from CI of Amended Application    01 April 2010  
Questionnaire: Communication Questionnaire  2  01 April 2010  
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Scoring Sheet  1  01 March 2010  
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on 
the attached sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK.  
 
After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Service website > After Review 
 
Here you will find links to the following: 
 
a)      Providing feedback. You are invited to give your view of the service you have 
received from the National Research Ethics Service and the application procedure. 
If you wish to make your views known please use the feedback form available on 
the website 
b)      Re-submission/Appeal.  
 
 
10/H0403/38   Please quote this number on all correspondence 
 
Yours sincerely 
 
Mr Robert Johnson 
Vice-Chair 
 
Email: trish.wheat@nottspct.nhs.uk 
 
Enclosures: List of names and professions of members who were present at the meeting 
and those who submitted written comments. 
 
 
Copy to: Mrs Tracey Moulton – University of East Anglia 
 
R&D Department for NHS care organisation at lead site – NHS 
Northamptonshire 
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Attendance at Committee meeting on 11 May 2010 
 
  
Committee Members:  
 
Name   Profession   Present    Notes    
Mr Alastair Allen  Lay Member  Yes    
Dr Walter P Bouman  Consultant Psychiatrist  No    
Professor 
 Cris S Constantinescu  
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Ms Helen Crow  Research Midwife  No    
Mr Robert Johnson  Research Co-ordinator  Yes    
Reverned Keith Lackenby  Lay member  Yes    
Mr Jon Merrills  Barrister / Pharmacist  Yes    
Mr Robert Oldroyd  Lay member  Yes    
Dr Noble Philips  General Practitioner  Yes    
Dr Kate Pointon  Consultant Radiologist  Yes    
Mr Ian Thompson  Lay member  Yes    
Mrs Shirley E White  Lay member  Yes    
  
Also in attendance:  
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Ms Trish Wheat  Committee Co-ordinator  
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     Clinical Governance Support Team 
Sudborough House 
St. Mary’s Hospital 
London Road, NN15 7PW 
 
Tel: 01536 494215 
Fax: 01536 494216 
                                                                                         Email: Anas.Salah@nht.northants.nhs.uk  
 
 
6th August 2010 
 
 
Dear Sheila, 
 
Re: An Evaluation of the Northampton Physical Health and Well-being Project 
(PhyHWell). 
 
I am pleased to confirm that you now have full management approval for the above 
research project.  
 
Please note that should you make any changes to the research in any respect, you will 
need to discuss this with our department and supply us with any copies of changed 
documentation. 
 
We wish you every success with your research and look forward to discussing the final 
outcome with you.  
 
 
In the meantime, please feel free to contact me should you require any information or 
assistance. 
 
 
Yours sincerely 
 
 
 
 
Emily Collins. 
Clinical Effectiveness Support Assistant. 
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Food diary  Patient  number……………….Date……………………… 
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Wednes 
 
Thurs 
 
Friday 
 
Saturday 
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7-8  
 
 
      
8-9  
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1-2  
 
 
      
2-3  
 
 
      
3-4  
 
 
      
4-5  
 
 
      
5-6  
 
 
      
6-7  
 
 
      
7-
bedtime 
 
 
 
      
Night-
time 
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Primary Care Physical Health Checks for people with 
Severe Mental Illness (SMI) – Best Practice GuideThe 
Health Improvement Profile for Primary Care (HIP-PC) 
Third Edition 
 
Introduction 
Severe mental illness such as schizophrenia and bipolar disorder is associated with high 
medical co-morbidity; mortality rates are approximately 50% higher than in the 
general population (Hennekens et al. 2005). The primary cause of death due to a 
physical cause is circulatory disease, diabetes and obesity. Evidence suggests excess 
weight gain can be 2-3 times more prevalent in people with schizophrenia than in the 
general population (Allison and Casey 2001). This may be due to high levels of 
smoking, unhealthy diets and lack of exercise which  are common lifestyle choices of 
people with schizophrenia (McCreadie 2003), and that antipsychotic medication can 
also exacerbate weight gain (Allison and Casey 2001).  
 
The National Institute for Clinical Excellence (Nice 2009, 2006a) recommends that 
physical health checks should normally be provided within primary care. However if 
the patient is not in contact with primary care then secondary services (the Mental 
Health Team) should monitor their  physical health. 
 
 The Sainsbury Centre for Mental Health (2003) advocates that a physical health review 
should include advice about diet, exercise, smoking and substance and alcohol abuse; 
protection against influenza, plus regular preventative care. Consequently, the General 
Medical Services contract requires that each primary care centre has a register of 
people with schizophrenia, bipolar disorder and other psychoses and that healthcare 
professionals achieve a number of clinical indicators in order to receive payment (NHS 
Employers 2011). 
 
The HIP-PC has been adapted for primary care from the Health Improvement Profile 
(HIP) (White et al. 2009). This is a specific tool designed to help mental health nurses 
outline the physical health of the SMI patients they work with and direct them towards 
the evidence base interventions available to address identified health problems. A 
rationale and recommended action has been specified for each intervention.  Unlike 
other tools such as the Physical Health Check (PHC) (Rethink 2008a), it is 
recommended that clinicians carrying out health checks using the HIP-PC have relevant 
training.  The guidance also takes into account that healthcare professionals in primary 
care are experienced in giving lifestyle advice. 
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Measurements 
 
Body Mass Index (BMI) 
Rationale 
Evidence suggests excess weight gain can be 2-3 times more prevalent in people with 
schizophrenia than in the general population (Allison and Casey 2001). 
The BMI is a simple index used to determine whether an individual is underweight, 
overweight or obese (WHO 2006). 
The BMI is defined as the weight divided by the square of the height. For example, a 
person who weighs 70 kg and has a height of 1.75 will have a BMI of 22.9. 
A BMI calculator can be found at: 
www.eatwell.gov.uk/healthydiet/healthyweight/bmicalculator/  
Although BMI values are the same for both sexes, they may not be accurate in people 
who are athletes or who weight-train, in pregnant or breastfeeding women, or those 
over the age of 60 years.  
Ethnicity should be considered; particularly in patients of South Asian origin 
(overweight varies from BMI > 23, obesity from BMI > 25). 
 
Recommended action 
Diet advice should be offered to all patients to prevent weight gain. Guidance about 
weight loss should be offered to patients with: 
 A BMI ≥ 28  
 Any degree of overweight coinciding with diabetes or other serious diseases 
 
Waist circumference 
Rationale 
People who carry their excess fat centrally (within the abdominal cavity) are more 
likely to suffer the consequences of being overweight. 
Waist circumference correlates with visceral adipose tissue, plasma lipids, lipoproteins 
and insulin levels in adults (Taylor et al. 1998).  
 
Recommended action 
Measure waist circumference: ensure that a tape of adequate length is available. The 
correct position for measuring waist circumference is midway between the upper hip  
bone and the uppermost border of the right iliac crest. The tape should be placed 
around the abdomen at the level of this midway point and a reading taken when the 
tape is snug but does not compress the skin. In practice it may be difficult for very 
overweight patients to accurately palpate those bony landmarks in which case placing 
the tape at the level of the belly button is recommended (National Obesity Forum 
2011). 
For patients with waist circumference ≥ 80 cm (female) / ≥ 94 cm (male) (Barnett et al. 
2007): 
 Support and exchange information on diet (ie meal planning) and exercise 
 Consider referral to a local weight/exercise management programme   
 Consider medication review 
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Pulse rate 
Rationale 
Most antipsychotic medications have the potential for lengthening of the QT interval 
(prolonged: in males >450ms, in females >470ms - Committee for Proprietary 
Medicinal Products 1997). Therefore, cardiac safety should be a routine part of clinical 
care in patients taking antipsychotic medication; a preventive strategy is valuable even 
if the absolute risk of serious cardiac events is low (Abdelmawla and Mitchell 2006). 
There is evidence that many typical antipsychotics increase the risk of ventricular 
arrhythmias and cardiac arrest (Ray et al.2001, Liperoti et al. 2005) and an association 
between many atypical antipsychotic drugs and the occurrence of unexplained sudden 
death (Abdelmawla & Mitchell, 2006).  
 Carrying out an ECG also allows the opportunity to look for other possible 
problems such as gynaecomastia, hygiene neglect and rashes. 
 
Recommended action 
Check pulse annually. If raised perform an ECG. 
Consider an ECG for all patients taking antipsychotics.  
The BNF recommends that an ECG should be performed on patients: 
 Taking pimozide, sertinol and clozapine or prescribed antipsychotics over the 
BNF limits  
 Who have specific cardiovascular risk  
 With a personal history of cardiovascular disease  
 Being admitted as an inpatient 
Patients with an abnormal ECG may be referred to a cardiologist or to the original 
prescriber for review of their treatment as appropriate. 
 
Blood pressure 
Rationale 
People with severe mental illness are at a higher risk of developing high blood pressure 
than the general population. The British Hypertension Society Guideline cites evidence 
that suboptimal blood pressure control leaves patients at an unacceptably high risk of 
cardiovascular complications and death, particularly from coronary heart disease 
(CHD) but also from stroke (Williams et al. 2004). Interventions actively combining 
exercise and diet have demonstrated a reduction of both systolic and diastolic blood 
pressure by only 4–5 mmHg (NICE 2006b), therefore medication is often required. 
 
Recommended action 
Check CVD risk using QRISK®2 (Hippisley-Cox et al. 2008) for all eligible patients and 
exchange information on weight loss/exercise (if overweight), improved diet and 
reduction in alcohol and salt intake, assistance with stopping smoking. 
For patients with blood pressure > 140/90 mmHg without a diagnosis of hypertension 
(NICE 2011): 
 offer ambulatory blood pressure monitoring (ABPM) to confirm the diagnosis of 
hypertension  
 if the patient is unable to tolerate ABPM, then offer home blood pressure 
monitoring (HBPM) 
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 test urine for the presence of protein by sending a sample for estimation of the 
albumin:creatinine ratio and test for haematuria using a reagent strip 
 take blood sample to test for plasma glucose, electrolytes, creatinine, 
estimated glomerular filtration rate (eGFR), serum total cholesterol and HDL 
cholesterol 
 perform an ECG 
 prescribe medication following the stepped NICE guidance 
 
Temperature 
Rationale 
A raised temperature maybe caused by infection, heat stroke, alcohol withdrawal, 
anticholinergic drugs, allergic drug reaction, and agonist drugs (Dougherty and Lister 
2004). 
Neuroleptic malignant syndrome is a rare but potentially life-threatening individual 
reaction to neuroleptic drugs. It causes fever, muscular rigidity, altered mental status 
and autonomic dysfunction. It is usually associated with potent neuroleptics such as 
haloperidol and fluphenazine. The underlying pathological abnormality is thought to 
be central D2 receptor blockade or dopamine depletion in the hypothalamus and 
nigrostriatal/spinal pathways. This leads to an elevated temperature set point, 
impairment of normal thermal homeostasis and extrapyramidally-induced muscle 
rigidity (Patient UK 2006a). 
 
Recommended action 
 Look for signs of infection and treat as appropriate 
 Ask about alcohol withdrawal 
 Check drug use 
 For abnormally high temperatures with a fluctuating blood pressure and/or 
dystonia consider neuroleptic malignant syndrome and refer urgently to 
medics. 
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Blood tests 
 
Liver Function Tests (LFTs) 
Rationale 
Antipsychotic medication can result in abnormal LFTs (Garcia-Unzueta et al. 2003). 
Hepatic disease should be detected early to prevent further serious complications. 
 
Recommended action 
Check LFTs every 12 months. 
 
If tests are slightly abnormal:  
 Repeat tests in 6 months 
 Check alcohol intake and reduce if necessary 
 Exchange information on diabetes control and weight loss if appropriate 
 If remains abnormal for longer than six months then consider referral to a 
specialist 
 If the patient is unwell despite slightly abnormal LFTs then they may need to be 
referred more urgently 
Very abnormal liver function tests (i.e. more than twice upper limit of abnormal):  
o Organise further blood tests and imaging. 
o Refer to out-patients - if you suspect the cause may be malignancy then 
an urgent cancer referral should be made. 
Consider urgent referral for hospital admission if patient unwell, for example: 
o Severe jaundice 
o Severe ascites 
o Encephalopathy 
o Septic 
(Patient UK 2006b) 
 
Lipid Levels 
Rationale  
Dyslipidaemia is a key component of the metabolic syndrome and a precursor for 
cardiovascular disease.  
 
Recommended action 
Check cholesterol levels annually – lipid profile if cholesterol is raised. Support and 
exchange information on diet (i.e. meal planning) and exercise. 
 
Primary prevention  
Consider for patients between 40-74 yrs with a high CVD risk (NICE 2008); offer 
simvastatin 40mg (or drug of similar efficacy and cost) for adults >40 years with 10-
year CVD risk ≥20% (NICE 2008). 
 
Abnormal levels (secondary prevention)  
o Offer simvastatin 40mg (or drug of similar efficacy and cost) to all adults 
with clinical evidence of CVD 
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o Consider increasing simvastatin dose to 80mg or drug of similar efficacy and 
cost if TC and LDL-C targets not reached 
o Offer higher intensity statin (eg simvastatin 80mg) to people with acute 
coronary syndrome. Do not delay until lipid levels available; measure 
fasting lipid levels after approximately 3 months 
o If potential drug interactions or simvastatin 40mg contraindicated, offer 
lower dose of simvastatin or pravastatin 
(NICE 2008) 
 
Glucose 
Rationale 
Diabetes occurs in 15% of people with schizophrenia (Holt and Peveler 2005), and only 
5% of the general population (Bushe and Holt 2004). 
Risk factors include: family history of diabetes, physical inactivity, poor diet, smoking 
and the metabolic effects of antipsychotic medication (Gough and Peveler 2004). 
Typical antipsychotics, in particular the low potency ones such as chlorpromazine may 
induce or make existing diabetes worse (Newcomer et al. 2002). The atypical 
antipsychotics clozapine and olanzapine are associated with new onset or exacerbating 
type 2 diabetes, not just through their propensity to cause greater weight gain than 
other newer agents, but because of their effects on glucose regulation (Newcomer et 
al. 2002). There are also case reports linking risperidone and quetiapine to impaired 
glucose intolerance, diabetes and ketoacidosis (Taylor et al. 2007). 
 
Recommended action 
Blood glucose should be checked at least annually. It may be more practical to do a 
random test though a fasting test will be more accurate. The World Health 
Organization (2011) recommends that HbA1c can also be used as a diagnostic test for 
diabetes providing that stringent quality assurance tests are in place and assays are 
standardised to criteria aligned to the international reference values, and there are no 
conditions present which preclude its accurate measurement. 
 More frequent assessments are required for patients with significant risk 
factors for diabetes (overweight, Asian/African ethnicity etc) (Barnett et al. 
2007).  Consider checking every 6 months 
 Support and exchange information on diet (ie meal planning) and exercise 
 
 If diabetes is diagnosed, refer to practice diabetes nurse for further 
investigations, education and treatment 
 
Prolactin 
Rationale 
Hyperprolactinaemia is a common side-effect of many antipsychotic drugs. Symptoms 
include gynaecomastia, galactorrhoea, amenorrhoea and sexual dysfunction. Switching 
to a prolactin sparing antipsychotic has been shown to lead to normalization of serum 
prolactin and resolution of the symptoms (Haddad et al. 2001).  
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Recommended action 
Consensus guidelines for managing prolactinaemia (Peveler et al. 2008) recommend 
that healthcare professionals should monitor proactively for hyperprolactinaemia as it 
maybe asymptomatic. 
 Patients prescribed prolactin elevating antipsychotics should, where possible, 
have this issue explained to them prior to commencing treatment and be 
screened for symptoms suggestive of hyperprolactinaemia before starting 
treatment (Haddad et al. 2001) and annually thereafter 
 If the elevation of prolactin levels is mild (<1000 mIU/L (~50 ng/mL)) then it 
may be reasonable to continue to monitor the level. However, if even a mildly 
elevated level persists for more than 3 months, particularly if accompanied by 
amenorrhoea, bone mineral density may be compromised, and the possibility 
of reducing dose or switching to an antipsychotic with lower potential for 
prolactin elevation should be discussed with the patient 
 When elevation is persistent and >1000 mIU/L (~50 ng/mL) then the clinician 
should consider switching to a drug with a lower potential to elevate prolactin 
if this can be achieved safely and is consistent with the clinical status of the 
patient as a whole 
 For female patients switching to a drug with a lower potential to elevate 
prolactin may result in the return of fertility, and contraceptive advice should 
be given.  
 If switching to a drug with a lower potential to elevate prolactin is not possible, 
it would be reasonable for clinicians to consider offering an oral contraceptive 
to female patients with amenorrhoea, if this is not contraindicated, to reduce 
the risk of subsequent osteoporosis. 
 In any patient with a prolactin elevation greater than 3000 mIU/L (~150 ng/mL) 
then a prolactinoma should be considered. 
 If the levels do not return to normal upon switching to a less prolactin-elevating 
antipsychotic, or if such switch is not possible for clinical reasons, then referral 
to a specialist in endocrinology is warranted to exclude a prolactinoma.  
Peveler, R. et al (2008) 
 
Urea and Electrolytes (U & Es) and calcium 
Rationale 
There is a risk of electrolyte imbalance when taking antipsychotic medication 
particularly at high doses. For patients taking lithium, there is a higher than normal 
incidence of hypercalcaemia and abnormal renal function (BMA 2009).  
 
Recommended action 
 Check U & Es and calcium annually or when presented with symptoms. 
 For patients taking lithium six monthly checks are recommended (BNF 2011). 
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Thyroid Function Test 
Rationale 
Studies have indicated that the elevated serum levels of T4 may be specific for acutely 
ill schizophrenic patients and that neuroleptic medication may affect thyroid hormone 
metabolism (Baumgartnera et al. 2000) and that there is a spectrum of thyroid 
function test abnormalities in chronic schizophrenia (Othman et al. 1994). 
For patients taking lithium, there is a higher than normal incidence of hypothyroidism 
(BMA 2009).  
 
Recommended action 
 Check thyroid function annually or in the presence of symptoms 
 For patients taking lithium six monthly checks are recommended (BNF 2011). 
 
Full Blood Count (FBC) 
Rationale 
A case-control study (Teixeira et al. 2009) in patients with schizophrenia showed a 
significantly higher number of patients with changes on leukocytes. Many patients 
presented low values of haemoglobin, erythrocytes and platelets. Leukopenia and 
neutropenia are recognised as side effects of antipsychotic medication (Taylor et al. 
2007). 
 
Recommended action 
Check FBC annually or in the presence of symptoms. 
 
B12 and Folate 
Rationale 
A case-control study (Teixeira et al. 2009) in patients with schizophrenia presented low 
values of vitamin B12. 
Having a deficiency of vitamin B12 just because of eating a poor diet is rare in Western 
countries, but unhealthy diets are common lifestyle choices of people with 
schizophrenia (McCreadie 2003). 
 
Recommended action 
Check B12 and folate annually or in the presence of symptoms. 
 
Plasma Levels 
Lithium 
Rationale 
There is potential toxicity caused by lithium therapy when the serum levels are outside 
of the narrow therapeutic range (BMA 2009). 
 
Recommended action 
It is recommended that lithium levels are monitored every three months (BNF 2011). 
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Carbamazepine 
Rationale 
Most authorities agree that plasma drug level monitoring is mandatory when using 
carbamazepine for seizure disorders and helpful for bipolar disorder (Taylor et al. 
2000). 
 
Recommended action 
Consider monitoring carbamazepine levels annually. 
 
Valproate 
Rationale 
Most authorities agree that plasma drug level monitoring is helpful for valproate in 
seizure disorders and bipolar disorder (Taylor et al. 2000). 
 
Recommended action 
Consider monitoring valproate levels annually. 
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Screening 
 
Cervical Cytology (Women only) 
Rationale 
Women with schizophrenia have a lower cervical cancer screening rate (63%) than 
those without severe mental health problems (73%-Disability Rights Commission 
2006). However, the evidence shows that if a woman has never been sexually active, 
then her risk of developing cervical cancer is very low indeed (NHS Cervical Screening 
Programme 2009a).  
Cervical screening saves approximately 4,500 lives per year in England (Peto et al. 
2004) and prevents up to 3,900 cases of cervical cancer per year in the UK (Sasieni et 
al. 1996). Cervical cancer incidence fell by 42 % between 1988 and 1997 (England and 
Wales). This fall is directly related to the cervical screening programme (National 
Statistics 2000). 
 
Recommended action 
Determine patient history of cervical cytology. (Recommendation: under 25 years - no 
screening; 25-49 years - three yearly; 50-64 years - five yearly; 65+ years  - those who 
have not been screened since age 50 or have had recent abnormal tests) 
If no recent cervical cytology and has been sexually active, then offer appointment 
with the practice nurse. 
 
Testicular examination (Men only) 
Rationale 
Cancer of the testicles accounts for only about 1% of all cancers in men. It is however, 
the most common type of cancer in males ages 16 to 35, and can occur anytime after 
age 15. Often, only one testicle is affected (Cancer Research 2002). 
 
Recommended action 
 Exchange information on testicular self-examination (Cancer Research UK 
2002). How to do a testicular self examination (leaflet): 
www.cancerhelp.org.uk/help/default.asp?page=3570 
 Advise if any abnormalities are found to make an appointment with their GP. 
 
Teeth 
Rationale 
Antipsychotics, antidepressants and mood stabilisers can cause reduced saliva flow 
leading to caries, gingivitis and periodontal disease (Robson and Gray 2007). 
Dental health may also be affected by poor diet and oral hygiene, and smoking 
(Robson and Gray 2007). 
The extent of dental disease can be directly related to schizophrenia intensity, impact 
of negative symptoms and the length of hospitalisation (Thomas et al. 1996). 
 
Recommended action 
Enquire about oral hygiene and give the appropriate advice. 
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Dental check-ups should be every three months to two years depending on need (DOH 
2009). Patients should be encouraged to take regular visits to the community dentist 
(NICE 2004a). 
 
Eyes 
Rationale 
Antipsychotic medication may cause lens and cornea damage, and has been associated 
with cataract development (Robson and Gray 2007). 
 
Recommended action 
Patients with severe mental illness should be encouraged to routinely visit a local 
optician/optometrist every two years. 
 
Feet 
Rationale 
Some patients with severe mental illness struggle to maintain their personal care. Lack 
of proper care, ill-fitting shoes and general foot neglect are responsible for the 
majority of foot problems.  Feet are the foundation of the body, so if the foot is not 
functioning correctly, ankles, knees, hips and lower back are not aligned correctly and 
problems can develop throughout the entire body. 
 
Recommended action 
 Exchange information on keeping feet healthy, eg washing daily, trimming nails, 
treatment for burns, cuts and breaks in the skin (The Society of Chiropodists 
and Podiatrists 2005) 
 Elderly patients or those with diabetes, osteoarthritis and/or rheumatoid 
arthritis should be a priority in NHS foot care, and should receive regular check-
up from a registered chiropodist (The Society of Chiropodists and Podiatrists 
2007) 
 If the patient is presenting any signs/symptoms of foot problems refer to the 
chiropodist. 
 
Breast Examination (Women) 
Rationale 
Breast cancer is the most common cancer in the UK (Breast Cancer Care 2000).  
Hyperprolactinaemia can be an adverse effect of antipsychotic therapy that leads to 
breast-related problems (Halbreich et al. 2003). 
 
Recommended action 
All patients should be advised on self examination (Breast Cancer Care 2010). 
 
 Teach the breast awareness 5-point code: 
1. Know what is normal for you  
2. Know what changes to look and feel for  
3. Look and feel  
4. Report any changes to your GP without delay  
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5. Attend routine breast screening if you are aged 50 or over  
 Check risk factors for breast cancer (eg previous history, family history, age) 
(Patient UK 2007) 
 If there are any breast abnormalities, refer for further investigations (Patient 
UK 2007) 
 Check for increased levels of serum prolactin (Halbreich et al. 2003) 
 
Breast Examination (Men) 
Rationale 
The causes of breast cancer in men are not fully known. However, the most important 
risk factor is increasing age. Most men who get breast cancer are over 60 although 
younger men can be affected (Breast Cancer Care 2008). 
Hyperprolactinaemia can be an adverse effect of antipsychotic therapy that leads to 
breast-related problems (Halbreich et al. 2003). 
 
Recommended action 
 Check risk factors for breast cancer (age > 60 years, previous radiotherapy to 
the chest, obesity, family history of breast cancer, high oestrogen levels, 
chromosomal syndromes) (Breast Cancer Care 2008) 
 Check for any symptoms (painless lump, nipple discharge, ulceration or 
swelling) (Breast Cancer Care 2008) 
 Refer to breast clinic for further investigations (Breast Cancer Care 2008) 
 Check for increased levels of serum prolactin (Halbreich et al. 2003) 
 
Menstrual Cycle 
Rationale 
Hyperprolactinaemia can cause amenorrhoea which is associated with anovulation 
(absence of ovulation), and infertility. 
 
Recommended action 
 Check for amenorrhoea - consider offering an oral contraceptive, if this is not 
contraindicated, to reduce the risk of subsequent osteoporosis 
 Check for increased levels of serum prolactin, disturbed menstrual cycle and 
irregular menstrual cycle (Halbreich et al. 2003). See under Blood Tests – 
prolactin 
 
 
 
Urine 
Rationale 
Many conditions and chronic urinary tract infection can be detected by using medical 
urine test strips, and the amount of urine produced can indicate certain conditions. 
Polyuria = the passing of excessive volumes of urine may be a sign of diabetes, renal 
failure, alcohol and drug misuse, metabolic abnormalities (Patient UK 2005) and 
polydipsia.   
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Oliguria = reduced urine volume. Cause maybe due to dehydration, vascular collapse 
or low cardiac output (Patient. UK 2008). 
 
Recommended action 
 Assess for signs of dehydration (NHS Direct 2007), encourage fluids and 
implement fluid balance chart to evaluate 
 Assess for symptoms of polyuria (Patient. UK 2005), implement fluid balance 
chart to evaluate 
 Check for any urine frequency/incontinence issues 
 Dip test urine using eight parameter (as a minimum) diagnostic strips. Follow 
usual protocols for abnormalities 
 
Bowels 
Rationale 
People with schizophrenia are almost twice as likely to have bowel cancer as the 
general population (DRC 2006). 
Patients with schizophrenia seldom complain of gastrointestinal symptoms unless 
specifically asked (Gupta et al. 1997). 
Eating a diet low in red or processed meat and high in fibre, fruit and vegetables can 
reduce the risk of bowel cancer. Being physically active helps to cut the risk, but being 
overweight or regularly drinking too much alcohol increases it (Cancer Research UK 
2009). 
 
Recommended action 
 Exchange information on increasing physical activity, lowering alcohol and a 
healthy diet 
 The NHS Bowel Cancer Screening Programme offers screening every two years 
to all men and women aged 60 to 69 (NHS Cancer Screening Programmes 
2009b) 
 Check for signs of irritable bowel symptoms, diarrhoea or constipation, 
excessive urgency, gastrointestinal symptoms, straining, bleeding, need for 
laxatives 
 Check for any bowel frequency/incontinence issues 
 Rapid referral for endoscopy if symptoms are suspicious (NICE 2004b) 
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Lifestyle 
 
Sleep 
Rationale 
Most adults need around 7–8 hours of sleep each night (Benson 2006). 
 In untreated schizophrenia, profound insomnia can result from psychotic 
symptoms (Benson 2006) 
 Although antipsychotic treatment can reduce insomnia, the side effects of 
sedation and residual insomnia can occur (Benson 2006) 
 Complaints of poor sleep quality are directly related to negative assessments of 
quality of life (Benson 2006) 
 Improved sleep may lead to improved ability to cope with stress, and increased 
energy (Hofstetter et al.  2005) 
 
Recommended action 
 Clarify any patient sleep problems (Hofstetter et al.  2005) 
 Provide education on good sleep hygiene and benefits of a sleep diary  
 Consider medication review  
 
Smoking 
Rationale 
Approximately 85% of people with schizophrenia smoke, compared with 23% of the 
general population (Goff et al. 2005). Smoking rates are higher in schizophrenia than in 
other severe mental illnesses (Goff et al. 2005). 
 
Neurobiological, psychological, behavioural and social factors make it difficult for 
patients with mental illness to stop smoking (Robson and Gray 2007). 
 
Smoking cessation medication and other non-pharmacological support can increase 
abstinence rates in those with mental health problems to as high as those in the 
general population (Foulds et al. 2006, Campion et al. 2008). However those with 
mental illness have previously been less likely to receive smoking cessation in primary 
care (Phelan et al. 2001). 
 
Stopping smoking reduces the risk of (NHS Choices 2009a): 
 Developing illness, disability or death caused by cancer, heart or lung disease  
 Gangrene or amputation caused by circulatory problems 
 Exposing others to secondhand smoke 
 Children in the same household suffering from asthma or glue ear 
 Infertility levels, and an unhealthy pregnancy and baby 
 Breathing difficulties and decreased general fitness 
 Less enjoyment of the taste of food 
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Recommended action 
 Give advice about the possible health risks associated with smoking 
 Ask about respiratory symptoms; chest examination if appropriate 
 Refer any patients wishing to quit smoking to NHS Stop Smoking Services if 
appropriate (DH 2007a) or the primary care clinic’s stop smoking service. They 
may need to be seen individually. Review medication regularly. 
 Cigarette smoking lowers the levels of many antipsychotic medications 
(Vazquez et al. 2007). Therefore, if a patient stops or reduces their smoking, a 
medication review should be undertaken. 
o Blood levels of olanzapine and clozapine should be measured before 
smoking cessation followed by 25% dose reduction during first week of 
cessation and then further blood levels (Taylor et al. 2007). 
o Doses of fluphenazine and benzodiazepine should be reduced by up to 
25% in first week of cessation.  
o Tricyclic antidepressants may need to be reduced by 10-25% in first 
week (Taylor et al. 2007).  
 
Nicotine replacement is available in a variety of forms and strengths to encourage 
patient preference and acceptability. Combining patch and faster-acting oral NRT 
improves efficacy. Side effects include mild local irritation of mouth, throat or nose.  
Bupropion is associated with seizures and is contraindicated in bipolar affective 
disorder and epilepsy. It should not be prescribed with drugs which increase risk of 
seizures such as tricyclic antidepressants and some anti-psychotics. Bupropion can also 
alter blood levels of medication such as antipsychotics and antidepressants.  
Varenicline has been reported to be more effective and have fewer side effects than 
bupropion (Cahill et al. 2007).  However, reports of exacerbation of depression and 
suicidal ideation are currently being reviewed. 
(Royal College of Psychiatrists and Royal College of General Practitioners 2010). 
 
Exercise 
Rationale 
People with severe mental illness are more physically inactive than the general 
population (Brown et al, 1999, McCreadie 2003). 
Physical activity can have a positive effect on psychological well-being in people with 
schizophrenia (DH 2004). 
 
Recommended action 
Identify the patient’s level of activity. The recommendation for exercise to be of 
benefit is 30 minutes five days a week (DH 2004). Help the patients make an exercise 
plan which fits in with their lifestyle and builds up activity gradually. For some 
individuals it may be appropriate to refer to an exercise scheme if there is one in your 
area. 
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Alcohol Intake 
Rationale 
Alcohol misuse is one of the most common and clinically significant co-morbidities 
among patients with severe mental illness (Brunette et al. 2004). There is considerable 
evidence to support the positive impact of reducing unsafe alcohol consumption on 
cardiovascular health (NHS Information Centre 2008).  
Many antipsychotics can cause sedation and impair alertness, concentration and 
coordination. The use of alcohol can further increase any impairment (rethink 2008b). 
 
Recommended action 
Offer recommendations on sensible daily alcohol intake: 
 Adult women should not regularly drink > 2–3 units of alcohol a day 
 Adult men should not regularly drink > 3–4 units of alcohol a day 
 Women who regularly drink > 6 units a day (or > 35 units a week) and men who 
regularly drink > 8 units a day (or 50 units a week) are at highest risk of alcohol-
related harm 
(Department of Health 2007b) 
Refer to the local Alcohol Support Agency. 
 
Diet 
Rationale 
In a survey of the dietary habits of 102 people with SMI by McCreadie (2003) the 
average fruit and vegetable intake for these people was 16 portions a week, compared 
with recommended intake of 35 per week (DH 2004). The physical health 
consequences of a poor diet include CVD, diabetes, obesity and some cancers.  
Studies of people with SMI repeatedly show that saturated fats from dietary intake of 
meat and dairy products are associated with worse outcomes in schizophrenia 
(Peet 2004). There is a particularly strong association between sugar consumption and 
poorer outcome in schizophrenia whereas consumption of fish and sea food, 
particularly omega 3 fatty acids, has been associated with better outcomes (Peet 
2004). 
 
Recommended action 
Agree and implement a diet plan with the patient (and any carers) – may include 
referral to other members of the multidisciplinary team. 
 Explain that five portions of fruit/vegetables each day and reducing fat intake, 
reduces the risk of cancer, coronary heart disease, and other chronic illnesses 
(DH 2007c). 
 Aim to address potential barriers (access and availability of fresh 
fruit/vegetables, awareness of health benefits and attitudes towards buying, 
preparing and eating fruit/vegetables) (DH 2007c). 
 
Fluid Intake 
Rationale 
Many people with severe mental illness do not drink enough fluid leading to 
dehydration. The body works less efficiently, even with a relatively low level of fluid 
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loss (NHS Choices 2009b). Some of the early warning signs are feeling thirsty and light-
headed, and having concentrated, strong-smelling urine.  
Overconsumption of fluid can also arise from a condition called polydipsia which is a 
serious complication of some psychotic illnesses, including schizophrenia. The exact 
reason for any one person developing polydipsia is unclear, but if untreated, the high 
intake of fluids can lead to hyponatraemia, which in turn can lead to coma or even 
death. It has been estimated that between six and 17% of psychiatric inpatients suffer 
from polydipsia (Brooks and Ahmed 2007). 
 
Recommended action 
Determine patient’s daily fluid intake:  
 
If < one litre/day: 
 Check for signs of dehydration  
 Encourage the patient to drink 1-2 litres (6–8 glasses) of fluid every day (more 
during hot weather and physical exertion)  
 Exchange information on increasing fluid intake (drinking semi-skimmed milk, 
diluted fruit juices, diluted fruit squash)  
(NHS Choices 2010) 
 
If > three litres/day check for signs of polydypsia, (Brooks and Ahmed 2007) such as 
increased urine output. 
Implement a fluid balance chart if possible; enlist help of carers and family. 
Electrolyte assessment if initial intervention is unsuccessful. 
 
Caffeine intake 
Rationale 
Caffeine is a central stimulant, ie it stimulates the brain. Caffeine is present in drinks 
such as coffee, tea and cola (NWMHP 2008). Too much caffeine can cause feelings of 
anxiety and nervousness, sleep disruption (especially difficulty getting off to sleep),  
restlessness, irritability, diuresis (passing lots of water/urine), stomach complaints, 
tremulousness, palpitations and arrhythmias (changed heart rate, especially faster  
beating) (NWMHP 2008). A moderate daily caffeine intake of 250–500 mg is not 
associated with adverse events (NWMHP 2008).  
Psychosis can be induced in normal individuals ingesting caffeine at toxic doses, and 
psychotic symptoms can also be worsened in schizophrenic patients using caffeine 
(Broderick and Benjamin 2004). 
 
 Food or drink item Average caffeine content 
1 cup of coffee 75–100 mg 
1 cup of tea 50 mg 
1 can of cola 40 mg 
1 energy drink 90 mg 
Bar of plain chocolate 50 mg 
Bar of milk chocolate 25 mg 
FSA (2004) 
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Recommended action 
 Exchange information on reducing caffeine intake (stopping gradually to avoid 
withdrawal effects) (NWMHP 2008) 
 Check for symptoms of caffeinism or caffeine toxicity (> 1000 mg/day), which 
can make illnesses such as anxiety more resistant to drug treatment (NWMHP 
2008) 
 
Safe Sex 
Rationale 
Although a smaller proportion of people with SMI are sexually active compared to the 
general population, those that are sexually active are more likely to engage in high risk 
behaviours that may lead to HIV, such as sex without a condom and injecting drug use 
(Cournos et al. 2005). Reasons for this include lack of knowledge about how sexually 
transmitted diseases (STIs) and HIV are transmitted and prevented (Arrufo et al. 1990, 
Kalichman et al. 1994), a susceptibility to coercion into unwanted sexual activity, 
difficulties in establishing stable social and sexual relationships, and comorbid alcohol 
and substance use (Coverdale and Turbott 2000). 
  
Recommended action 
 Identify if the patient is engaging in behaviours that increase the risk of STIs 
 Provide sexual health advice 
 If STI is suspected, refer to the Genito-Urinary Medicine Clinic 
 
Sexual Satisfaction 
Rationale 
Antipsychotic medication can have an adverse effect on sexual function, which impacts 
greatly on quality of life (Hanssens et al. 2006).  
A study (Smith et al. 2002) showed that sexual dysfunction occurred in 45% of patients 
taking antipsychotic medication. The main cause of sexual dysfunction in both men 
and women was hyperprolactinaemia. 
 
Recommended action 
 Determine the patient’s level of sexual activity – refer for gynaecological 
examination and laboratory assessments if required (EAU 2005) 
 Use side effects scale for antipsychotic medication such as SESCAM (Bennett et 
al. 1994) 
 Perform systemic assessment (eg Arizona Sexual Experience Scale- go to: 
www.psy-world.com/asex_print.htm ) (McGahuey et al. 2000) 
 Check for increased levels of serum prolactin = decreased libido and arousal, 
orgasmic dysfunction (Halbreich et al. 2003) 
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Cannabis 
Rationale 
Cannabis use is associated with poor outcomes in existing schizophrenia (Henquet et 
al. 2005). 
Cannabis use is a contributing factor in 10% of schizophrenia cases and there are 1,500 
expected new cases of cannabis-related schizophrenia each year (BBC 2007). 
 
Recommended action 
 Patients’ cannabis use should be recorded during a physical health check 
 Ask about other non-prescribed drug use (BMA 2009) 
 Work with support of dual diagnosis worker/service - systemically evaluate 
using a drug use scale 
 Implement health behaviour interventions 
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Medication review 
 
People with an established diagnosis of schizophrenia or bipolar disorder who are 
managed in primary care require monitoring of medication use, medication adherence 
and side-effects (NICE 2006a, 2009). The accuracy of other medication can also be 
checked at the same time as reviewing the antipsychotics and/or mood stabilisers 
(BMA 2009). 
 
Antipsychotics 
Rationale 
Antipsychotics have a wide range of side effects. The most widely researched include 
(Rethink 2006):  
Sedation: The antipsychotics that cause the most sedation include chlorpromazine, 
promazine, thioridazine, clozapine and zotepine. Often this can be dealt with by the 
patient taking their medication at night just before they go to bed. The dose may need 
to be reduced or changed if this is a big problem. 
Movement disorders: There are different types of movement disorder. These include: 
 Dystonia - prolonged muscle spasms often involving the face, neck, shoulders 
and upper limbs. Drugs such as procyclidine and orphenadrine are given to 
treat dystonia 
 Akathisia - fidgety movements of the legs which may be accompanied by a 
strong sense of inner restlessness and unease. This often means that a person 
cannot sit comfortably, and may be driven to walk up and down to try and gain 
relief. It is best treated with clonazepam or propranolol 
 Parkinsonian movement disorders - involve stiffness and shakiness, and 
resembles the unrelated condition of Parkinson's disease. The limbs move 
slowly and muscles of the face may be quite immobile, producing an 
expressionless, staring face. Rhythmic shaking may occur but is not usually very 
severe, and is most obvious in the hands. Procyclidine and orphenadrine, 
amongst other drugs, are given to treat Parkinsonian movement disorders 
 Tardive dyskinesia - major signs of the condition are excessive movement of 
the lips, tongue and jaw, (known as oro-facial dyskinesia). The term "tardive" 
means delayed or late-appearing and this reflects the fact that treatment may 
have gone on for some months or years before the movement disorder 
becomes apparent. Oro-facial dyskinesia is the most common form of tardive 
dyskinesia. Other abnormal movements are seen including jerky, abrupt 
movements of the limbs and body, but these are less common. 
 
Recommended action 
Side effects should be monitored in a systematic manner using a recognized tool such 
as SESCAM (Bennett et al. 1995). This is a two part scale, one for the observing health 
care professional and the other is self rated by the patient. 
Blood tests should be taken as described previously. 
Refer back to original prescriber (NICE 2009) in the case of: 
 Observed side effects 
 Return of symptoms  
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 Any physical problems which may be related to the drug 
 Any issues flagged up by the patient 
 
Mood stabilisers  
Lithium  
Rationale 
In long-term use lithium has been associated with thyroid disorders and mild cognitive 
and memory impairment. Lithium salts have a narrow therapeutic/toxic ratio, 
therefore it is important to determine the optimum range for each individual patient. 
Lithium toxicity is made worse by sodium depletion (BNF 2011). 
 
Recommended action 
 Check thyroid function, U & Es, and calcium six monthly  
 Check lithium levels three monthly. Refer back to prescriber if not in 
therapeutic range 
 Patients should be maintained on lithium after three to five years only if benefit 
persists. 
(BNF 2011) 
 
Carbamazepine 
Rationale 
In order to be effective, carbamazepine has to reach a given level in the blood 
(NWMHFT 2005a). Side effects include dizziness, drowsiness, shaky movements and 
feeling sick. Carbamazepine can cause a chronic low white blood cell count which 
increases susceptibility to infection (NWMHFT 2005a). This can be monitored with 
regular blood tests. 
 
Recommended action 
 Consider monitoring carbamazepine levels annually  
 Check full blood count annually 
 If abnormal FBC (without any other cause) and/or carbemazepine not in 
therapeutic range, refer back to prescriber 
 
Valproate 
Rationale 
Valproate causes an increase in appetite and therefore weight gain (NWMHFT 2005b). 
Side effects include dizziness, drowsiness, shaky movements, feeling sick, impaired 
liver function, thrombocytopenia and impaired platelet function (NWMHFT 2005b). 
 
Recommended action 
 Give advice regarding a diet high in vegetables and fibre, refer to dietician if 
appropriate (NWMHFT 2005b) 
 Advise if bruises without reason or bleeds easily, to stop taking valproate and 
refer back to prescriber (NWMHFT 2005b) 
 Consider monitoring valproate levels  
 Check full blood count and LFT annually 
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 If abnormal FBC and/or LFT (without any other cause) and/or valproate not in 
therapeutic range, refer back to prescriber  
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Additional factors 
 
Care plan 
Rationale 
The GMS contract (BMA 2009) requires the patient to have their care plan 
documented in the records; this is agreed between individuals, their family and/or 
carers as appropriate.  
The Care Programme Approach (CPA) is the process which mental health service 
providers use to co-ordinate the care for people who have mental health problems 
(Care programme approach association 2011).  
 
Recommended action 
 If the patient is under the care of secondary care, Care Programme Approach 
(CPA), the care plan is scanned into the patient record 
 If the patient is on the register but not under the care of secondary care, the 
healthcare professional should document an accurate and easily understood 
plan of care as part of the annual review by discussing this with the patient, 
family and/or carers. The discussion should include the patient’s preferred 
course of action in the event of a clinical relapse; it should also contain a 
discussion around the following issues (NICE 2009): 
o Social support 
o Input from secondary and /or voluntary mental health 
o Early warning signs that may indicate possible relapse  
o Occupational status 
 
Flu vaccination 
Rationale 
Patients with severe mental illness are at an increased risk of cardiac, respiratory 
disorders and diabetes (Sainsbury Centre for Mental Health 2003). 
 
Recommended action 
Offer annual immunisation (Sainsbury Centre for Mental Health 2003). 
 
Follow up 
Rationale 
The patient may not attend for the health check due to his/her mental state. It is 
important  to set up a robust system to allow further opportunities to attend.  
 
Recommended action 
 Try contacting the patient (or carer if known) by telephone 
 Send a letter requesting that they contact the surgery to make a new 
appointment 
 If unknown to secondary care, inform the GP of their non-attendance 
 If known to secondary care, inform the secondary care link worker 
 If patient does not make a further appointment they can be exception reported 
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Knowledge Quiz (Pre-training) 
 
Please supply the following information 
 
Gender: 
Ethnicity: 
Year of first registered nursing qualification: 
 
Please circle your answer 
 
1. People with mental illness die five years earlier than the general population. 
Agree      Disagree 
 
2. Antipsychotic medication should be increased if the patient stops smoking 
Agree      Disagree 
 
3. Psychotic symptoms can be improved in schizophrenic patients by using 
caffeine 
Agree      Disagree 
 
4. If the patient is not under the care of the Community Mental Health team, 
then they do not need a care plan 
Agree      Disagree 
 
5. Patients who take lithium need their lithium levels monitored every six 
months  
Agree      Disagree 
 
6. If the elevation of a patient’s prolactin levels is <2000 mIU/L, then it is 
reasonable to continue to monitor the level without any further action 
Agree      Disagree 
 
7. It is important to encourage all patients with severe mental illness to drink 
lots of fluid 
Agree      Disagree 
 
8. People with SMI are at less risk of acquiring a sexually transmitted infection 
compared to the general population  
Agree      Disagree 
 
 
9. Cannabis use is a contributing factor in 50% of schizophrenia cases 
Agree      Disagree 
 
10 The side effect of sedation from taking an antipsychotic, cannot be dealt 
with by the patient taking their medication just before they go to bed 
Agree      Disagree 
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Attitudes Quiz (Pre-training) 
 
Please supply the following information 
 
Gender: 
Ethnicity: 
Year of first registered nursing qualification: 
 
Please circle your answer 
 
1. Having a diagnosis of severe mental illness, means that recovery is not 
possible 
Agree      Disagree 
 
2. I do not need to know the views of my patients with severe mental illness 
regarding their psychiatric medications 
Agree      Disagree 
 
3. I am not in a position to help your patients with severe mental illness 
identify people who can assist them during a crisis 
Agree      Disagree 
 
4. I am not in a position to  identify triggers that cause symptoms of your 
patients with severe mental illness to get worse and identify warning signs 
that come before they get symptoms  
Agree      Disagree 
 
5. It is sometimes necessary to disregard the patients’ preferences regarding 
their physical health in order to provide the best treatment 
Agree      Disagree 
 
6. Many patients with severe mental illness cannot make sensible choices 
about their physical care 
Agree      Disagree 
 
7. When providing patients with severe mental illness a health check, I should 
keep focused on their physical  health 
Agree      Disagree 
 
8. I should invalidate the patient’s goal when it is unrealistic 
Agree      Disagree 
 
9. A physical health check appointment does not need to include assisting 
patients with severe mental illness in maintaining activities that are 
meaningful to them 
Agree      Disagree 
 
10 The physical health goals of “normal” people are often too stressful for 
patients with severe mental illness to reach 
Agree      Disagree 
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Communication Questionnaire 
  
Please supply the following information 
 
Gender: 
Ethnicity: 
Year of first registered nursing qualification: 
Working in primary care or secondary care: 
 
After receiving training to improve the physical health for people with 
severe mental illness (PhyHWell) will you (Please circle your response): 
 
 
Contact your own primary/secondary care colleague to inform them about changes 
in health or circumstances of a particular patient? 
 
a) Much more likely b) More likely c) less likely d) will not e) don’t know 
 
 
Contact your own primary/secondary care colleague to ask them about a particular 
patient? 
 
a) Much more likely b) More likely c) less likely d) will not e) don’t know 
 
 
Contact your own primary/secondary care colleague to inform them about new or 
changes in service developments? 
 
a) Much more likely b) More likely c) less likely d) will not e) don’t know 
 
 
Contact your own primary/secondary care colleague to ask them about new or 
changes in service developments? 
 
a) Much more likely b) More likely c) less likely d) will not e) don’t know 
 
 
Develop an individual system of communication between your own 
primary/secondary care colleagues? 
 
a) Much more likely b) More likely c) less likely d) will not e) don’t know 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 9      
  
 
  
326 
 
 
 
 
 
 
Strategy and System Management Directorate 
NHS Northamptonshire 
Francis Crick House 
Summerhouse Road 
Moulton Park 
Northampton NN3 6BF   
        
 
 
 
Evaluation of the Northampton Physical Health and Well-being Project 
(PhyHWell) 
 
 
As you have accepted to take part in the Northampton Physical Health and Well-being 
project, we would like to invite you to take part in our research study. It is up to you 
whether you decide to join the study. The study is described in the enclosed 
information sheet. If you agree to take part, we will then ask you to sign a consent form. 
You are free to withdraw at any time, without giving a reason and will still be eligible for 
the training and support. 
 
The overall aim of this study is to evaluate the Northampton Physical Health and 
Wellbeing Project (PhyHWell). Specifically we wish to determine:  
The impact of the PhyHWell project on cardiovascular risk in patients with severe 
mental illness. 
The impact of the PhyHWell project on patients’ adherence with medicine 
The acceptability of the PhyHWell project to the patients 
The acceptability of the PhyHWell project to the nurses 
 
The data will be evaluated and you will be provided with the results. The project has 
been reviewed by the local Research Ethics Committee and the part you will be 
involved in has been classified as a service evaluation which has been approved by the 
local R & D centre. 
Should you wish to take part, I will come and explain the study to you and answer any 
questions you may have. Please contact me on telephone number 07825934800 or 
email Sheila.Hardy@uea.ac.uk to arrange a convenient time.  
 
Yours faithfully 
 
 
 
 
Sheila Hardy 
Principal Investigator 
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Information about the research (GP Practice) 
 
An evaluation of the Northampton Physical Health and Well-being Project 
(PhyHWell) 
 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would involve 
for you. We will answer any questions you have. You may wish to discuss this with the 
GP partners and practice nurses before making a decision. 
 
(Part 1 tells you the purpose of this study and what will happen to you if you take part. 
Part 2 gives you more detailed information about the conduct of the study). Ask us if 
there is anything that is not clear. 
 
Part 1 
 
What is the Purpose of the Study? 
The overall aim of this study is to evaluate the Northampton Physical Health and 
Wellbeing Project (PhyHWell). Specifically we wish to determine:  
The impact of the PhyHWell project on cardiovascular risk in patients with severe 
mental illness 
The impact of the PhyHWell project on patients’ adherence with medicine 
The acceptability of the PhyHWell project to the patients 
The acceptability of the PhyHWell project to the nurses 
 
Why have I been invited? 
You have been invited because you have accepted to undertake the PhyHWell project 
training. 
  
Do I have to take part? 
It is up to you to decide to join the study. The study is described in this information 
sheet. If you agree to take part, we will then ask you to sign a consent form. You are 
 
 
 
 
 
 
Northamptonshire Teaching Primary Care Trust 
Francis Crick House 
Summerhouse Road 
Moulton Park 
Northampton 
NN3 6BF 
Tel: 01604 651201 
Fax: 01604 651101 
Web: www.northamptonshire.nhs.uk 
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free to withdraw at any time, without giving a reason and will still be eligible for the 
training and support. 
 
What are the benefits of taking part? 
There is no direct benefit to you in taking part. You will be providing evidence to 
illustrate how training contributes to service delivery. 
 
What are the possible disadvantages and risks of taking part? 
It is anticipated that there are no disadvantages from participating in this research. All 
information will remain anonymous and you are free to withdraw at anytime. 
 
What will we have to do? 
 Sign a consent form to permit use of anonymised data for the research 
 The clinical team member identified to undertake training and responsibility for 
SMI health checks to complete two questionnaires before and after training 
 Release an admin team member for one hour to set up the audit with the 
principle investigator 
 Release an admin team member for one hour per year to run the audit under 
the guidance of the principle investigator 
 
What is the alternative? 
There is no other training at present for providing physical health checks for people 
with severe mental illness in primary care. Therefore there is no alternative way to 
collect the evidence needed to distinguish its effect. 
 
What happens if the research study stops? 
This will not affect any training or support you have been offered.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study will be 
addressed. The detailed information on this is given in Part 2. 
 
Will taking part in the study be confidential? 
We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any 
decision. 
 
 
Part 2 
 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, 
the researcher will tell you.  
 
What will happen if we don’t want to carry on with the study? 
If you choose to take part and then decide you do not want your information used, 
providing it has not already been published or shared then your information will be 
withdrawn. If it has already been published, then it will be impossible to withdraw it. 
 
What if there is a problem? 
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If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions [Sheila Hardy 
07825934800, Professor Richard Gray 01603 597132]. If you remain unhappy and 
wish to complain formally, you can do this, contact Sue Palmer-Hill, R&D Centre NHS 
Northamptonshire, email sue.palmer-Hill@northants.nhs or telephone 01604 651632 or 
write to the address above.     
 
NHS based research 
In the event that something does go wrong during the research and this is due to 
someone‘s negligence then you may have grounds for a legal action for compensation 
against the University of East Anglia, but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be available to you. 
 
Will taking part in this study be kept confidential?  
All information which is collected from the practice during the course of the research 
will be kept strictly confidential, and any information about patients which leaves the 
surgery will have their name and address removed so that they cannot be recognised. 
Data will be collected by audit which will be carried out by your own member of staff 
with guidance from the researcher. No-one outside the practice will have access to 
patient identifiable data. Data will be stored securely and coded to ensure anonymity. 
No-one other than the researchers, sponsors, regulatory authorities and Research and 
Development department will have access to view data that identifies the practice. Data 
will be stored in a locked room at the University of East Anglia for 5 years. It will then 
be disposed of securely.  
What will happen to the results of the research study?  
The information you give will remain anonymous. You will not be identified in any 
report/publication. It is intended to publish the results in reports and relevant medical 
journals. Individual GP surgeries will be informed and a poster will be displayed in the 
surgery. The results will also be made available on the Northamptonshire teaching 
Primary Care Trust website and by conference presentation. 
Who is organising and funding the research? 
The Principle Investigator is Sheila Hardy who is undertaking this research as a PhD at 
the University of East Anglia. This is being funded by Northamptonshire teaching 
Primary Care Trust. 
Who has reviewed this study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests. This study was reviewed by a Research 
Ethics Committee through the Integrated Research Application System (IRAS) and the 
part you will be involved in has been classified as a service evaluation which has been 
approved by the local R & D Centre. 
Further information and contact details 
1. General information about NHS research ethics. Go to the National Research Ethics 
Agency, National Patient Safety Agency website http://www.nres.npsa.nhs.uk/   
2. Specific information about this research project. Contact Sheila Hardy 
Sheila.Hardy@uea.ac.uk  
3. Advice about participating in the study. Contact Professor Richard Gray 
Richard.Gray@uea.ac.uk  
4. Who you should approach if you are unhappy with the study. Contact Sue Palmer-
Hill, R&D Centre NHS Northamptonshire, email sue.palmer-Hill@northants.nhs or 
telephone 01604 651632.  
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 . 
 
You will be given a copy of this information sheet and a signed consent form to 
keep. 
Sheila Hardy 
Chief Investigator 
Email – Sheila.Hardy@uea.ac.uk 
Telephone - 07825934800 
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Centre Number:  
 
Identification Number for this trial: 
 
CONSENT FORM (General Practice) 
 
Title of Project: Northampton Physical Health and Wellbeing Project 
 
Name of Researcher: Sheila Hardy 
 
 
 Please initial box 
1. I confirm that I have read and understand the information 
sheet dated....................  for the above study. I have had the 
opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
  
2. I understand that our participation is voluntary and that we 
are free to withdraw at any time without giving any reason, 
without our access to the training being affected. 
 
  
3. I understand that the data collected during the study will be 
looked at by the principal researcher, project leaders 
(Northamptonshire teaching Primary Care Trust) and 
research supervisors (University of East Anglia). I give 
permission for this information to be used anonymously. 
 
  
4. I agree to take part in the above study.  
  
 
Name of Participant     Date  
(On behalf of Practice) 
 
 
Signature  
 
 
Name of Person taking consent   Date  
 
 
Signature  
 
 
 
 
 
 
 
Northamptonshire Teaching Primary Care Trust 
Francis Crick House 
Summerhouse Road 
Moulton Park 
Northampton 
NN3 6BF 
Tel: 01604 651201 
Fax: 01604 651101 
Web: www.northamptonshire.nhs.uk 
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When completed: 1 for participant (original); 1 for researcher site file. 
   
 
 
 
 
 
 
 
 
 
Information about the research (Primary Care Nurse) 
 
An evaluation of the Northampton Physical Health and Well-being Project 
(PhyHWell) 
 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would involve 
for you. We will answer any questions you have.  
(Part 1 tells you the purpose of this study and what will happen to you if you take part. 
Part 2 gives you more detailed information about the conduct of the study). Ask us if 
there is anything that is not clear. 
 
Part 1 
 
What is the Purpose of the Study? 
The overall aim of this study is to evaluate the Northampton Physical Health and 
Wellbeing Project (PhyHWell). Specifically we wish to determine:  
The impact of the PhyHWell project on cardiovascular risk in patients with severe 
mental illness 
The impact of the PhyHWell project on patients’ adherence with medicine 
The acceptability of the PhyHWell project to the patients 
The acceptability of the PhyHWell project to the nurses 
 
Why have I been invited? 
You have been invited because you have accepted to undertake the PhyHWell project 
training. 
  
Do I have to take part? 
It is up to you to decide to join the study. The study is described in this information 
sheet. You are free to withdraw at any time, without giving a reason and will still be 
eligible for the training and support. 
 
What are the benefits of taking part? 
 
 
 
 
 
 
Northamptonshire Teaching Primary Care Trust 
Francis Crick House 
Summerhouse Road 
Moulton Park 
Northampton 
NN3 6BF 
Tel: 01604 651201 
Fax: 01604 651101 
Web: www.northamptonshire.nhs.uk 
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There is no direct benefit to you in taking part. You will be providing evidence to 
illustrate how training contributes to service delivery. 
 
 
 
What are the possible disadvantages and risks of taking part? 
It is anticipated that there are no disadvantages from participating in this research. All 
information will remain anonymous and you are free to withdraw at anytime. 
 
What will we have to do? 
Complete two questionnaires before training and three questionnaires after training. 
Each questionnaire will take about five minutes to complete. 
As this is a survey design you will not be required to sign a consent form. However, 
consent is implied to participate in the survey by filling out the questionnaires. 
 
What is the alternative? 
There is no other training at present for providing physical health checks for people 
with severe mental illness in primary care. Therefore there is no alternative way to 
collect the evidence needed to distinguish its effect. 
 
What happens if the research study stops? 
This will not affect any training or support you have been offered.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study will be 
addressed. The detailed information on this is given in Part 2. 
 
Will taking part in the study be confidential? 
We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any 
decision. 
 
 
Part 2 
 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, 
the researcher will tell you.  
 
What will happen if we don’t want to carry on with the study? 
If you choose to take part and then decide you do not want your information used, 
providing it has not already been published or shared then your information will be 
withdrawn. If it has already been published, then it will be impossible to withdraw it. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions [Sheila Hardy 
07825934800, Professor Richard Gray 01603 597132]. If you remain unhappy and 
wish to complain formally, you can do this, contact Sue Palmer-Hill, R&D Centre NHS 
Northamptonshire, email sue.palmer-Hill@northants.nhs or telephone 01604 651632 or 
write to the address above.    
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NHS based research 
In the event that something does go wrong during the research and this is due to 
someone‘s negligence then you may have grounds for a legal action for compensation 
against the University of East Anglia, but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be available to you. 
 
 
Will taking part in this study be kept confidential?  
All information which is collected from the questionnaires you completed will be kept 
strictly confidential.  
Data will be stored securely and coded to ensure anonymity. No-one other than the 
researchers, sponsors, regulatory authorities and Research and Development 
department will have access to view data that identifies the practice. Data will be stored 
in a locked room at the University of East Anglia for 5 years. It will then be disposed of 
securely.  
What will happen to the results of the research study?  
The information you give will remain anonymous. You will not be identified in any 
report/publication. It is intended to publish the results in reports and relevant medical 
journals. Individual GP surgeries will be informed and a poster will be displayed in the 
surgery. The results will also be made available on the Northamptonshire teaching 
Primary Care Trust website and by conference presentation. 
Who is organising and funding the research? 
The Principle Investigator is Sheila Hardy who is undertaking this research as a PhD at 
the University of East Anglia. This is being funded by Northamptonshire teaching 
Primary Care Trust. 
Who has reviewed this study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed by a 
Research Ethics Committee through the Integrated Research Application System 
(IRAS) and the part you will be involved in has been classified as a service evaluation 
which has been approved by the local R & D Centre. 
Further information and contact details 
1. General information about NHS research ethics. Go to the National Research Ethics 
Agency, National Patient Safety Agency website http://www.nres.npsa.nhs.uk/   
2. Specific information about this research project. Contact Sheila Hardy 
Sheila.Hardy@uea.ac.uk  
3. Advice about participating in the study. Contact Professor Richard Gray 
Richard.Gray@uea.ac.uk  
4. Who you should approach if you are unhappy with the study. Contact Sue Palmer-
Hill, R&D Centre NHS Northamptonshire, email sue.palmer-Hill@northants.nhs or 
telephone 01604 651632.  
 . 
 
You will be given a copy of this information sheet to keep. 
Sheila Hardy 
Chief Investigator 
Email – Sheila.Hardy@uea.ac.uk 
Telephone – 07825934800 
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Trent Research Ethics Committee 
Research Ethics Office 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
 
Tel: 0115 8839435 
Fax: 0115 9123300 
22 March 2011 
 
Mrs Sheila Hardy 
Project Lead 
Northamptonshire teaching Primary Care Trust 
Francis Crick House 
Summerhouse Road 
Northampton 
NN3 6BF 
 
 
Dear Mrs Hardy 
 
Study title: The Northampton Physical Health and Wellbeing (PhyHWell) 
project - The patients’ perspective 
REC reference: 11/EM/0006 
Amendment date: 08 March 2011 
 
The above amendment was reviewed at the meeting of the Sub-Committee held on 15 
March 2011.  
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the amendment on the basis described in the notice of amendment form 
and supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date  
GP/Consultant Information Sheets  1 - Focus 
Group  
28 February 2011  
Participant Consent Form: Focus Group  1  28 February 2011  
Participant Information Sheet: Focus Group  1  28 February 2011  
Notice of Substantial Amendment (non-CTIMPs)    08 March 2011  
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Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for 
the relevant NHS care organisation of this amendment and check whether it affects 
R&D approval of the research. 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
 
11/EM/0006:     Please quote this number on all correspondence 
 
Yours sincerely 
 
 
Miss Jennifer Lea 
Assistant Committee Co-ordinator 
 
E-mail: jennifer.lea@nottspct.nhs.uk 
 
 
Enclosures: List of names and professions of members who took part in the review 
 
Copy to: Tracey Moulton, University of East Anglia 
Norwich NR4 7TJ 
 
Trent Research Ethics Committee 
 
Attendance at Sub-Committee of the REC meeting on 15 March 2011 
 
Name   Profession   Capacity    
Mr Peter Korczak  Consultant Maxillo-facial Surgeon  Expert  
Dr Helen Sammons  Senior Lecturer  Expert  
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Protocol for the management of Physical Health in SMI 
 
All patients at first point of presentation/at point of initiation of treatment/change in treatment in 
secondary care (use the physical health guidance for prescriber’s manual): 
 
Step 1 –  Record family history and patient history of previous CVD, diabetes and other 
  physical disease, smoking, exercise and dietary habits. 
Step 2 –  Examine blood pressure and body mass index (and/or waist circumference),
  ECG.  
Step 3 –  Blood tests – Fasting cholesterol and glucose (if possible – otherwise do  
  random), Hba1c, FBC, TFT, full profile, prolactin, B12 and folate (once only 
  unless abnormal), plasma levels (for lithium, carbemazepine, valproate if  
  appropriate).  
Step 4 –  Advice: smoking cessation; food choices; physical activity. 
Step 5 –  When choosing medication, consider cardio metabolic risk profile of available 
  SGA drugs.  
Step 6 –  Week 6 and 12: repeat steps 2, 3 and 4. Check for weight gain – if > 7%, 
  review choice of antipsychotic.  
Step 7 –  If measurements are normal repeat annually in primary care as part of full 
  health check (if patient has no contact with primary care or is an inpatient, then 
  is the responsibility of secondary care – follow guidance from the Health  
  Improvement Profile for Primary Care manual - HIP-PC*). 
 
 
*The HIP-PC manual can be downloaded from: http://physicalsmi.webeden.co.uk  
 
 
The guidance in this protocol has been adapted from: 
 
De Hert M, Dekker J, Wood D et al. (2009) Cardiovascular disease and diabetes in people with 
severe mental illness position statement from the European Psychiatric Association (EPA), 
supported by the European Association for the Study of Diabetes (EASD) and the European 
Society of Cardiology (ESA). European Psychiatry. doi 10.1016/j.eurpsy.2009.01.005. 
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Initiating antipsychotic medication in people with 
Severe Mental Illness: Physical health guidance for 
prescribers 
 
Introduction 
The purpose of this guidance is to assist clinicians prescribing antipsychotic medication 
to look for side effects and prevent cardiovascular disease (CVD) in their patients. CVD 
is a term mainly used to describe disorders that can affect the heart (cardio) and/or 
the body’s system of arteries and veins (vascular) that are associated with 
atherosclerosis (the build up of fatty deposits and debris in the inner walls of blood 
vessels). Most are long-term conditions such as coronary heart disease (CHD) or 
peripheral artery disease (PAD), but acute events such as myocardial infarction and 
stroke can occur suddenly when a vessel supplying blood to the heart or brain 
becomes blocked. 
 
Severe mental illness such as schizophrenia and bipolar disorder is associated with high 
medical co-morbidity; mortality rates are approximately 50% higher than in the 
general population (Hennekens et al. 2005). The primary cause of death due to a 
physical cause is circulatory disease, diabetes and obesity. Evidence suggests excess 
weight gain can be 2-3 times more prevalent in people with schizophrenia than in the 
general population (Allison and Casey 2001). This may be due to high levels of 
smoking, unhealthy diets and lack of exercise which are common lifestyle choices of 
people with schizophrenia (McCreadie 2003).  
 
Antipsychotic medication can exacerbate weight gain (Allison and Casey 2001). 
Additionally, several reports have raised concerns that some of the second-generation 
antipsychotics may further increase the risk of type II diabetes (Newcomer et al. 2002). 
Clozapine and olanzapine are the agents most commonly associated with diabetes. 
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Family and personal History of Cardiovascular disease 
 
Family History 
Rationale 
Individuals with a positive family history of CVD are at a greater risk of an early CVD 
event (Williams et al. 2001). A positive family history is seen as fathers who succumb 
earlier than 55 years of age, and mothers before 65 years (Wood et al. 1998). 
 
Recommended action 
Obtain family history as soon as practicably possible. 
 
Personal History 
Rationale 
A patient’s risk increases with age. They will be at a higher risk if they are male or 
South Asian. Modifiable risk factors are obesity, smoking, dyslipidaemia, physical 
inactivity, poor diet, raised blood pressure, high alcohol intake and diabetes. 
 
Recommended action 
Obtain personal history as soon as practicably possible. Provide advice on diet, 
exercise, alcohol and smoking as appropriate. 
 
Measurements 
 
Body Mass Index (BMI) 
Rationale 
The BMI is a simple index used to determine whether an individual is underweight, 
overweight or obese (WHO 2006). 
The BMI is defined as the weight divided by the square of the height. For example, a 
person who weighs 70 kg and has a height of 1.75 will have a BMI of 22.9. 
A BMI calculator can be found at: 
www.eatwell.gov.uk/healthydiet/healthyweight/bmicalculator/  
Although BMI values are the same for both sexes, they may not be accurate in people 
who are athletes or who weight-train, in pregnant or breastfeeding women, or those 
over the age of 60 years.  
Ethnicity should be considered; particularly in patients of South Asian origin 
(overweight varies from BMI > 23, obesity from BMI > 25). 
 
Recommended action 
Calculate BMI before initiation of antipsychotic medication and at six and twelve 
weeks. Check for weight gain – if >7%, review choice of antipsychotic  
Diet and exercise advice should be offered to all patients to prevent weight gain.  
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Waist circumference 
Rationale 
People who carry their excess fat centrally (within the abdominal cavity) are more 
likely to suffer the consequences of being overweight. 
Waist circumference correlates with visceral adipose tissue, plasma lipids, lipoproteins 
and insulin levels in adults (Taylor et al. 1998).  
 
Recommended action 
Measure the patient’s waist circumference before initiation of antipsychotic 
medication and at six and twelve weeks. Patients at risk are those with a waist 
circumference ≥ 80 cm (female) / ≥ 94 cm (male) (Barnett et al. 2007). If 
measurements are increasing, consider switching medication. Offer diet and exercise 
advice. 
 
Electrocardiogram (ECG) 
Rationale 
Most antipsychotic medications have the potential for lengthening of the QT interval 
(prolonged: in males >450ms, in females >470ms - Committee for Proprietary 
Medicinal Products 1997). Therefore, cardiac safety should be a routine part of clinical 
care in patients taking antipsychotic medication; a preventive strategy is valuable even 
if the absolute risk of serious cardiac events is low (Abdelmawla and Mitchell 2006). 
There is evidence that many typical antipsychotics increase the risk of ventricular 
arrhythmias and cardiac arrest (Ray et al.2001, Liperoti et al. 2005) and an association 
between many atypical antipsychotic drugs and the occurrence of unexplained sudden 
death (Abdelmawla & Mitchell, 2006).  
 
Recommended action 
Perform an ECG on all patients before prescribing antipsychotics if possible, or as soon 
as practicably achievable.  Recheck at six and twelve weeks. If abnormal following 
initiation of medication then consider switching. You may refer to the GP or a 
cardiologist as appropriate. 
 
Blood pressure 
Rationale 
People with severe mental illness are at a higher risk of developing high blood pressure 
than the general population. The British Hypertension Society Guideline cites evidence 
that suboptimal blood pressure control leaves patients at an unacceptably high risk of  
cardiovascular complications and death, particularly from coronary heart disease 
(CHD) but also from stroke (Williams et al. 2004). Interventions actively combining 
exercise and diet have demonstrated a reduction of both systolic and diastolic blood 
pressure by only 4–5 mmHg (NICE 2006), therefore medication is often required. 
 
Recommended action 
Check blood pressure before initiation of antipsychotic medication. Recheck at six and 
twelve weeks. Most antipsychotic medications have a hypotensive effect. For patients 
with blood pressure > 140/90 mmHg, refer to their GP 
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Blood tests 
 
Liver Function Tests (LFTs) 
Rationale 
Antipsychotic medication can result in abnormal LFTs (Garcia-Unzueta et al. 2003). 
Hepatic disease should be detected early to prevent further serious complications. 
 
Recommended action 
Check LFTs before initiation of medication and at six and twelve weeks. If tests are 
abnormal, then review medication. If not associated with medication, refer to GP.  
 
Lipid Levels 
Rationale  
Dyslipidaemia is a key component of the metabolic syndrome and a precursor for 
cardiovascular disease.  
 
Recommended action 
Check fasting cholesterol level before initiation of medication and at six and twelve 
weeks. If there is difficulty in obtaining a fasting sample then do a random one. If tests 
are abnormal, then review medication. If not associated with medication, refer to GP.   
 
Glucose 
Rationale 
Diabetes occurs in 15% of people with schizophrenia (Holt and Peveler 2005), and only 
5% of the general population (Bushe and Holt 2004). Risk factors include: family history 
of diabetes, physical inactivity, poor diet, smoking and the metabolic effects of 
antipsychotic medication (Gough and Peveler 2004). Typical antipsychotics, in 
particular the low potency ones such as chlorpromazine may induce or make existing 
diabetes worse (Newcomer et al. 2002). The atypical antipsychotics clozapine and 
olanzapine are associated with new onset or exacerbating type 2 diabetes, not just 
through their propensity to cause greater weight gain than other newer agents, but 
because of their effects on glucose regulation (Newcomer et al. 2002). There are also 
case reports linking risperidone and quetiapine to impaired glucose intolerance, 
diabetes and ketoacidosis (Taylor et al. 2007). 
 
 
Recommended action 
Check random or fasting glucose and HbA1c before initiation of medication and at six 
and twelve weeks. If tests are abnormal, then review medication. If not associated 
with medication, refer to GP.  
 
Prolactin 
Rationale 
Hyperprolactinaemia is a common side-effect of many antipsychotic drugs. Symptoms 
include gynaecomastia, galactorrhoea, amenorrhoea and sexual dysfunction. Switching 
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to a prolactin sparing antipsychotic has been shown to lead to normalization of serum 
prolactin and resolution of the symptoms (Haddad et al. 2001).  
 
Recommended action 
Consensus guidelines for managing prolactinaemia (Peveler et al. 2008) recommend 
that healthcare professionals should monitor proactively for hyperprolactinaemia as it 
maybe asymptomatic. 
 Patients prescribed prolactin elevating antipsychotics should, where possible, 
have this issue explained to them prior to commencing treatment and be 
screened for symptoms suggestive of hyperprolactinaemia before starting 
treatment (Haddad et al. 2001) and at six and twelve weeks. 
 If the elevation of prolactin levels is mild (<1000 mIU/L (~50 ng/mL)) then it 
may be reasonable to continue to monitor the level. However, if even a mildly 
elevated level persists for more than 3 months, particularly if accompanied by 
amenorrhoea, bone mineral density may be compromised, and the possibility 
of reducing dose or switching to an antipsychotic with lower potential for 
prolactin elevation should be discussed with the patient 
 When elevation is persistent and >1000 mIU/L (~50 ng/mL) then the clinician 
should consider switching to a drug with a lower potential to elevate prolactin 
if this can be achieved safely and is consistent with the clinical status of the 
patient as a whole 
 For female patients switching to a drug with a lower potential to elevate 
prolactin may result in the return of fertility, and contraceptive advice should 
be given.  
 If switching to a drug with a lower potential to elevate prolactin is not possible, 
it would be reasonable for clinicians to consider offering an oral contraceptive 
to  
female patients with amenorrhoea, if this is not contraindicated, to reduce the 
risk of subsequent osteoporosis. 
 In any patient with a prolactin elevation greater than 3000 mIU/L (~150 ng/mL) 
then a prolactinoma should be considered. Refer to GP 
 If the levels do not return to normal upon switching to a less prolactin-elevating 
antipsychotic, or if such switch is not possible for clinical reasons, then referral 
to a specialist in endocrinology via GP is warranted to exclude a prolactinoma.  
 
 
Urea and Electrolytes (U & Es) and calcium 
Rationale 
There is a risk of electrolyte imbalance when taking antipsychotic medication 
particularly at high doses. For patients taking lithium, there is a higher than normal 
incidence of hypercalcaemia and abnormal renal function (BMA 2009).  
 
Recommended action 
Check U & E’s and calcium before initiation of medication and at six and twelve weeks. 
If tests are abnormal, then review medication. If not associated with medication, refer 
to GP.  
  
347 
 
Thyroid Function Test 
Rationale 
Studies have indicated that the elevated serum levels of T4 may be specific for acutely 
ill schizophrenic patients and that neuroleptic medication may affect thyroid hormone 
metabolism (Baumgartnera et al. 2000) and that there is a spectrum of thyroid 
function test abnormalities in chronic schizophrenia (Othman et al. 1994). 
For patients taking lithium, there is a higher than normal incidence of hypothyroidism 
(BMA 2009).  
 
Recommended action 
Check thyroid function before initiation of medication and at six and twelve weeks. If 
tests are abnormal, then review medication. If not associated with medication, refer to 
GP.  
 
Full Blood Count (FBC) 
Rationale 
A case-control study (Teixeira et al. 2009) in patients with schizophrenia showed a 
significantly higher number of patients with changes on leukocytes. Many patients 
presented low values of haemoglobin, erythrocytes and platelets. Leukopenia and 
neutropenia are recognised as side effects of antipsychotic medication (Taylor et al. 
2007). 
 
Recommended action 
Check FBC before initiation of medication and at six and twelve weeks. If tests are 
abnormal, then review medication. If not associated with medication, refer to GP.  
 
B12 and Folate 
Rationale 
A case-control study (Teixeira et al. 2009) in patients with schizophrenia presented low 
values of vitamin B12. Having a deficiency of vitamin B12 just because of eating a poor 
diet is rare in Western countries, but unhealthy diets are common lifestyle choices of 
people with schizophrenia (McCreadie 2003). 
 
Recommended action 
Check B12 and folate before initiation of medication. If tests are abnormal refer to GP.  
 
Plasma Levels 
Lithium 
Rationale 
There is potential toxicity caused by lithium therapy when the serum levels are outside 
of the narrow therapeutic range (BMA 2009). 
 
Recommended action 
It is recommended that lithium levels are monitored every three months (BNF 2011). 
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Carbamazepine 
Rationale 
Most authorities agree that plasma drug level monitoring is mandatory when using 
carbamazepine for seizure disorders and helpful for bipolar disorder (Taylor et al. 
2000). 
 
Recommended action 
Consider monitoring at six and twelve weeks and/or until levels are stable. 
 
Valproate 
Rationale 
Most authorities agree that plasma drug level monitoring is helpful for valproate in 
seizure disorders and bipolar disorder (Taylor et al. 2000). 
 
Recommended action 
Consider monitoring at six and twelve weeks and/or until levels are stable. 
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Normal blood test values 
 
Liver function test  
Albumin (ALB) = 35-50 g/L 
Alkaline Phosphatase (ALK PHOS) = 38-126 IU/L 
Alanine Aminotransferase (ALT) = M 21 - 72: F 9 - 52 IU/L  
Aspartate Aminotransferase (AST) = M 17 - 59: F 14 - 36 U/L  
Bilirubin (BIL) = 3 - 22 umol/L  
 
Lipids  
HDL = >0.9 mmol/L  
If HDL is less than 1.0 mmol/L for men and less than 1.3 mmol/L for women, there is an 
increased risk of heart disease that is independent of other risk factors, including the 
LDL level.  
 
Total Cholesterol = 3.0 - 5.5 mmol/L  
If no CVD risk: 
 Total cholesterol - less than 5.0mmol/l 
 LDL cholesterol - less than 3.0mmol/l 
If CVD risk: 
 Total cholesterol - less than 4.0mmol/l 
 LDL cholesterol - less than 2.0mmol/l 
   
Glucose  
Glucose = (fasting) 3.5 - 6.0 mmol/L (above 7mmols = diabetes) 
Random glucose = > 11.1 mmols = diabetes, if > 6 mmols repeat fasting 
Hba1c = less than 48mmols if do not have diabetes (cannot use alone if an 
antipsychotic has been initiated within eight weeks), 48-58mmols is the desired range 
for people with diabetes 
 
Prolactin   
Prolactin = M 45 - 375: F 59 – 619 mu/L   
 
Urea 
Urea = 3.3 - 6.7 mmol/L  
 
Electrolytes  
Sodium = 135 - 145 mmol/L  
Potassium = 3.5 - 5.0 mmol/L  
Creatinine = M 68 - 127: F 59 - 101 umol/L  
 
Calcium 
Calcium = 2.25 - 2.65 mmol/L  
   
 
Thyroid function test 
Thyroid Stimulating Hormone (TSH) = 0.35 - 5.5 mU/L  
   
  
350 
 
Full blood count 
Haemoglobin (Hb) - M 13-18 g Dl,  F 11.5-15.5 g dL  
White cell count (WCC or WBC) = 4-11x10 9/L 
Red blood cells (RBC) = M 4.5-6.5x10 9/L. F 3.80-5.80x10 9/L 
Neutrophils/Granulocytes = 2-7.5 x10 9/L 
Eosinophils = ≤ 0.4 
Platelets = 150-400 x10 9/L 
Mean cell volume (MCV) = 83-101 Fl 
Mean Corpuscular Haemaglobin (MCH) = 27-32 pg 
 
Haematinic levels 
B12 = 210-910 ng/L 
Folate = 5.4-24 ug/L   
 
Plasma levels 
Lithium = 0.6 - 1.0 mmol/L  
Carbemazepine = 8 - 12 mg/L (single dose regimen)  
Valproate = 50 - 100 mg/L  
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Lifestyle advice 
 
Smoking 
Rationale 
Approximately 85% of people with schizophrenia smoke, compared with 23% of the 
general population (Goff et al. 2005). Smoking rates are higher in schizophrenia than in 
other severe mental illnesses (Goff et al. 2005). 
Neurobiological, psychological, behavioural and social factors make it difficult for 
patients with mental illness to stop smoking (Robson and Gray 2007). 
Smoking cessation medication and other non-pharmacological support can increase 
abstinence rates in those with mental health problems to as high as those in the 
general population (Foulds et al. 2006, Campion et al. 2008).  
 
Recommended action 
 Give advice about the possible health risks associated with smoking 
 Ask about respiratory symptoms; chest examination if appropriate 
 Refer any patients wishing to quit smoking to NHS Stop Smoking Services if 
appropriate (DH 2007a) or the primary care clinic’s stop smoking service. They 
may need to be seen individually.  
 Cigarette smoking lowers the levels of many antipsychotic medications 
(Vazquez et al. 2007). Therefore, if a patient stops or reduces their smoking, a 
medication review should be undertaken. 
o Blood levels of olanzapine and clozapine should be measured before 
smoking cessation followed by 25% dose reduction during first week of 
cessation and then further blood levels (Taylor et al. 2007). 
o Doses of fluphenazine and benzodiazepine should be reduced by up to 
25% in first week of cessation.  
o Tricyclic antidepressants may need to be reduced by 10-25% in first 
week (Taylor et al. 2007).  
 
Exercise 
Rationale 
People with severe mental illness are more physically inactive than the general 
population (Brown et al, 1999, McCreadie 2003). 
Physical activity can have a positive effect on psychological well-being in people with 
schizophrenia (DH 2004). 
 
Recommended action 
Identify the patient’s level of activity. The recommendation for exercise to be of 
benefit is 30 minutes five days a week (DH 2004). Help the patients make an exercise 
plan which fits in with their lifestyle and builds up activity gradually. For some 
individuals it may be appropriate to refer to an exercise scheme if there is one in your 
area. 
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Alcohol Intake 
Rationale 
Alcohol misuse is one of the most common and clinically significant co-morbidities 
among patients with severe mental illness (Brunette et al. 2004). There is considerable 
evidence to support the positive impact of reducing unsafe alcohol consumption on 
cardiovascular health (NHS Information Centre 2008).  
Many antipsychotics can cause sedation and impair alertness, concentration and 
coordination. The use of alcohol can further increase any impairment (rethink 2008). 
 
Recommended action 
Offer recommendations on sensible daily alcohol intake: 
 Adult women should not regularly drink > 2–3 units of alcohol a day 
 Adult men should not regularly drink > 3–4 units of alcohol a day 
 Women who regularly drink > 6 units a day (or > 35 units a week) and men who 
regularly drink > 8 units a day (or 50 units a week) are at highest risk of alcohol-
related harm 
(Department of Health 2007b) 
Refer to the local Alcohol Support Agency if appropriate. 
 
Diet 
Rationale 
In a survey of the dietary habits of 102 people with SMI by McCreadie (2003) the 
average fruit and vegetable intake for these people was 16 portions a week, compared 
with recommended intake of 35 per week (DH 2004). The physical health 
consequences of a poor diet include CVD, diabetes, obesity and some cancers.  
Studies of people with SMI repeatedly show that saturated fats from dietary intake of 
meat and dairy products are associated with worse outcomes in schizophrenia (Peet 
2004). There is a particularly strong association between sugar consumption and 
poorer outcome in schizophrenia whereas consumption of fish and sea food, 
particularly omega 3 fatty acids, has been associated with better outcomes (Peet 
2004). 
 
Recommended action 
Agree and implement a diet plan with the patient (and any carers) – may include 
referral to other members of the multidisciplinary team. 
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Medication review 
Observe for side effects. See appendix 1 
 
Antipsychotics 
Antipsychotics have a wide range of side effects. The most widely researched include 
(Rethink 2006):  
Sedation: The antipsychotics that cause the most sedation include chlorpromazine, 
promazine, thioridazine, clozapine and zotepine. Often this can be dealt with by the 
patient taking their medication at night just before they go to bed. The dose may need 
to be reduced or changed if this is a big problem. 
Movement disorders: There are different types of movement disorder. These include: 
 Dystonia - prolonged muscle spasms often involving the face, neck, shoulders 
and upper limbs. Drugs such as procyclidine and orphenadrine are given to 
treat dystonia 
 Akathisia - fidgety movements of the legs which may be accompanied by a 
strong sense of inner restlessness and unease. This often means that a person 
cannot sit comfortably, and may be driven to walk up and down to try and gain 
relief. It is best treated with clonazepam or propranolol 
 Parkinsonian movement disorders - involve stiffness and shakiness, and 
resembles the unrelated condition of Parkinson's disease. The limbs move 
slowly and muscles of the face may be quite immobile, producing an 
expressionless, staring face. Rhythmic shaking may occur but is not usually very 
severe, and is most obvious in the hands. Procyclidine and orphenadrine, 
amongst other drugs, are given to treat Parkinsonian movement disorders 
 Tardive dyskinesia - major signs of the condition are excessive movement of 
the lips, tongue and jaw, (known as oro-facial dyskinesia). The term "tardive" 
means delayed or late-appearing and this reflects the fact that treatment may 
have gone on for some months or years before the movement disorder 
becomes apparent. Oro-facial dyskinesia is the most common form of tardive 
dyskinesia. Other abnormal movements are seen including jerky, abrupt 
movements of the limbs and body, but these are less common. 
 
Mood stabilisers  
Lithium  
In long-term use lithium has been associated with thyroid disorders and mild cognitive 
and memory impairment. Lithium salts have a narrow therapeutic/toxic ratio, 
therefore it is important to determine the optimum range for each individual patient. 
Lithium toxicity is made worse by sodium depletion (BNF 2011). Patients should be 
maintained on lithium after three to five years only if benefit persists. 
(BNF 2011) 
 
Carbamazepine 
In order to be effective, carbamazepine has to reach a given level in the blood 
(NWMHFT 2005). Side effects include dizziness, drowsiness, shaky movements and 
feeling sick. Carbamazepine can cause a chronic low white blood cell count which 
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increases susceptibility to infection (NWMHFT 2005). This can be monitored with 
regular blood tests. 
 
Valproate 
Valproate causes an increase in appetite and therefore weight gain (NWMHFT 2005). 
Side effects include dizziness, drowsiness, shaky movements, feeling sick, impaired 
liver function, thrombocytopenia and impaired platelet function (NWMHFT 2005). 
 
Follow up 
The patients may not attend for follow up appointments due to their mental state. It is 
important, therefore to set up a robust system to allow further opportunities to 
attend.  
 
Recommended action 
 Try contacting the patient (or carer if known) by telephone 
 Send a letter requesting that they contact the department to make a new 
appointment 
 Inform the patient’s link worker 
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Glasgow Antipsychotic Side-effect Scale (GASS) 
 
Name:                                                                          Age:                      Sex:  M  /  F 
Please list current medication and total daily doses below: 
 
 
 
This questionnaire is about how you have been recently. It is being used to determine if you are suffering 
from excessive side effects from your antipsychotic medication.    
Please place a tick in the column which best indicates the degree to which you have experienced the 
following side effects. Tick the end box if you found that the side effect distressed you.      
                                                                                                                                            © 2007 Waddell & 
Taylor 
Over the past week: Never 
 
Once A few                          
times 
Everyday 
 
Tick this box if 
distressing 
1. I felt sleepy during the day      
2. I felt drugged or like a zombie 
 
     
3. I felt dizzy when I stood up and/or have fainted  
 
 
     
4. I have felt my heart beating irregularly or unusually fast 
 
     
5. My muscles have been tense or jerky       
6. My hands or arms have been shaky       
7. My legs have felt restless and/or I couldn’t sit still 
 
     
8. I have been drooling      
9. My movements or walking have been slower than usual  
 
     
10. I have had, or people have noticed  uncontrollable movements of 
my face or body 
 
 
 
     
11. My vision has been blurry  
 
     
12. My mouth has been dry  
 
     
13. I have had difficulty passing urine 
 
     
14. I have felt like I am going to be sick or have vomited      
15. I have wet the bed  
 
     
16. I have been very thirsty and/or passing urine frequently 
 
     
17. The areas around my nipples have been sore and swollen  
 
     
18. I have noticed fluid coming from my nipples  
 
     
19. I have had problems enjoying sex  
 
     
20. Men only: I have had problems getting an erection 
 
     
 
Tick yes or no for the following questions about the last three months No                                      Yes                                     Tick this box if 
distressing 
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21. Women only: I have noticed a change in my periods    
22. Men and women: I have been gaining weight     
 
 
Staff Information 
 
1. Allow the patient to fill in the questionnaire themselves. Questions 1-20 
relate to the previous week and questions 21-22 to the last three months. 
 
2. Scoring 
 
For questions 1-20 award 1 point for the answer “once”, 2 points for the 
answer “a few times” and 3 points for the answer “everyday”. 
Please note zero points are awarded for an answer of “never”.  
 
 
For questions 21 and 22 award 3 points for a “yes” answer and 0 points 
for a “no”. 
 
 
Total for all questions= 
 
 
3. For male and female patients a total score of:  
                  0-12 = absent/mild side effects 
    13-26 = moderate side effects  
  over 26 = severe side effects 
 
  
4. Side effects covered by questions 1-2 sedation and CNS side effects 
            3-4 cardiovascular side effects 
            5-10 extra-pyramidal side effects 
            11-13 anticholinergic side effects 
            14 gastro-intestinal side effects 
            15 genitourinary side effects  
            16 screening for diabetes mellitus 
            17-21 prolactinaemic side effects  
            22 weight gain 
 
 
The column relating to the distress experienced with a particular side effect is 
not scored, but is intended to inform the clinician of the service user’s views and 
condition. 
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